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ABSTRACT OF THE DISSERTATION
CORRELATES OF VITAMIN D STATUS IN HEALTHY OLDER ADULTS LIVING
IN MIAMI-DADE AND ITS ASSOCIATION WITH NONSKELETAL OUTCOMES: A
CROSS-SECTIONAL STUDY
by
Johanna Lopez
Florida International University, 2015
Miami, Florida
Professor Adriana Campa, Major Professor
Examining factors that affect vitamin D status in the fast-growing elderly
population of Miami-Dade, Florida, is needed. Vitamin D deficiency in older adults has
been linked to correlates of disability, including falls and fractures, and cardiovascular
disease. The purpose of this study was to determine the proportion of vitamin D
insufficient individuals and their relationship with vitamin D insufficiency in older adults
(n=97) living in Miami-Dade. We evaluated the association between vitamin D status and
1) dual task physical performance to understand the link between vitamin D and
cognition in the context of mobility; and 2) cardiometabolic risk, measured by galvanic
skin response, pulse oximetry, and blood pressure to create a composite score based on
autonomic nervous system and endothelial function. Participants completed baseline
assessments that included serum levels of vitamin D, anthropometrics, body composition,
dual task physical performance and cardiometabolic risk. Surveys to evaluate vitamin D
intake, sun exposure, physical activity, and depressive symptoms were completed.
Spearman’s correlations, independent t-tests, paired t-tests, repeated measures ANOVAs,
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and multiple logistic and linear regressions were used to examine the relationship of
vitamin D insufficiency (25(OH)D <30 ng/ml) and sufficiency (25(OH)D ≥30 ng/ml)
with determinants of vitamin D status, dual task physical performance variables and
cardiometabolic risk scores. Although the proportion of vitamin D insufficient
individuals was lower when compared to the prevalance of the general United States
elderly population, it was still common in healthy community-dwelling older adults
living in Miami-Dade County, especially among Hispanics. Factors that affected skin
synthesis (ethnicity, and sun exposure), and bioavailability/metabolism (obesity) were
significant predictors of vitamin D status. Vitamin D insufficiency was not significantly
correlated with worse dual task physical performance; however, cognitive performance
was worse in the vitamin D insufficient group. Our results suggest a relationship of
vitamin D insufficiency with executive dysfunction, and support an association with
cardiometabolic risk using an innovative electro-sensor complex, possibly by modulating
autonomic nervous system activity and vascular function, thus affecting cardiac
performance.

vii

TABLE OF CONTENTS
CHAPTER

PAGE

CHAPTER I: INTRODUCTION .........................................................................................1
Statement of Problem...........................................................................................................1
Significance of Proposed Study ...........................................................................................4
Specific Aims and Hypotheses ............................................................................................5
CHAPTER II: LITERATURE REVIEW ..........................................................................19
Vitamin D Deficiency in the Elderly .................................................................................19
Defining Vitamin D Deficiency Based on its Main Function ...........................................19
Recommended Vitamin D Intake, Vitamin D Sources, and the Older Adult ....................21
Vitamin D, Fall Risk, and Mobility as Measured by Gait Speed in the Elderly ................26
Vitamin D Deficiency, Cognitive Impairment, and Executive Dysfunction in
the Elderly ..........................................................................................................................28
Vitamin D and Other Non-Skeletal Outcomes: Cardiovascular Disease ..........................32
Vitamin D and Cardiovascular Health: Possible Mechanism ............................................34
The Relationship Between Vitamin D and Cardiac Autonomic Nervous System.............35
VItamin D and Its Relationship to Other Cardiovascular Risk Correlates ........................39
Literature Review Summary ..............................................................................................40
CHAPTER III: METHODS ...............................................................................................59
CHAPTER IV: CORRELATES OF VITAMIN D DEFICIENCY IN SOUTH
FLORIDA OLDER ADULTS ...........................................................................................94
CHAPTER V: ASSOCIATION OF VITAMIN D STATUS WITH DUAL TASK
PHYSICAL PERFORMANCE IN OLDER ADULTS ...................................................133
CHAPTER VI: RELATIONSHIP BETWEEN VITAMIN D STATUS AND
CARDIOMETABOLIC RISK .........................................................................................174
CHAPTER VII: SUMMARY AND CONCLUSIONS ...................................................206
CHAPTER VIII: STRENGTHS AND LIMITATIONS ..................................................212
CHAPTER IX: FUTURE RESEARCH...........................................................................214
APPENDICES .................................................................................................................217
VITA ................................................................................................................................260

viii

LIST OF TABLES
TABLE

PAGE

CHAPTER I
Table 1: Summary of Hypotheses and Statistical Methods .................................................8
CHAPTER II
Table 1: Vitamin D Status in Relation to Bone Health ......................................................21
CHAPTER III
Table 1: Inclusion and Exclusion Criteria .........................................................................59
Table 2: Statistical Analyzes Methods for individual Hypotheses ....................................85
CHAPTER IV
Table 1: Comparison of Vitamin D Related Variables and Sociodemographic
Characteristics Between Vitamin D Insufficient and Sufficient Participants ..................120
Table 2: One-Way ANOVA Comparison of Vitamin D Levels Between Ethnic
Groups ..............................................................................................................................121
Table 3: Comparison of Vitamin D Levels, Vitamin D Intake, Sun Exposure and
Other Potential Correlates Between Vitamin D Insufficient and Sufficient
Participants.......................................................................................................................122
Table 4: Vitamin D Status Correlation with Vitamin D Intake, Sun Exposure, and
Other Potential Predictors ................................................................................................123
Table 5: The Relationship Between Vitamin D Status and Potential Correlates in
Multiple Linear Regressions ............................................................................................124
Table 6: The Relationship Between Vitamin D Status and Potential Correlates in
Multiple Logistic Regression ...........................................................................................125
CHAPTER V
Table 1: Characteristics of Participants ...........................................................................156
Table 2: Vitamin D Status Correlation with Dual Task Physical Performance
Variables ..........................................................................................................................157
Table 3: Comparison of Dual Task Physical Performance Variables Between
Vitamin D Insufficient And Sufficient Participants.........................................................160
Table 4: The Relationship Between Vitamin D Status and Dual to Single Task
Difference in Gait Velocity and Counting Rate in Multiple Logistic Regressions .........161
CHAPTER VI
Table 1: Characteristics of Participants ...........................................................................195
Table 2: Comparison of Cardiometabolic Risk Scores (CMRS) Between Vitamin D
Insufficient and Sufficient Participants ............................................................................196
Table 3: The Relationship Between Vitamin D Levels and CMRS in Multiple Linear
Regressions ......................................................................................................................197

ix

APPENDIX A
Table 1: Observational Studies Investigating the Association Between Vitamin D
Status and Gait Velocity in Healthy Community-Dwelling Older Adults ......................218
Table 2: Interventional Studies Investigating the Effect of Vitamin D on Gait
Velocity in Healthy Community-Dwelling Elderly .........................................................222
Table 3: Observational Studies Investigating the Association Between Vitamin D
Status and Cognition in Healthy Community-Dwelling Older Adults ............................225
Table 4: Observational Studies Investigating the Association Between Vitamin D
Status, Gait Velocity and Cognition (Independently) in Healthy CommunityDwelling Older Adults .....................................................................................................233
APPENDIX B
Table 1: Description of ESC software variables used to calculate CMRS ......................244

x

LIST OF FIGURES
FIGURE

PAGE

CHAPTER V
Figure 1: Comparison of Dual and Single Task Gait Velocity Within and Between
Vitamin D Insufficient and Sufficient Participants ..........................................................158
Figure 2: Comparison of Dual and Single Task Counting Rate Within and Between
Vitamin D Insufficient and Sufficient Participants ..........................................................159
APPENDIX B
Figure 1: The GAITRite Walkay for the Assessment of Gait .........................................240
Figure 2: The Electro Sensor Complex Device and Procedure .......................................242
Figure 3: Heart Rate Variability Time and Frequency Domains .....................................243

xi

ABBREVIATIONS AND ACRONYMS
1,25(OH) 2 D

1, 25-dihydroxyvitamin D

25(OH)D

25- hydroxyvitamin D

ANS

Autonomic Nervous System

BDI

Beck Depression Inventory

BIA

Bioelectrical Impedance

BMD

Bone Mineral Density

BMI

Body Mass Index

CDC

Center for Disease Control and Prevention

CI

Confidence Interval

CKD

Chronic Kidney Disease

CV

Coefficient of Variability

CVD

Cardiovascular Disease

DBP

Diastolic Blood Pressure

d.f.

Degrees of freedom

DRI

Dietary Reference Intakes

DSM-IV

Diagnostic and Statistical Manual of Mental Disorders, 4th Edition

DVP

Digital Volume Pulse wave

ESC

Electro Sensor Complex

ESKD

End Stage Kidney Disease

FES-I

Fall Efficacy Scale International

FFM

Fat-Free Mass

FFQ

Food Frequency Questionnaire

FIU

Florida International University

FM

Fat Mass

FTT

Fourier Transform

GABA

Gamma-Aminobutyric Acid

xii

HC

Hip Circumference

HF

Heart Failure

HHHQ

Health Habits History Questionnaire

HR

Heart Rate

HRV

Heart Rate Variability

ICMA

Immunochemiluminometric Assay

IGT

Impaired Glucose Tolerance

IOM

Institute of Medicine

IPAQ

International Physical Activity Questionnaire

IR

Insulin Resistance

IRB

Institutional Review Board

IU

International Unit

MD

Mean Difference

MMSE

Mini Mental State Examination

MRI

Magnetic Resonance Imaging

ng/ml

Nanogram per milliliter

NHANES

National Health and Nutrition Examination Survey

Nmol/L

Nanomol per liter

PNS

Parasympathetic Nervous System

OGTT

Oral Glucose Tolerance

OR

Odds Ratio

PTG

Plethysmograph

PTGHF

Plethysmograph High Frequency

PTGi

Plethysmograph index

PTGLF

Plethysmograph Low Frequency

PTGTP

Plethysmograph Total Power

PTGVLF

Plethysmograph Very Low Frequency

xiii

RCT

Randomized Controlled Trial

RMSSD

Root of Mean Squared Standard Deviation

RXR

Retinol X Receptor

SD

Standard Deviation

SDNN

Standard Deviation of Normal to Normal wave

SBP

Systolic Blood Pressure

SCD

Sudden Cardiac Death

SNS

Sympathetic Nervous System

SPMSQ

Short Portable Mental Status Questionnaire

UM

University of Miami

VDBP

Vitamin D Binding Protein

VDR

Vitamin D Receptor

WC

Waist Circumference

WHI

Women’s Health Initiative

WHR

Waist to Hip Ratio

xiv

CHAPTER I: INTRODUCTION

Statement of Problem
Approximately one billion people in the world have deficient or insufficient levels
of vitamin D.1 The National Health and Nutrition Examination Survey (NHANES) 20052006 revealed that 41.6% of United States adults (18 years or older) had deficient vitamin
D levels, defined as <20 ng/ml of 25-hydroxyvitamin D (25(OH)D).2,3 Elderly are at
higher risk of vitamin D deficiency. NHANES 1988-1994 data indicated that serum
vitamin D levels among adults 65 years and older were lower when compared to middle
aged (40-59 years of age) and younger adults (18-29 years of age). Of these older adults,
23% and 62.5% had vitamin D deficient (<20 ng/ml) and insufficient (<30 ng/ml) levels,
respectively.4,5 The main sources of vitamin D are skin synthesis and dietary intake.
Vitamin D deficiency may be more prevalent in theelderly population due to a complex
interplay between several factors affecting dietary intake, skin synthesis and
bioavailability. These include age-related decreased appetite, impaired intestinal
absorption, decreased capacity of the skin to synthesize vitamin D, and less sun exposure,
which may be related to physical inactivity and decreased outdoor activities.6,7
Furthermore, elderly are at higher risk of vitamin D deficiency due to age-related
increased adiposity, which may be secondary to decreased metabolic rate, use of
medications and the presence of comorbidities that affect vitamin D metabolism.8,9
In the United States, very few foods contain significant amounts of vitamin D;
therefore, vitamin D intake through food may be minimal as shown in NHANES 19881994.10,11 Although supplement use may compensate for the lack of vitamin D intake
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from foods; however, low vitamin D intakes from food and supplements have been
reported in the elderly populations and associated with low serum vitamin D.6,7,12 Thus,
for those who are not meeting the vitamin D requirements through diet, sunlight is often
the main source of vitamin D.13,14 The skin’s ability to synthesize vitamin D depends on
the amount of solar radiation reaching the biosphere that is influenced by latitude, season
and time of day.8,15 Based on the impact of sunlight exposure on vitamin D status, it has
been assumed that vitamin D deficiency is less prevalent in populations living at lower
latitudes and/or where seasonal variations are not as pronounced, like in South Florida,
where the weather is sunny and warm year-round.9 However, other investigators have
reported that the prevalence of hypovitaminosis D (25(OH)D <20 ng/ml) is 38-40% in
adult men and women (>18 years of age) living in South Florida.9
Vitamin D deficiency in older adults has been linked to non-skeletal outcomes
that go beyond bone health. In 2010, of the 30 leading causes of disability and death in
the United States, 19 were associated with deficient vitamin D levels, including cancer,
diabetes, falls and fractures, and cardiovascular disease.16-25 Vitamin D deficiency has
received much attention as a risk factor for falls because of its effect on musculoskeletal
health thus affecting gait.26-33 The mechanism by which vitamin D affects mobility and
fall risk, however, may go beyond its role in musculoskeletal health. Since mobility
depends on the musculoskeletal and nervous systems, it could be possible that the role of
vitamin D in fall risk is not only through its effects on musculoskeletal health but also
through its role in brain function and cognition.34 Several investigators have reported the
association of vitamin D deficiency with higher risk of cognitive impairment and/or
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lower scores on cognitive performance tests.5,17,35-54 Little is known, however, about the
role of this nutrient in cognitive function in the context of mobility.
Another potential role of vitamin D in the brain is on the regulation of cardiac
autonomic nervous system (ANS) function, affecting cardiovascular health. Vitamin D
deficiency and cardiovascular disease (CVD) are prevalent worldwide.1,55 Furthermore,
the prevalence of vitamin D deficiency is high among those with CVD.56,57 Several
observational studies and meta-analyses have demonstrated associations between vitamin
D deficiency and outcomes related to CVD and CVD-related deaths.58-72 Furthermore,
dysfunction of cardiac autonomic function, more specifically of the cardioprotective
parasympathetic tone, results in an imbalance between sympathetic (SNS) and
parasympathetic (PNS) nervous systems. This imbalance has been well-established as a
risk factor for adverse cardiovascular events, such as sudden cardiac death (SCD) or
congestive heart failure.73-78 Besides affecting heart rate, the ANS also influences cardiac
performance by controlling vascular dynamics and blood pressure, which in part is also
affected by endothelial health. Low vitamin D status has been independently associated
with ANS and endothelial dysfunction; thus affecting cardiovascular health.55,57,79,80 The
observations that vitamin D deficiency, cardiac ANS, and endothelial dysfunction are
independently linked to each other and CVD-related outcomes suggest a potential
mechanism by which vitamin D affects CVD risk. The mechanisms that explains the
relationship between vitamin D deficiency and CVD-related outcomes and mortality is
unclear and therefore, a growing area of research.55
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Significance of the Proposed Study
Currently, vitamin D status and factors associated with vitamin D serum levels in
the elderly population in Miami-Dade have not been well studied. This is important
because according to the Florida Department of Elder Affairs, the top county for elders in
2010 and 2012 was Miami-Dade, with 14.9% of the Miami-Dade population being over
the age of 65 in 2010.81 Also, Miami is the fourth city in the national ranking that is
graying the fastest.81-85 Between 2007 and 2009, falls were the leading cause of injury of
residents in Miami-Dade aged over 65 years and responsible for 79% of injury
hospitalizations. One-third of hospitalizations related to falls resulted in a hip fracture and
11% involved traumatic brain injury.86
Vitamin D deficiency, which is still common among elderly living in warm South
Florida, despite year-round sunshine, is associated with the risk of falls.28,87-94 The role of
vitamin D deficiency in increasing the risk of falls may be dual; through its function in
both the musculoskeletal and nervous systems. Vitamin D is involved in brain
physiology. Lower vitamin D status has been associated with impaired neuronal function
in the caudal primary motor cortex of older adults, which may contribute to the
pathophysiology of gait disorders in older adults with vitamin D deficiency.95
Furthermore, several studies have demonstrated an association of vitamin D deficiency,
with gait impairment (slower gait speed), global cognitive impairment and impaired
executive function.5,17,35-54 Studies that investigated vitamin D status’ relationship to gait
and cognition, however, have looked at these factors independently. Until now, no crosssectional study has evaluated how vitamin D status is related to cognitive processing
during motor activity.
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To date very few studies have investigated the role of vitamin D deficiency in the
development of cardiac ANS and vascular dysfunctions, which are risk factors for poor
cardiovascular related health.58,71,96 In addition, no studies have correlated vitamin D
insufficiency with cardiometabolic risk, as assessed by cardiovascular risk indicators
such as ANS dysfunctions, endothelial dysfunction and anthropometric characteristics.
Objectives of this study were:
1.

To determine the proportion of vitamin insufficient individuals and correlates
of vitamin D status in a healthy older adult (>55 years of age) sample living in
Miami-Dade County.

2.

To investigate the association of vitamin D status with cognitive processing
during movement, as measured using the dual task physical performance tests.

3.

To investigate the association between vitamin D status and cardiometabolic
risk , measured by a combination of body composition, ANS activity, and
endothelial function markers.

Specific Aims and Hypotheses
Specific Aim 1: To determine the proportion of vitamin D insufficient individuals
and correlates of vitamin D status in a healthy older adult (>55 years old)
population living in Miami-Dade County.
Hypothesis 1a: The proportion of vitamin D insufficient individuals (25(OH)D <30
ng/ml) in a healthy older adult (>55 years old) sample living in Miami-Dade will be
lower than the prevalence reported for the general United States population.
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Hypothesis 1b: Vitamin D dietary intake will not be a determinant of vitamin D status in
an older adult sample living in Miami-Dade. Thus vitamin D intake will not predict
vitamin D status and will not be significantly different between vitamin D insufficient
(25(OH)D <30 ng/ml) and vitamin D sufficient (25(OH)D ≥30 ng/ml) individuals.
Hypothesis 1c: Sun exposure will be a significant positive correlate of vitamin D status in
older adults living in Miami-Dade County. Those who are vitamin D insufficient
(25(OH)D <30 ng/ml) will have significantly lower sun exposure scores than those who
are vitamin D sufficient (25(OH)D ≥30 ng/ml).

Specific Aim 2: To investigate the association of vitamin D status with cognitive
processing during movement as measured using the dual task physical performance
tests.
Hypothesis 2: Vitamin D status of healthy older adults (>55 years old) will be
significantly associated with worse performance in dual tasking compared to single
tasking.
Hypothesis 2a: Participants who are vitamin D insufficient (25(OH)D <30 ng/ml) will
have significantly slower dual task velocities as well as a larger dual to single task gait
velocity difference than those who are vitamin D sufficient (25(OH)D ≥30 ng/ml)
Hypothesis 2b: Participants who are vitamin D insufficient (25(OH)D <30 ng/ml) will
have significantly slower dual task counting rates and a larger dual to single task counting
rate difference than those who are vitamin D sufficient (25(OH)D ≥30 ng/ml).
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Specific Aim 3: To investigate the association between vitamin D status and
cardiometabolic risk (CMR), measured by integrating markers of body
composition, ANS activity function, and endothelial function markers.
Hypothesis 3: Vitamin D status of healthy older adults (>55 years old) will be
significantly and inversely associated with cardiometabolic risk (as calculated from the
assessment of body composition, ANS activity and endothelial function).
Hypothesis 3a: Participants who are vitamin D insufficient (25(OH)D <30 ng/ml) will
have significantly higher cardiometabolic risk scores than those who are vitamin D
sufficient (25(OH)D ≥30 ng/ml).
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Table 1: Summary of Hypotheses and Statistical Methods
Hypotheses
Independent
Variable and
Assessment
1a

Dependent
Variable and
Assessment
Vitamin D status

Prevalence of vitamin D status

Serum 25(OH)D
Categorical
(insufficient <30
ng/ml, sufficient ≥
30 ng/ml)

1b

Vitamin D intake

Vitamin D status

Vitamin D status and dietary intake

Vitamin D and
calcium short food
frequency
questionnaire

Serum 25(OH)D

Continuous

Categorical
(insufficient <30
ng/ml, sufficient ≥
30 ng/ml)
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Statistics

Vitamin D status was described using
frequencies, percentages, ranges, means and
standard deviations. Spearman’s correlations
were used to estimate associations between
vitamin D status and correlates. Independent ttests and chi-squares were used to compare
potential correlates of vitamin D status between
vitamin D insufficient (25(OH)D <30 ng/ml) and
sufficient (25(OH)D ≥30 ng/ml) participants.
Multiple linear and logistic regressions were
used to examine the relationship between
vitamin D status and explanatory variables.
Vitamin D intake was described using
frequencies, percentages, ranges, means and
standard deviations. Spearman correlations were
performed to evaluate the relationship between
vitamin D status and vitamin D intake.
Independent t-tests were used to compare
vitamin D insufficient (25(OH)D <30 ng/ml) and
sufficient (25(OH)D ≥30 ng/ml) participants in
vitamin D dietary intake. Multiple linear and
logistic regressions were used to examine the
relationship between vitamin D status and
vitamin D intake.

Table 1 continued
Hypotheses
1c

Independent Variable
and Assessment
Sun exposure

Dependent Variable
and Assessment
Vitamin D status

Vitamin D status and sun
exposure and related factors

Sun exposure
questionnaire

Serum 25(OH)D

Continuous

Categorical
(insufficient <30 ng/ml,
sufficient ≥ 30 ng/ml)

2a

Dual task gait speed

Vitamin D status

Vitamin D status, dual task
velocity and dual to single task
gait velocity difference.

GAITRite system will
record gait speed when
walking while counting
backward by from 50
by 1.

Serum 25(OH)D

Continuous

Categorical
(insufficient <30 ng/ml,
sufficient ≥ 30 ng/ml)
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Statistics
Sun exposure was described using frequencies,
percentages, ranges, means and standard
deviations. Spearman correlations were performed
to evaluate the relationship between vitamin D
status and sun exposure. Independent t-tests and
chi-squares were used to compare vitamin D
insufficient (25(OH)D <30 ng/ml) and sufficient
(25(OH)D ≥30 ng/ml) participants in sun
exposure. Multiple linear and logistic regressions
were used to examine the relationship between
vitamin D status and sun exposure.
Gait speed variables were described using
frequencies, percentages, ranges, means and
standard deviations. Spearman correlations were
performed to evaluate the relationship between
vitamin D status and single task, dual task and the
dual to single task difference in gait speed. Paired
t-tests were used to compare dual and single task
gait velocities. Independent t-tests were performed
to compare mean single and dual task gait
velocities between vitamin D insufficient
(25(OH)D <30 ng/ml) and sufficient (25(OH)D
≥30 ng/ml) participants. One-way repeated
measures ANOVAs were used to compare the
dual to single task difference in gait velocity
between vitamin D status categories. Multiple
logistic regressions were used to examine the
relationship between vitamin D insufficiency and
the dual to single task difference in gait speed.

Table 1 continued
Hypotheses

2b
Vitamin D status, dual task
counting rate and dual to single task
counting rate difference.

Independent
Variable and
Assessment
Dual task counting
rate
Voice recorder to
count number of
enumerate figures
when walking while
counting backwards
from 50 by 1.
Continuous

3a

Vitamin D status

Vitamin D status and
cardiometabolic risk scores
(CMRS)

Serum 25(OH)D

Categorical
(insufficient <30
ng/ml, sufficient ≥
30 ng/ml)

Dependent
Variable and
Assessment
Vitamin D
status

Statistics

Counting rate variables were described using
frequencies, percentages, ranges, means and standard
deviations. Spearman correlations were performed to
evaluate the relationship between vitamin D status and
single task, dual task and the dual to single task
Serum
difference in counting rate. Paired t-tests were used to
25(OH)D
compare dual vs. single task counting rates.
Independent t-tests were performed to compare mean
single and dual task counting rates between vitamin D
insufficient (25(OH)D <30 ng/ml) and sufficient
(25(OH)D ≥30 ng/ml) participants. One-way repeated
measures ANOVAs were used to compare the dual to
single task difference in counting rates between vitamin
Categorical
(insufficient
D status categories. Multiple logistic regressions were
<30 ng/ml,
used to examine the relationship between vitamin D
sufficient ≥30
insufficiency, and the dual to single task difference in
ng/ml)
counting rate.
Cardiometabolic CMRS was analyzed using frequencies, percentages,
Risk Score
ranges, means and standard deviations. Spearman
(CMRS)
correlations were performed to evaluate the relationship
between vitamin D status and CMRS. Independent ttests or chi-square were used to compare CMRS and
Device that
covariates between vitamin D insufficient (25(OH)D
integrates body
<30 ng/ml) and sufficient (25(OH)D ≥30 ng/ml)
composition,
participants. Multiple linear regressions were used to
ANS activity,
examine the relationship between CMRS and vitamin D
and endothelial
levels after adjusting for potential confounders.
function
Continuous
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CHAPTER II: LITERATURE REVIEW

Vitamin D Deficiency in the Elderly
Approximately one billion people in the world have deficient or insufficient levels
of vitamin D.1 The National Health and Nutrition Examination Survey 2005-2006
revealed that 41.6% of United States adults (18 years or older) had deficient vitamin D
levels, defined as 25(OH)D <20 ng/ml.2,3 The elderly are at a higher risk of vitamin D
deficiency as indicated in the National Health and Nutrition Examination Survey
(NHANES) 1988-1994 data that serum vitamin D levels were lower among adults 65
years and older compared to middle aged (40-59 years of age) and younger adults (18-29
years of age). Of these older adults, 23% and 62.5% had vitamin D deficient (<20 ng/ml)
and insufficient (<30 ng/ml) levels, respectively.4,5 The main sources of vitamin D are
skin synthesis and dietary intake. Vitamin D deficiency may be more prevalent in the
elderly population due to a complex interplay between several age-related factors
affecting these sources like decreased dietary intake, bioavailability and skin synthesis, as
discussed below.6,7

Defining Vitamin D Deficiency Based on its Main Function
Vitamin D deficiency in the elderly has received much attention as a risk factor
for falls because of its effect on musculoskeletal health, thus affecting gait.8-15 The most
studied physiological role of vitamin D is in calcium homeostasis and maintenance of
bone health through its endocrine function in the intestine, bone, parathyroid glands, and
kidneys.1 Vitamin D2 (ergocalciferol from plant sources) and D3 (cholecalciferol from
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animal sources) are transported to the liver bound to Vitamin D Binding Protein (VDBP),
where it is hydroxylated by microsomal 25-alpha hydroxylase (CYP2R1) to 25hydroxyvitamin D (25(OH)D or calcidiol).16 25(OH)D binds to VDBP and is transported
to the kidney or extra-renal tissues, where it is hydroxylated again by mitochondrial 1alpha hydroxylase (CYP27B1) to the most biologically active form, 1,25
dihydroxyvitamin D (1,25(OH) 2 D or calcitriol).16,17 This active form binds to nuclear
vitamin D receptors (VDRs) with high affinity (Kd 10-10 M compared to 25(OH)D Kd 108

M), causing VDR heterodimerization with other transcription factors like retinol X

receptors (RXR) to induce or repress genomic signaling of more than 200 target genes.16
1,25(OH) 2 D is catabolized in the kidney and extra-renal tissue by mitochondrial 24hydroxylase (CYP24A1), producing a series of 24-hydroxylated inactive metabolites.16
Serum 25(OH)D, and not 1,25(OH) 2 D (the active form), is widely accepted as the
best clinical indicator of vitamin D status. Compared to 1,25(OH) 2 D, 25(OH)D is the
major circulating form of vitamin D (500-1000 times more abundant), and it has a halflife of 2-3 weeks, compared to 4-6 hours for 1,25(OH) 2 D. Also, it reflects both dietary
and sun exposure sources from the previous 4-6 weeks, while 1,25(OH) 2 D reflects
immediate physiological needs due to the tight regulation of 25(OH)D hydroxylation and
1,25(OH) 2 D catabolism.18,19
Through the regulation of genes involved in bone remodeling, intestinal calcium
absorption, and calcium and phosphate renal reabsorption, vitamin D maintains blood
levels of calcium and phosphorus for the mineralization of bones to preserve bone
mineral density.16 It is well known that vitamin D deficiency leads to a reduction in
calcium absorption and eventually in the release of calcium from bones to maintain blood
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circulating levels of calcium. In adults, the most common manifestation of severe vitamin
D deficiency is osteomalacia, in which the newly formed bone matrix does not mineralize
and is characterized by symptoms of muscle weakness and discomfort, and throbbing
aching bone pain.20 However, studies in the last two decades have provided evidence on
roles of vitamin D that go beyond calcium homeostasis and bone health.21
Vitamin D “non-bone” effects may be achieved through its modulation of gene
expression by binding VDRs in other tissues. Recent data have shown that VDRs are
found in other tissues such as macrophages, liver, pancreas, colon, lung, breast, skin,
adipose tissue, muscle, and brain.17,22
Table 1: Vitamin D Status in Relation to Bone Health22,23
Category
ng/ml nmol/L
Clinical symptoms
Very Deficient <25
<10
Rickets, osteomalacia, myopathy
Severe hyperparathyroidism
Calcium malabsorption
Deficient
25-50 10-20
Mild hyperparathyroidism
Decreased calcium absorption
Decreased bone mineral density (osteoporosis)
May have subclinical myopathy
Insufficient
50-75 20-30
Parathyroid hormone may be high
Sufficient
75-375 30 -150 No vitamin D dependent function disturbances
Toxicity
>375
>150
Hypercalemcia
Soft tissue calcification

Recommended Vitamin D Intake, Vitamin D Sources, and the Older Adult
Vitamin D is considered a steroid hormone obtained naturally from dietary
sources and synthesized by the body from sunlight. Vitamin D is not stored in the muscle
and fat tissue until serum concentrations are higher than 20 ng/ml. Only then is the body
able to use vitamin D reserves independently of sun exposure and dietary intakes.2,23,24
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For older adults, however, reaching this vitamin D threshold is difficult due to complex
interactions between factors that affect dietary intake, bioavailability and skin synthesis.
The body of an older adult tends to draw more vitamin D reserves than a younger
person.2,23,24 Several explanations have been proposed to explain why reaching optimal
serum vitamin D levels is harder for the elderly compared to younger adults. First of all,
vitamin D intake is below recommendations for older adults. The 2010 report of the
Institute of Medicine (IOM) committee established Dietary Reference Intakes (DRIs) for
vitamin D of 600 International Units (IU) per day for adults below the age of 70, and 800
IU per day for adults over the age of 70, with a tolerable upper limit of 4,000 IU per day,
to maintain serum 25(OH)D above 20 ng/ml, which was deemed necessary to preserve
bone health.20,25-27 The Endocrine Society, however, recommended that adults over the
age of 18 should take between 1500 and 2000 IU/day, with an upper limit of 10,000
IU/day, to maintain 25(OH)D between 40-60 ng/ml and preserve physiological functions
that go beyond bone health, based on 100 IU of vitamin D3 increasing 25(OH)D by 1
ng/ml in serum.28
In the United States, very few foods contain significant amounts of vitamin D;
thus, dietary intake may minimally affect 25(OH)D status.29-31 Dietary sources include
fatty fish like salmon, tuna, sardines, and fish oil, egg yolks, organ meats, mushrooms,
and fortified foods like milk and dairy products, breakfast cereals, bread, margarine,
spreads, and vegetable oils.29,30 Supplement use may compensate for the lack of vitamin
D intake from foods. Use of vitamin D supplement has increased over time in adults, as
25% reporting use of vitamin D supplements in NHANES 1999-2002 and 37% in
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NHANES 2003-2006.32 Low vitamin D intakes from food and supplements, however,
have been reported in older adults, and it has been associated with low serum vitamin
D.6,7,33
Recommended dietary intake of vitamin D is higher for the elderly; however,
dietary intake usually decreases with age.34 This may be due to physiological and
psychological factors, such as depression, age-related lactose intolerance that limits the
intake of fortified milk products, and hormonal factors regulating satiety.3,34-39 Age is an
important and complex risk factor for vitamin D deficiency because it affects
bioavailability due to impaired gut absorption of vitamin D.3,34 Bioavailability is also
decreased due to the age-related decrease in metabolic rate with hormonal changes that
occur during aging that often result in weight gain, as seen in the growing prevalence of
obesity among the elderly in the United States.40,41 Obesity has been correlated with low
vitamin D status in the elderly, probably due to the sequestration of vitamin D by
increased body fat.3,7,34 Besides obesity, the presence of other comorbidities and
behavioral factors, such as liver, kidney, and gastrointestinal diseases, and the use of
medication, tobacco and alcohol, may directly affect vitamin D metabolism and
bioavailability.34
For those who are not taking adequate amounts of vitamin D through diet,
sunlight would often be their main source of vitamin D.17,42 Vitamin D is mostly
synthesized in the skin from 7-dehydrocholesterol after solar exposure, where ultraviolet
B (UVB, 290–315 nm) light from the sun causes a photochemical rearrangement of 7dehydrocholesterol to pre-vitamin D3, which then undergoes thermal isomerization into
vitamin D3.17,30,43,44 It is believed that sunlight exposure of arms and legs for 5-15

23

minutes at midday during the summer months could produce about 3,000 IU of vitamin
D.23 The effectiveness of vitamin D synthesis in the skin, however, is determined by skin
pigmentation, amount of skin exposed and sunscreen use, and amount of solar radiation,
which depends on the latitude, season, time of day, and time in the sun.
Darker pigmentation decreases the skin’s capacity to use sunlight for making
vitamin D because melanin absorbs UVB radiation effectively.6, 47 Ethnicity and race are
often used as a proxy for skin pigmentation, and a substantial amount of evidence that
indicates a significant difference in vitamin D deficiency between different ethnic
groups.44 For example, NHANES 2005-2006 revealed that the prevalence of vitamin D
deficiency (<20 ng/ml) was higher in blacks (82.1%), followed by Hispanics (69.2%) and
whites (30.9%).3 A more recent study evaluated vitamin D status in a communitydwelling elderly population (>60 years old) in South Florida and found a higher
prevalence of vitamin D insufficiency (<25 ng/ml) among Afro-Caribbeans (30.8%) and
African Americans (30.4%) compared to Hispanics (13%) and European Americans
(13%).45 Those with darker skin pigmentation need four to10 times more sun exposure
than lighter skin individuals.28
Unfortunately, most people avoid sunshine in order to stay cool, prevent skin
aging, and reduce the risk of skin cancer by covering the skin with clothes and using
sunscreen, all of which interfere with UVB transmission to the skin.34 A study in Europe
in 1995 showed that wearing short sleeves instead of long, and thus bearing arms as well
as the face, is associated with better vitamin D status in older people living in sunnier
climates.46 Likewise, sufficient exposure to sunlight is unusual with modern lifestyles,
since most people live and work indoors. 34 Outdoor activity is associated with vitamin D
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status as shown by an analysis of NHANES 1988-1994 data that revealed that those who
were 60 years or older and participated in daily outdoor activities had optimal vitamin D
levels (>30 ng/ml) similar to young adults.47 Furthermore, physical activity, which is
often used as a surrogate for outdoor activity, has been positively associated with serum
vitamin D levels, such that lower levels of serum vitamin D have been correlated with
physical inactivity in middle-aged and older adults.7,48
Also, the skin’s ability to synthesize vitamin D depends on the amount of solar
radiation reaching the biosphere, which depends on latitude, season and time of day.30,43
Based on the impact of sunlight exposure on vitamin D status, it has been assumed that
vitamin D deficiency is less prevalent in populations living in lower latitudes and/or
where seasonal variations are not as pronounced as in South Florida, where the weather is
sunny and warm year-round.31 In contrast, other investigators reported a prevalence of
38-40% of hypovitaminosis D (25(OH)D < 20 ng/ml) in adult men and women (>18
years old) living in South Florida.31 A more recent study evaluated vitamin D status in a
community-dwelling elderly population (>60 years old) in South Florida and found a
prevalence of vitamin D insufficiency (<25 ng/ml) of 15.6%.45
In summary, vitamin D deficiency and insufficiency in the elderly may be a result
of the complex interplay between age-related factors that affect dietary intake,
bioavailability, and skin biosynthesis. Since 90-95% of vitamin D comes from skin
synthesis, it would be expected that vitamin D deficiency is not a public health concern in
populations where sunlight for synthesis is available year round.6,7 This is not the case for
older adults living in Miami-Dade, however, and understanding the factors that affect
vitamin D status in this population is deemed necessary.
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Vitamin D, Fall Risk, and Mobility as Measured by Gait Speed in the Elderly
Besides vitamin D deficiency, falls is another common public health concern
among older adults living in Miami-Dade. Vitamin D deficiency in older adults has been
linked to important correlates of disability, including falls and fractures.49-57 The major
cause of physical disability in the elderly is mobility limitations, which eventually may
lead to falls.58 According to the World Health Organization (WHO), a fall is defined as
an event that results in the person unintentionally coming to rest on the ground or other
lower level that is not due to a major intrinsic event, like seizure, stroke, loss of
consciousness, epilepsy, or excess alcohol, or an environmental hazard like sustaining a
blow.59 It is estimated that approximately 30% of community-dwelling adults and 50% of
institutionalized adults more than 65 years of age experience one fall each year.60, 61
In the United States, the elderly population (>65 years of age) is expected to
increase by 20%-50% by the year 2030.62 Miami is the fourth city in the United States
that is graying the fastest, and Florida Department of Elder Affairs reported that the top
county for elders >60 years of age in 2010 and 2012 was Miami-Dade, with 14.9% of the
population in this age range.63 Furthermore, the Miami-Dade County Department of
Health in 2003 observed that falls were among the three leading causes of
hospitalizations due to injury (36.7% of all injury hospitalizations). Of these, 67.3% were
attributed to residents over the age of 65.64 In later years, between 2007 and 2009, falls
were the leading cause of injury of residents of Miami-Dade aged over 65 years and
responsible for 79% of injury hospitalizations. One-third of hospitalizations related to
falls resulted in hip fracture and 11% involved traumatic brain injury.65
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Falls can result in increased morbidity and mortality and decreased quality of life,
all of which translate to greater burden for the individual and healthcare system.60 Hence,
understanding the risk factors and mechanisms behind falls is important for the
development of effective interventions that protect the elderly from disability.
An extensive amount of research supports the relationship between the risks of
falls and vitamin D deficiency and the reduction of this risk by vitamin D
supplementation in the elderly.10,25,60,66-71 For instance, a recent meta-analysis found that
fallers have lower 25(OH)D concentrations (25(OH)D <20 ng/ml), more often than nonfallers.72 The mechanism by which vitamin D is related to fall risk is still unclear but it
may be through its relationship with gait and cognition.
Gait impairments are one of the main risk factors for falls in the elderly.73 Older
adults, compared to their younger counterparts, have significantly reduced gait speed73-75
and those over the age of 70 years have a 12-16% decline in gait speed per decade.76-79
This decline may be due to a compensatory adaptation to the age-related neuro-motor
changes that increase the complexity of walking to provide a safer gait. Although these
changes in gait pattern may be compensatory to stabilize posture, sometimes they are
dysfunctional and are correlated with increased risk of accidental falls.80
One of the ways vitamin D may be related to fall risk is through its role in
mobility as measured by gait speed. A systematic search of Medline Ovid found 11
observational and 6 interventional studies evaluating the relationship between vitamin D
status and gait speed, or the effect of vitamin D supplementation on gait speed in
community-dwelling older adults (Appendix A). Six of the 11 studies found a significant
positive association between vitamin D deficiency and slower gait speed. 81-85 In these
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studies, gait speed was measured on its own or as part of a physical performance battery,
and it involved different tasks such as timed walking at different distances (6 meters82,86,
5 meters84, 8 feet83, and 30 meters and returning81), or walking on electronic walkways.85
Of the six randomized controlled trials, only two found an improvement in gait speed
with vitamin D supplementation.52,87 One of the studies did not adjust for potential
confounders and included calcium supplementation and exercise training,87 while the
other did not report initial and final vitamin D levels, walking speeds, and involved other
interventions such as hormone treatment.52 In these two studies, gait speed was also
measured as part of a physical performance battery, and gait tasks included timed 6-meter
walks52 and distance walking for 12 minutes.87 These studies demonstrate that vitamin D
may play a role in mobility as measured by gait speed; however, the exact mechanism is
unclear since vitamin D can affect gait through its role in the musculoskeletal and/or
nervous systems and cognition.

Vitamin D Deficiency, Cognitive Impairment, and Executive Dysfunction in the
Elderly
Cognitive impairment is another major cause of physical disability in the
elderly.88 Cognitive and mobility problems tend to coexist in the same individual; older
adults with cognitive problems are twice as likely to fall, when compared with
cognitively normal older adults.88 Since mobility depends on the musculoskeletal and
nervous systems, it could be possible that the role of vitamin D in the risk of a fall is not
only through its effects on the musculoskeletal system, but also through its role in the
brain and cognition that affect mobility.
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Vitamin D receptors have been found to be expressed in neurons and glial cells,
especially in areas that regulate behavior and motor activity such as the limbic system,
cerebellum, hippocampus, hypothalamus, cortex, and spinal motor zones.8,89 Through
these receptors, vitamin D is involved in the expression of proteins involved in DNA
repair and genome stability, synaptogenesis and synaptic plasticity, calcium
signaling/homeostasis, neurotransmission, and differentiation and survival of neurons and
glial cells.90-95 Furthermore, vitamin D is involved in the metabolism of neurotransmitters
such as gamma-aminobutyric acid (GABA), serotonin, dopamine, and acetylcholine,
which implies its role in cognition, behavior, and motor activity.94,96-98 Recently, a study
found that older adults who had the VDR receptor FF genotype had higher MMSE scores
than the ff genotype, suggesting that single nucleotide polymorphisms may be possibly
involved in cognitive function and supporting vitamin D’s role in cognition.99
Additionally, lower vitamin D status has been associated with reduced neuronal function
in the caudal primary motor cortex, which may explain the pathophysiology of gait
disorders in older adults with lower vitamin D status.100
The association between vitamin D and cognitive status has been explored in
several studies. A systematic search in Medline, Ovid found 20 observational studies
evaluating the relationship between vitamin D status and cognitive impairment or scores
in cognitive tests in community-dwelling older adults (Appendix A). Only one
randomized clinical trial of 1,000mg of calcium carbonate and 400 IU of vitamin D3 per
day or placebo reported no association between treatment assignment and incident of
cognitive impairment.101 This trial included 4,143 women over the age of 65, who did not
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have probable dementia at baseline, and participated in the WHI Calcium and Vitamin D
trial and WHI Memory Study.
Of the 20 observational studies, 16 found a significant positive correlation
between vitamin D and cognitive impairment and/or decline5,102-109 or cognitive test
scores.108-115 The studies that found that vitamin D status was associated with the
incidence of cognitive impairment used different definitions based on either multidisciplinary meetings that evaluated standardized neuropsychological tests, physical
examination, blood tests, and MRI imaging116; pre-established characteristics107;
composite scores of different tests5; or cutoff scores in cognitive performance tests such
as the Pfeiffer Short Portable Mental State Questionnaire (SPMSQ)103, Abbreviated
Mental Test Score102, Mini Mental State Examination (MMSE)105,106,109, and Trails
Making Test B.105 The studies that found a significant association between vitamin D and
cognitive performance scores used one or more tests to assess global cognition like the
MMSE112,113,117 and/or executive function/information processing (Digit Symbol
Substitution Test109-111, Trail Making Test A110,113,115, Trail Making Test B110,113,115,118,
Block Design 110, and Verbal Fluency).110,115 Overall, these studies support the
association between vitamin D and cognition, especially in executive cognitive function.
A recent meta-analysis of cross-sectional and longitudinal studies suggests that
there is an increased risk of cognitive impairment in those with low vitamin D compared
with normal vitamin D (OR 2.39; CI 1.91-3.00; P<0.0001).119 Another meta-analysis of
observational and interventional studies showed that lower vitamin D concentration was
significantly associated with executive dysfunction in processing speed, mental shifting,
and information updating.120 Executive function refers to the cognitive processes that
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orchestrate goal-directed behavior and decision-making, such as problem-solving,
initiating and maintaining tasks, working memory (holding multiple pieces of transitory
information and manipulating it), abstract reasoning, and dividing attention.121,122
Interestingly, age-related decline in executive function is common among elderly123-125,
and it has been associated with an increased fall risk and gait impairments, including
slower gait speed, even with no obvious cognitive impairments.122,126-135
With aging the ability to perform automatic tasks, such as walking, becomes
harder and more cognitively demanding.80 According to recent evidence, age-related
deficits in mobility might be partially compensated by effortful higher order cognitive
strategies involving executive function that replace the automated sensorimotor
processing.80 As people age, their cognitive capacity, however, tends to decrease as well,
and their compensatory response becomes impaired. Hence, cognitive resources like
attention allotted to movement in older adults are no longer accessible for other activities
such as talking, avoiding obstacles, watching for traffic, or other gait-unrelated tasks.80
Consequently, older adults often have more problems than younger adults to orchestrate
tasks simultaneously, as shown by decreased gait speed and stride length and increased
stride time variability of older adults during dual task performance.80 This may be due to
lack of coordination of limited cognitive resources and decreased mental processing
speed, which is especially evident in the elderly and people with cognitive problems.
Dual task physical performance tests, in which participants are asked to perform
an automatic task like walking while performing an executive function cognitive task like
counting backwards, have been used to evaluate the interaction between cognition and
mobility as an indicator of fall risk in older adults.136 Thus, dual task physical
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performance tests can be used to assess the relationship between lower vitamin D
concentration with executive dysfunction in the context of mobility.120

Vitamin D and Other Non-Skeletal Outcomes: Cardiovascular Disease
Besides its association with fall risk and fractures, vitamin D deficiency has also
been associated with cardiovascular disease (CVD). Vitamin D deficiency and
cardiovascular disease (CVD) are prevalent worldwide.1,137 Furthermore, the prevalence
of vitamin D deficiency is high among those with CVD. Analysis of data from the
NHANES 2001-2004, showed 68% of whites, 88% of Hispanics and 97% of blacks with
CVD also had vitamin D levels, as measured by 25-hydroxyvitamin D (25(OH)D), of less
than 30 ng/ml.138,139 The possible relationship between vitamin D deficiency and CVDrelated outcomes and mortality in both diseased and healthy populations is a growing
area of research.137
Several observational studies and meta-analyses have demonstrated associations
between vitamin D deficiency and outcomes associated with CVD and CVD-related
deaths.140-154 In 2008, Wang et al.141 observed that normotensive participants from the
Framingham Offspring Study, free of CVD and with 25(OH)D of <15 ng/ml at baseline,
had a 62% higher CVD risk (i.e., myocardial infarction) over a 5.4 year follow-up.
Giovannucci et al.149 reported from the Health Professionals Follow-up study a graded
independent correlation between low 25(OH)D and myocardial infarction risk in 18,225
men aged 40-75 years, who were free of CVD at baseline. They found that those who had
levels of 25(OH)D <15 ng/ml compared to those with ≥30 ng/ml had a relative risk of
CVD of 2.1. Deo et al.140 in their report from the Cardiovascular Health Study showed
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that lower 25(OH)D levels were independently associated with increased risk of sudden
cardiac death (SCD) in healthy adults. Perna et al.142 investigated the relationship
between serum 25(OH)D and the incidence of fatal and nonfatal cardiovascular events
and found that low 25(OH)D levels were associated with a moderate increase in CVD
risk, which was stronger for fatal than nonfatal events. In their dose-response analysis,
cardiovascular risk increased at 25(OH)D <30 ng/ml. A study of 9,578 German
participants, 50-74 years of age, followed for 5 years as part of the ESTHER study, found
vitamin D deficiency (25(OH)D < 12 ng/ml) and insufficiency (25(OH)D 12-20 ng/ml)
increased overall and cardiac mortalities.148 They risk increased at 25(OH)D
concentrations of <30 ng/ml. This was supported by results from a meta-analysis in 2012
that found a linear, inverse association of 25(OH)D levels between 8-24 ng/ml and CVD
risk.147
Other systematic reviews and meta-analyses have further supported a potential
link between CVD risk and vitamin D status and the benefit of vitamin D
supplementation on heart health. A meta-analysis found strong associations between
25(OH)D and all-cause and cardiac mortality, which was consistent after adjusting for
confounders.143 Another meta-analysis of 28 studies showed that higher 25(OH)D levels
were associated with a 33% lower risk of CVD in middle-aged and elderly individuals.
Wang et al.154 reported in their systematic review of 5 prospective studies that patients
taking vitamin D supplements had a reduction in CVD-related mortality. A meta-analysis
of 18 randomized controlled trials (RCTs) showed that vitamin D intake of more than 500
IU/day improved all-cause mortality, partly by decreasing cardiovascular deaths.144,150
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Besides cardiovascular mortality in the general healthy populations, other studies
have investigated the relationship between vitamin D and heart-related outcomes in
diseased populations. Gotsman et al.151 reported that vitamin D deficiency was
significantly higher in heart failure (HF) patients compared to healthy controls, with
vitamin D deficiency being an independent predictor of increased mortality in HF
patients, and prescription of vitamin D supplementation independently associated with
reduced mortality risk. In a study by Dobnig et al.153, of the 3,258 patients referred for
coronary angiography, those within the lowest quartiles of 25(OH)D (<14 ng/ml) were at
highest risk of sudden cardiac death (SCD). Pliz et al.152 studied another cohort of
patients referred for coronary angiography over a period of 7.7 years and found that after
adjusting for CVD risk factors the risk of SCD was higher in those with severe vitamin D
deficiency (25(OH)D <10 ng/ml) compared to those with 25(OH)D <30 ng/ml. Drechsler
et al.145 found vitamin D deficiency in diabetic patients on hemodialysis was associated
with SCD, combined cardiovascular events, and mortality, after four years. They
observed that vitamin D deficiency had a three-fold higher risk of SCD compared to
those with sufficient vitamin D.

Vitamin D and Cardiovascular Health: Possible Mechanism
The mechanism by which vitamin D affects heart health is still unclear. Vitamin
D affects multiple cellular signaling pathways via genomic and non-genomic actions that
have the potential to affect cardiovascular health. These include vitamin D effects on
parathyroid hormone (PTH), the renin-angiotensin-aldosterone system (RAAS), cytokine
production, endothelial growth and function, and myocyte calcium influx.155
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Furthermore, vitamin D has also been shown to be involved in molecular mechanisms
like biosynthesis of neurotransmitters and inflammatory signaling in areas of the central
nervous system (CNS) that regulate cardiovascular activity.98,156 Vitamin D has been
shown to permeate the blood-brain barrier and bind to VDRs located in extremely high
concentrations in the midbrain and brainstem where some autonomic nervous system
(ANS) neurons are located.98,156 These findings, together with previous evidence of the
effect of vitamin D in neurotransmitter biosynthesis and nervous system activity, suggest
that vitamin D may contribute to the function of the cardiac ANS and subsequently,
contribute to CVD-risk by orchestrating non-genomic regulatory activity at higher brain
centers of the ANS.137

The Relationship Between Vitamin D and Cardiac Autonomic Nervous System
The ANS is a branch of the peripheral nervous system that controls involuntary
processes throughout the body to regulate the internal environment and body functions
like hemodynamics, blood glucose levels, sweating, and other visceral functions,
including digestion, bladder and sexual organ function, respiration, and cardiovascular
activity.157 The ANS controls autonomic body functions by the balanced opposition of
the stimulatory sympathetic (SNS) and inhibitory parasympathetic (vagal) nervous
systems (PNS). The cardiac ANS is composed of post-ganglionic sympathetic plexus of
nerves and the parasympathetic Vagus nerve, both of which innervate the heart at the
atrioventricular and sinoatrial nodes. Both act concomitantly to control cardiac
performance and thus, changes in the duration of time between heartbeats can be
attributed to changes in the balance between the SNS and PNS. Dysfunction of cardiac
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autonomic function, more specifically of the cardioprotective vagal tone, results in an
imbalance between SNS and PNS. This imbalance has been well-established as a risk
factor for adverse cardiovascular events such as SCD or congestive heart failure.158-163
Furthermore, cardiovascular autonomic neuropathy (CAN), which is a consequence of
damage to the cardiac autonomic nerve fibers, results in abnormalities in heart rate (i.e.,
reduced heart rate variability or HRV) and irregular vascular dynamics (i.e., changes in
blood flow, volume and pressure).164,165
Several lines of evidence support a relationship between vitamin D and cardiac
ANS. In animal studies, cardiac myocytes isolated from VDR knockout mice display
accelerated contractility rates when compared to wild type.166 When stimulated to
increase contractility, exposure to 1,25(OH)2D only attenuated the rapid contractility in
the wild type but not the VDR knockout cardiac myocyte, suggesting a relationship
between vitamin D and parasympathetic inhibitory activity. Another study showed that
rats fed with a vitamin D deficient diet had increased ventricular and vascular muscle
contraction and increased sensitivity to the sympathetic neurotransmitter
norepinephrine.167 In arteries of spontaneously hypertensive rats, vitamin D
supplementation normalized the relaxant and hyperpolarizing effects of the vagal
neurotransmitter acetylcholine.168 In isolated chick myocardial cells, beta-adrenergic
signal transduction was enhanced in the presence of activated vitamin D3.169
To date, very few studies have investigated the role of vitamin D in modulation of
cardiac ANS, a risk factor for poor CV-related outcomes in diseased and healthy
humans.140,153,170 Some evidence has shown a relationship between vitamin D and ANS
function in diseased populations. For instance, in 36 patients with non-ischemic dilated
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cardiomyopathy (NIDCM) 25(OH)D was positively correlated with HRV parameters,
with vitamin D insufficiency having deleterious effects on cardiac ANS function.171
Krause et al.172 showed that chronic kidney disease (CKD) patients, who have impaired
vitamin D synthesis, when exposed to short-term artificial sunlight heliotherapy had a
significant increase in 25(OH)D levels and in measurements of vagal activity that were
severely depressed at baseline. The magnitude of 25(OH)D increase was directly
correlated with the level of elevated cardioprotective parasympathetic activity, implying
that vitamin D levels may constitute an important role in the development of CVDrelated outcomes by affecting the ANS. Also, Chan et al.173 reported that patients with
CKD demonstrated poor cardiac ANS activity, which was characterized by decreased
activity of the inhibitory PNS. Furthermore, in the end-stage kidney disease (ESKD)
population, in which the prevalence of vitamin D deficiency is high, depressed HRV is
extremely common and usually presents as suppressed PNS activity with increased SNS
input to the sino-atrial node.173,174 For the doctoral dissertation by Mann, a crossover
study was conducted in which 56 participants with ESKD on hemodialysis were
randomized to either conventional (0.25 mg alfacalcidol 3 times per week plus placebo 3
times per week for 6 weeks) or intensive (0.25 mg alfacalcidol 3 times per week plus
50,000 IU ergocalciferol once a week plus placebo 2 days per week for 6 weeks) vitamin
D therapy followed by a 12-week washout period and another 6 weeks of vitamin D
therapy.174 They did not observe significant changes in measures of cardiac autonomic
tone, mineral metabolism, or RAAS activity. However, an exploratory subgroup analysis
found that after treatment participants who remained vitamin D deficient (25(OH)D <20
ng/ml), compared to those who achieved sufficiency, had significant ANS imbalance. In
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the ESKD population, the association between low vitamin D levels and SCD may be
mediated by ANS dysfunction.173,175-180
The association of vitamin D and cardiac ANS function has also been observed in
healthy adult populations. A study in 2014 observed that 25(OH)D was positively
associated with decreased HRV in a healthy Korean population over the age of 20
years.181 They observed that vitamin D deficient individuals (25(OH)D <15 ng/ml) were
3.1 times more likely to have low HRV. In 2013, Mann et al.181 used power spectral
analysis of electrocardiogram recordings to measure HRV and thus assess cardiac ANS
activity at baseline and during a graded angiotensin II challenge in 34 healthy humans.
They found a significant suppression of ANS balance in vitamin D deficient (25(OH)D
<20 ng/ml) participants at baseline, but no difference was observed during the challenge.
In an intervention study, the same group demonstrated that healthy adults supplemented
with 10,000 IU of vitamin D for four weeks had a significant improvement in cardiac
ANS balance, more specifically in enhancing the cardio-protective PNS activity.182
Studies that evaluated the relationship between vitamin D and ANS activity have
measured HRV only at baseline. Since the early 1970’s, valid cardiovascular reflex tests
have been used to assess cardiac ANS function and diagnose CAN by measuring the
variations in heart rate and blood pressure in response to the Valsalva maneuver, deep
breathing, and postural change (i.e., standing up).183 HRV parameters measured during
cardiac autonomic function tests have been proven to detect ANS dysfunction and CAN
in asymptomatic patients (i.e., patients without any symptoms of cardiovascular disease
or CVD).165,184 To date, only one study has evaluated the relationship between vitamin D
status and CAN in type 2 diabetics using cardiac autonomic reflex tests.185 In this study,
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several HRV parameters during ANS tests were assessed and scored as normal,
borderline, and abnormal to calculate a CAN risk score. They found that vitamin D
deficiency (25(OH)D <10 ng/ml) was significantly correlated with decreased HRV in the
supine and upright position, and those with vitamin D levels <10 ng/ml had significantly
increased CAN risk compared to those with 25(OH)D between 10-20 ng/ml.185

Vitamin D and Its Relationship to Other Cardiovascular Risk Correlates
Besides modulating heart rate, the ANS influences vascular dynamics and blood
pressure, which is also affected by endothelial function. Endothelial function is related to
the blood vessel's ability to dilate when necessary; therefore, dysfunction is characterized
by decreased ability to balance vasodilation and vasoconstriction, usually due to an
imbalance of nitric oxide bioavailability.139,186-189 Endothelial dysfunction is also related
to prothrombotic and proinflammatory states that increase arterial stiffness. Human
endothelial cells express VDRs, and recent studies have suggested an association between
endothelial function and vitamin D status.139,186-189 In healthy individuals, 25(OH)D
levels were independently associated with several tests of endothelial function, arterial
stiffness, and coronary flow reserve tests.187,190 Other studies have demonstrated that
vitamin D treatment improved arterial stiffness measured by pulse wave velocity.191,192
Thus, vitamin D has a role in vascular physiology by either directly affecting the
endothelium or indirectly via modulation of ANS.
The observations that vitamin D deficiency, cardiac ANS, and endothelial
dysfunction are independently linked to each other and CVD-related outcomes suggests a
potential mechanism by which vitamin D deficiency affects CVD risk.
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Literature Review Summary
Vitamin D insufficiency and deficiency are still common among older adult
populations living in communities where with more opportunity for vitamin D skin
synthesis through sun exposure, which is the main source of vitamin D.28,31,193 The
elderly population in Miami-Dade is increasing rapidly, falls are a major cause of injury
in this community-dwelling population, and vitamin D deficiency is still a major public
health issue among them.64,65,194,195 The determinants of vitamin D status are not well
documented among Miami-Dade older adults. Assessing the factors affecting vitamin D
status of this older adult community is important to help improve health outcomes such as
gait impairments and cognition related to the risk of falls.10,25,60,66-71
Furthermore, the role of vitamin D in the mechanism of falls needs further
investigation. Several studies have demonstrated an association between vitamin D
deficiency, gait impairment (slower gait speed), global cognitive impairment and
impaired executive function. Studies that investigate vitamin D status’ relationship to gait
and cognition have looked at these factors independently. A systematic search in Medline
Ovid found eight observational studies evaluating the relationship between vitamin D
status, gait and cognitive impairment, independently, in community-dwelling adults
(Appendix A). Of these, two studies found gait speed only21,196, one study found
cognitive performance only197, and five studies found that both gait speed and cognitive
performance were associated with vitamin D status.57,198-201 Among the latter four studies,
gait speed was measured as part of a physical performance battery including timed
walking at different distances (20 meters199,200, 6 meters198, and 4 meters57) or electronic
walkway201, and cognition was measured by global cognitive performance tests
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(MMSE)57,198-201 or tests of executive function (Trail Making Test B).198 Even though
evidence indicates that vitamin D levels are associated with cognition and gait,
independently, until now no cross-sectional study has evaluated how vitamin D status is
related to cognitive processing during motor activity.
In addition, vitamin D can affect other non-skeletal outcomes, like cardiovascular
health. Since CVD and vitamin D deficiency are prevalent worldwide, the relationship
between these two health problems has become a growing area of translational
research.140,153,170 Vitamin D deficiency, cardiac ANS and endothelial dysfunctions are
independently linked to each other and CVD-related outcomes, suggesting a potential
relationship between vitamin D deficiency and CVD risk. To date, very few studies have
investigated the role of vitamin D in modulation of cardiac ANS and endothelial
function.140,153,170 Furthermore, until today no study has evaluated the relationship
between low vitamin D levels and cardiometabolic risk, using a non-invasive rapid test
that integrates the assessment of other cardiovascular risk factors like body composition,
ANS activity function markers, and endothelial function markers.
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CHAPTER III: METHODS

Design
This was an observational study. Its purpose was to determine the proportion of
vitamin D insufficient individuals and investigate the correlates of vitamin D status (i.e.,
vitamin D intake, sun exposure, etc.) in community-dwelling adults over the age of 55. In
addition, it evaluated the possible relationships between vitamin D status with dual task
physical performance and cardiovascular disease (CVD) risk factors. The study used the
baseline assessment data from the parent study, which was a randomized placebo
controlled trial (RCT) that examined the effects of vitamin D supplementation on vitamin
D status, musculoskeletal health markers and physical performance, conducted by John
E. Lewis, Ph.D., Principal Investigator at the University of Miami. This study was
approved by the Institutional Review Board (IRB) at University of Miami (20120195)
and Florida International University (13-0390).

Selection of Participants and Eligibility Criteria
Table 1: Inclusion and Exclusion Criteria
Inclusion:
• Age 55 or older men and women
• English/Spanish speaking
• Community dwelling
• Scoring 0-2 errors in Short Portable
Mental Status Questionnaire (SPMSQ)
• Ability to give informed consent
• Ability to perform motor tasks without
aid
• Participating in the parent study
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•
•
•
•
•
•
•

Exclusion:
Age younger than 55 years
Not English/Spanish speaking
Living in nursing home/
institutionalized
Scoring >2 errors in SPMSQ
Unable to consent
Unable to walk without aid
Not participating in parent study

Sample Size
Using a two-tailed independent t-test with 5% significance and 80% power and
assuming an allocation ratio of 60/40 (1.5), based on published prevalence of vitamin D
deficiency in the general United States older adult population, and an effect size of 0.5
for the dual task gait speed as the primary outcome variable, the total sample size
calculated using G power statistical software was 134 (expected 54 vitamin D deficient
and 80 vitamin D sufficient). Due to financial constraints, only 101 participants were
enrolled in the study of which 4 were excluded from the analysis due to incomplete
assessments and missing data.

Recruitment
Participants for this study were recruited from the parent study at the University
of Miami. For the parent study, potential participants were identified through the
clinicians and researchers from the Department of Medicine and Psychiatry clinics on a
daily basis. The clinicians determined the level of interest in participating in the study by
briefly describing the purpose of the study without using any coercive or suggestive
language to imply that participation in the study was expected or demanded. All study
personnel were CITI certified for human research and were familiar with enrolling
patients and the issues of confidentiality and respect of human subjects in research.
Patients who expressed interest in participating in the study were instructed to call
study staff to proceed with the formal screening and enrollment process. Study staff was
informed of any potential participant who had consented to be contacted. The study staff
called the individual to set up a screening/appointment.
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Screening
Participants for the parent study were screened over the phone to determine if
they met the inclusion and exclusion criteria. Each potential participant was given a brief
introduction to the nature and purpose of the study and then asked if they would like to
participate. Once the person agreed to participate, they were administered the Short
Portable Mental Status Questionnaire (SPMSQ) to evaluate mental functioning and thus,
assess participant competency, or in other words, mental capacity to understand
information, appreciate risks/benefits of choices, make rational decisions regarding
personal health, and communicate choice during the process of informed consent.
Subjects were allowed up to 2 errors on the SPMSQ. Once they answered the SPMSQ
successfully, then they were asked a series of questions related to the general inclusion
criteria such as age, medical history, medication use and general exclusions. If responses
to the inclusion/exclusion criteria were satisfactory, those who were still interested in
participating were scheduled to undergo the consent process and their assessment visit.
Potential participants who did not meet the inclusion criteria were thanked for their time
and told they did not meet study eligibility.

Informed Consents
There were two informed consents were signed at the initial visit. The informed
consent for University of Miami explained this study and the intervention study. The
informed consent for Florida International University explained this study only. Both
informed consent forms were available in English and Spanish, and the information was
presented in a language understandable to the subject population. The consent forms
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contained the studies’ purposes, procedures, confidentiality/privacy methods,
risks/discomforts, benefits, and alternatives associated with the studies. They contained in
bold an explanation of whom to contact for answers to pertinent questions about the
studies, their subject rights, and protocols in case of any research-related injury. The
statement also had the number and contact person at both IRBs and the office numbers of
John E. Lewis, Ph.D. (the PI) and the student investigator, Johanna Lopez, in case of
additional questions or if they wanted to place any complaint.
The informed consent procedure took place in a private room in either Dr. Lewis’
office or the Department of Psychiatry and Behavioral Sciences interviewing rooms. All
of the information on the consent form was verbally explained including but not limited
to the purpose, procedures and expected duration of the study. Once the participant had
expressed interest in taking part in the study, adequate time was given to read the IRB
approved informed consent form before signing it to avoid the possibility of coercion. If
the participant was unable to read or had any limitation, the consent form was read to the
potential participant. Sufficient time was provided to allow the participant the opportunity
to consider enrollment in the study and to receive answers to any questions. Once the
informed consents were signed, the participant received a copy of both. Participants were
also asked to sign a HIPAA Research Authorization Template form, which authorizes the
researcher to use and disclose health information from medical and research records that
were relevant to the research.
Following receipt of signed informed consent, participants were assigned a study
Participant Identification (PID) number to track the participant’s responses over time. A
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master list of the participant PIDs is being kept in the PI’s office in a locked file cabinet.
Participant PIDs were created following a coded alphanumeric combination.

Assessments
Participants were reimbursed for time, travel and effort by the parent study
sponsor. The reimbursement was believed to be fair and not constitute coercion, given the
commitment required for completing the entire protocol. Once the participant consented,
the study staff collected the outcome measurements. To decrease observer bias, all
researchers were trained for administering all screening and assessments battery using
standardized procedures and uniform protocols. A research chart identified only by the
PID was created for every participant containing a checklist of documents completed
during screening and assessments and copies of socio-demographic and medical history
questionnaires, laboratory test results, and the outcome assessments in questionnaires.
Copies of the screening forms and informed consents, which contained the participant
personal information and list of PID codes, were stored separately in the principal
investigator’s locked file cabinet in his office.
The assessments were performed in 2 baseline visits, one which lasted about 3 to
3.5 hours and the second took 15 to 20 minutes. All of the participants included in this
analysis were seen between February and June 2015, before randomization to parent
study intervention. The following measures were assessed during the baseline assessment
visit for the parent study, which were used for this study:
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Vitamin D Status
Vitamin D status was measured by serum 25-hydroxyvitamin D (25(OH)D).
Fasting venous blood (15 ml) was collected from every participant by a certified
phlebotomist in the morning. The samples were sent the same day they were collected for
analysis to LabCorp (2700 N. 29th Ave, Suite 203A, Hollywood, Fl 33020) identified
with the date of the draw and the subject PID number. Lab Corp used the
immunochemiluminometric assay (ICMA) on the DiaSorin Liaison instrument to assess
serum 25(OH)D. The dynamic range of the assay is 4.0-150 ng/ml, with a functional
sensitivity of <4 ng/ml, a specificity of 100% and a high correlation with the DiaSorin
25(OH)D radioimmunoassay, which has been used as the standard for clinical diagnosis
for many years. ICMA is a competitive chemiluminescence immunoassay that uses
magnetic particles coated with 25(OH)D antibody and 25(OH)D conjugated to the
chemiluminescent isoluminol derivative. These beads are incubated with the sample, and
the 25(OH)D in the sample competes with the labeled vitamin D bound to the particles.
Then the sample is incubated with the labeled 25(OH)D tracer and the unbound material
is washed off. The sample is reacted with substances that cause a chemiluminescent
reaction that is measured by a photomultiplier. The signal is inversely related to the levels
of 25(OH)D.1 This is a highly automated test that measures total 25(OH)D, and it has
been widely used by others.

Vitamin D Intake
Vitamin D intake (continuous variable) was measured by a vitamin D and calcium
specific short food frequency questionnaire (FFQ) developed by Blalock et al.2 based on

64

the Block-National Cancer Institute Health Habits and History Questionnaire (HHHQ), a
tool that is widely used in epidemiological studies and has been previously validated for
measuring vitamin D in a population of postmenopausal women by comparing it to a 3day food records and in university employees by comparing it to 7-day food records.2-6 It
includes only 23 foods and beverages that were identified in the HHHQ as rich in either
or both vitamin D and calcium. This self-administered questionnaire asks how frequently
(never or less than once per month; 1/ month; 2-3/month; 1/week; 2/weeks; 3-4/week; 56/week; 1/day; 2-3/day) and how much of each of these foods was consumed based on
serving sizes (small, medium, large). The short FFQ is associated with a database;
therefore, allowing the estimation of nutrient intakes for the reported portion size.
Vitamin D and calcium values for the 23 foods were recorded from the Diet History
Questionnaire database developed by the National Cancer Institute, according to serving
size. The raw values were multiplied by the frequencies to calculate the amount of
vitamin D and calcium per day using Microsoft Access.2
The advantage of this instrument is that it is short; therefore, decreasing the
burden on the participant, and it does not mix many different foods into one category,
thus not affecting the respondents’ cognitive complexity.7 Furthermore, Blalock et al.2
validated this tool showing that the vitamin D and calcium intakes estimated from this
short FFQ were significantly correlated with estimates from the 7-day food diary (r=0.72
and 0.66; respectively) and the original HHHQ (r=0.65 and 0.66, respectively). Positive
predictive values of 100% for vitamin D and 91.7% for calcium were reported for the
short instrument to identify those with low intakes as based on the 7-day food record.
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Sun Exposure
Sun exposure (continuous variable) was assessed using a questionnaire developed
by Hanwell et al.8 This tool categorically measures the amount of time spent outdoors
and amount of skin exposed for every day of the week. A scoring system is used to
quantify sun exposure by multiplying time outdoors, (<5 minutes = 0; 5-30 minutes = 1;
and >30 min = 2); to amount of skin exposed (hands and face = 0; hands, face, arms = 1;
hands, face, arms, legs = 2; bathing suit = 3) for every day. The sum of the scores for
each day was added for a total score.
The researchers who developed this tool found that the sun exposure score was
significantly correlated with serum vitamin D levels during the summer, which was
mostly explained by the time in the sun than by the amount of skin exposed. The sun
exposure score, however, did not correlate with vitamin D levels during the winter.8

Dual Task Physical Performance
Dual task physical performance tests have been used to evaluate the interaction
between cognition and mobility as an indicator of fall risk in older adults.9 The dual task
physical performance test was developed with the consultation of the Department of
Physical Therapy. We conducted an extensive review of literature, overseen by Edgar
Ramos Vieira, P.T., Ph.D., to investigate the methodological variations implicated in dual
task analysis using mental tracking as the secondary task, and walking as the primary
motor task. This was done by investigating the types of mental tracking task, secondary
task outcomes, gait tasks, methods for the assessment of gait, the gait outcomes, and how
dual tasking affects gait and secondary task and predicts falls in selected studies.
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From this systematic review, it was evident that the gait task most commonly used
was straight forward walking at different distances ranging from 3 to 25 meters, at selfselected pace, using own footwear and a pressure pad system like the GAITRite. Of all
the spatiotemporal variables measured in all of the studies, decrease in speed during dual
tasking was consistently found to predict falls in older adults. In these studies, however,
speed was calculated by measuring distance and dividing it by ambulation time. Experts
suggest using pressure pads or other systems instead, because they are more reliable and
allow for the measurement of changes in other gait parameters that may be more relevant
for assessing fall risk besides speed.10 Some researchers, however, argue that a pressure
pad systems like GAITRite, which has been shown to be a reliable tool for measuring
spatiotemporal parameters in the elderly, have the limitation that they are of short length,
hence, limiting the measurement of gait variability.11 Given this shortcoming, for this
study participants were asked to repeat the trial three times to get at least ten steps.
Our review of literature also indicated that the most common mental tracking
tasks, which predicted fall outcomes, were serial subtractions by one and three. When
measuring the secondary task, different outcomes have been described from number of
enumerated figures to number of mistakes; therefore, for this study number of
enumerated figures was measured, and counting rate (number of enumerated figures
divided by time) was calculated. In most studies, task order was randomized, and
participants were not asked to prioritize either task during the dual task. When
participants prioritize either task, fewer changes are observed in that particular task.
Therefore, it is important to measure both the gait and cognitive task, because dual task
performance results from the interference that is caused by the competing demands of
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two tasks for attention resources.12,13 Hence, in the present study, task order was
randomized, and participants were not asked to prioritize either task, and thus
performance in both tasks were measured.
Despite the heterogeneity of the populations studied and the diverse sample sizes,
the results from our systematic review indicated that changes in speed and stride
variability while performing a simple gait task, such as walking in a straight line, and a
simple mental tracking secondary task, such as counting backwards from 50 by 1, using
the speed analysis method or even better, a spatiotemporal assessment system like the
GAITRite, yield enough sensitivity and predictive value for falls. Therefore, for this
study, a dual task test that involved walking in a straight line while counting backward
from 50 by 1 using the GAITRite system was used to measure gait speed as the primary
outcome variable.

Description of Dual Task Test:
After a practice walk, participants were asked to perform the following tasks in a
random order, determined from a random order table.
•

Usual walking (single gait task)

•

Counting backward from 50 by one while standing (single cognitive task)14

•

Counting backward from 50 by one while walking (dual task)

Gait Speed
Gait speed (distance walked/time; cm/s; continuous variable) was measured using
the GAITRite system (Appendix B). The GAITRite system includes a 6 meter-long and

68

64 centimeter-wide walkway mat that is used to measure spatiotemporal gait parameters
through its embedded sensors that are activated and deactivated according to foot
pressure. The participants wore comfortable, low-heeled shoes. Before each trial,
participants’ leg length was measured using a measuring tape from the trochanter of the
femur to the medial malleolus (bony part of the ankle). The GAITRite software was
initiated to enter the participant ID, height, weight and leg length. Participants were given
a demonstration of how to walk on the walkway from the start to the finish line that was
located 2 meters before and after the walkway to account for acceleration and
deceleration. Data collection was initiated by pressing “START.”
Participants were given standardized instructions for practice and data collection
trials in which they were asked to walk only or walk while dual tasking without
prioritizing either task on the GAITRite walkway at their preferred gait speed. The
instructions for the practice trials were: “This is the walkway that we will use for some
walking tests. For each walk, you must start behind the line in front of you and continue
walking until you pass the line at the other end of the walkway. To familiarize yourself
with the walkway, start at this line and walk across the mat at the pace you prefer during
daily activities. Do not run. Continue walking until you reach the line on the other side.
You can start when you are ready.” The instructions for the single gait task were:
“Starting at this line, walk across the mat at a pace you prefer during daily activities. Do
not run. Continue walking until you reach the line on the other side. You can start
whenever you are ready.” The instructions for the dual task were: “For the following test,
you will walk across the mat at a pace you prefer during daily activities while you
simultaneously count backward out from 50 by one. Do not run. If you make mistakes
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during counting keep on going. Continue walking without prioritizing either of the tasks
until you reach the line on the other side. You can start when you are ready.”
Participants were required to perform three trials per data recording session. To
ensure safety, the researcher walked beside the walkway, slightly behind the participants.
The GAITRite software was used to process the information and gather the data. The first
ten gait cycles were used in each gait condition to determine spatial-temporal gait
parameters, which were normalized by individual leg length.

Counting Rate in Secondary Cognitive Task
Counting rate (continuous variable) was used to assess cognitive secondary task
performance. It was measured by using a voice recorder while single and dual tasking.
The number of enumerated figures was defined as the number achieved at the completion
of the walking distance for the dual task. For the single task, the number of enumerated
figures was defined as those spoken during the same time required for the completion of
the dual task.15 The instructions for the single cognitive task were: “For the following
test, you will remain standing the whole time, no walking. You will count backward out
loud from 50 by one while you are standing. If you make mistakes during counting keep
on going. You can start when you are ready.” They were recorded until they stopped
walking if dual tasking or reached 30 if single tasking. The time to complete the dual task
was used to calculate the number of figures enumerated during the single task. For
instance, if the participant took 30 seconds to finish counting during the dual task, the
number of enumerated figures for the single task was counted in the first 30 seconds of
single tasking. The average of the three trials was used.
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Cardiometabolic Risk Score (CMRS)
We used the FDA approved and patented Electro Sensor Complex (ESC)
software, which combines three devices (ES-BC, TM-Oxi and SudoPath) that use
bioelectrical impedance, galvanic skin response, spectrophotometry, and an oscillometric
blood pressure device. It measures different parameters of body composition, endothelial
function and autonomic nervous system (ANS) function during baseline and the
performance of cardiac autonomic function tests.16,17 Steps of the procedure are shown in
Appendix B. Briefly, study staff, trained by the manufacturer, asked participants to sit on
a comfortable chair with their shoes and socks off, feet on the metal plates, right index
finger in the pulse oximeter, and blood pressure cuff on the left arm. After inputting
demographic, anthropometric and physical activity data, the software initiated the
baseline assessment for 1-2 minutes while the participant was sitting relaxed. Then the
participant was asked to perform the Valsalva maneuver by clamping their nose with
their left hand while trying to breath out for 15 seconds with their mouth closed, building
pressure like when popping ears. After releasing their nose, participants were asked to
breath deeply for 30 seconds, inhaling for 5 seconds and exhaling for 5 seconds. Finally,
participants were asked to stand up, while straightening their left arm to their side and
keeping their index finger in the pulse oximeter. The whole assessment lasted about 5
minutes.
Details of the devices are discussed in previous publications and the
manufacturer's website (http://www.ldteck.com).16,17 The Electro-Sensor Body
Composition (ES-BC) device uses a single-frequency bioelectrical impedance analyzer in
a tetrapolar mode to measure current, voltage, and phase angle to calculate impedance
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resistance and reactance.16 This information is used by the software to compute percent
body fat mass (%FM) using accepted peer-reviewed published algorithms tailored to the
general and obese population based on gender, height, weight, age, and activity level.16,1821

The accuracy of ES-BC has been compared to dual-energy X-ray absorptiometry

(DXA) and found an adequate relative and absolute agreement for %FM between both.16
The TM-Oxi system assesses cardiac autonomic nervous system ANS function,
including both sympathetic (SNS) and parasympathetic nervous systems (PNS), during
baseline and validated cardiac autonomic reflex tests (i.e., Valsalva maneuver, deep
breathing, and change from sitting to standing) (Appendix B).22 The software uses an
automatic oscillometric blood pressure device and pulse oximeter, which uses an optical
technique (spectrophotometry) to measure vascular dynamics and HRV.23,24 Briefly, the
pulse oximeter directs red and infrared light into the nail bed area of the right index
finger, which is absorbed, reflected, and scattered by blood hemoglobin. During systole,
the arteries’ diameter increases as blood fills the capillary beds at the fingertip, increasing
the concentration of hemoglobin in the vessels in the nail bed and thus affecting the
absorption, reflection and scattering of light that is measured by the photosensor. The
change in light absorption, reflection, and scattering between systole and diastole creates
a pulsatile signal or waveform, illustrated as a plethysmograph (PTG), which varies in
time with each heartbeat (Appendix B). From the time domain, the TM-Oxi calculates the
standard deviation of the normal wave ( SDNN, the variation between each successive
heart beat) and the square root of the mean squared differences of successive normal to
normal R-R intervals (RMS SD, indicator of parasympathetic activity) (Appendix B).25
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The TM-Oxi applies a mathematical algorithm, the Fast Fourier Transform (FFT),
to the PTG recording (FFTPTG) to manipulate the beat to beat RR intervals into a sine
wave function thus converting the signal from a time domain to a frequency domain
(Appendix B). The frequency domains are then categorized by oscillating frequency,
which are the three frequencies of HRV: (1) very low frequency (PTGVLF) associated
with thermoregulation and sweating that results in oscillation in vasomotor tone
controlled by SNS; (2) low frequency (PTGLF) related to baroreflex which is under
control of both SNS and PNS; and (3) high frequency (PTGHF) associated with R-R
interval changes associated with breathing under PNS control. 17 From these components,
the software calculates PTG total power (PTGTP, the sum of the areas under the curve
covered by the 3 frequency domains) and PTG index (PTGi, the sum of the amplitudes of
the 3 frequency domains) which are used to assess baseline ANS function (Appendix B).
After baseline evaluation, the software measures heart rate and blood pressure
changes during autonomic reflex tests (Appendix B). The first test to be performed is the
Valsalva maneuver in which the participant is asked to perform a moderately forceful
exhalation against a closed airway by pinching the nose shut, closing the mouth, and
pressing out like popping the ears for 15 seconds and then breathing normally.16,17 This
test involves 4 phases: (1) straining and beginning on intrathoracic pressure increase; (2)
maintenance of increased intrathoracic pressure, resulting in decreased systemic blood
pressure and increased heart rate; (3) release of breathing and sudden drop in
intrathoracic pressure; and (4) transient bradycardia resulting from the baroreflex
response to the sudden increase in aortic pressure due to increased cardiac output. Phase
2 can be divided into 2 phases: (1) early phase in which preload and stroke volume are
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reduced causing a fall in cardiac output despite tachycardia that resulted from decreased
vagal activity; and (2) late phase in which total peripheral resistance rises due to
increased sympathetic discharge and plasma epinephrine concentration, stopping the fall
in blood pressure. The vagal function is evaluated by calculating the heart rate ratio
(Valsalva ratio) during phase four and two, which are compared to age-adjusted normal
Valsalva ratios. Sympathetic function is evaluated by the beat to beat blood pressure
response during phase 2 and phase 4.16,17
The second autonomic reflex test is deep breathing, which measures PNS function
since the vagal nerve mediates heart rate changes in response to deep breathing.16,17
During the inspiration phase, intrathoracic pressure is reduced, decreasing venous return
from the pulmonary circulation to the left atrium, decreasing preload, and thus causing an
increase in heart rate to compensate and maintain cardiac output. During expiration, the
opposite happens. Vagal function during this test is measured by the heart rate ratio
between expiration and inspiration (E/I ratio). The final cardiac autonomic reflex test is
changing in posture. The participant is in a seated position and asked to stand up. Heart
rate increases during the first 15 seconds and decreases until it stabilizes at 30 seconds.
At the same time, the blood pressure increases at the standing position, and this change
should be greater than 10 mmHg when compared to blood pressure while sitting. PNS is
evaluated by measuring the heart rate ratio at 15 and 30 seconds (K30/15). SNS is
evaluated by measuring the systolic blood pressure response to standing (BPRS).16,17
PTG also provides information about arterial stiffness and endothelial function.
The TM-Oxi system quantizes PTG into a digital volume pulse (DVP) waveform that
represents the pressure wave that spreads from the heart to the periphery (systolic peak)
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and reflects back to the heart (diastolic peak) during the cardiac cycle.17,26-28 Arterial
stiffness, which is partially a result of endothelial dysfunction, is defined as the
opposition to the pressure wave in the arteries, resulting in abnormal systolic and
diastolic peaks. Thus, the DVP waveform, which may be affected by perfusion and body
temperature, is mainly regulated by myocardial and arterial characteristics and is used by
the software to calculate indicators of vascular health and arterial status (i.e., reflection
index, and stress index).16,17
Finally, the SudoPath system measures sudomotor activity, which is controlled by
post sympathetic cholinergic nerve fibers (C-fibers) that innervate sweat glands, using 2
stainless steel electrodes on which the participant places the soles of the feet, where very
high density of sweat glands are located.17 This system evaluates skin blood flow
(microcirculation), C-fiber condition, and sweat gland activity using galvanic skin
response. Briefly, the SudoPath system measures the electrical conductance of the skin
that is dependent on the amount of sweat-induced moisture. The device generates a low
voltage signal with weak DC current that is fed to the active electrode, passes through
interstitial fluid, and reaches the skin in contact with the passive electrode. This current
electrically stimulates C-fibers, which release acetylcholine, and thus, stimulate nicotinic
muscarinic receptors (M-receptors) in the skin and sweat glands.17,29 In the skin,
activation of M-receptors result in nitric oxide (NO) production, which causes
vasodilation of vascular smooth muscle and increase blood flow to the skin. In the sweat
glands, activation of M-receptors result in chloride movement across the apical
membrane of sweat gland cells, depolarizing it and thus generating a negative potential
that drives water and sodium into the lumen of the sweat gland cells to produce sweat.29
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The change in blood flow and sweat production disturbs the electrical conductance of the
skin, which is then measured by the device using the principles of electrolysis as the
electric skin response to nitric oxide, a marker for SNS function.17
The ESC complex software calculates the cardiometabolic risk score (CMRS)
using the variables input into the software (age, gender, height, weight, and physical
activity level) and those measured by the three devices (systolic and diastolic blood
pressure, ANS function and endothelial function) during baseline and autonomic cardiac
reflex tests. Appendix B shows the ten markers (in gray) and the variables used to
calculate the score for each marker. Each marker measured is scored as 0=normal,
1=borderline or 2=abnormal and then used to calculate CMRS, which is normal if ≤4, or
represents mild risk (5-7), moderate risk (8-10) or high risk (≥11) (Appendix B).17
Previous studies have shown the accuracy of these three devices, compared to
standardized assessments of body composition, ANS activity, and cardiac output, thus
supporting the usefulness of these devices in detecting complications related to metabolic
syndrome, diabetes and CVD.16 Recently, a study comparing diabetic and healthy
controls showed that the CMRS calculated by this software is significantly correlated
with glucose and insulin measured during the oral glucose tolerance tests (OGTT) and
was significantly higher in participants with diabetes. Also, specificity (92%) and
sensitivity (83%) were high for the CMRS in differentiating patients with diabetes and
healthy controls.17
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Assessment of Potential Covariates and Other Outcomes for All Specific Aims:
Sociodemographics were assessed by a questionnaire developed by parent study
staff that asked about gender, marital status, race/ethnicity, socioeconomic status, and
other.
Health history and medications were assessed by a questionnaire developed by
parent study staff on current health status and medication use. It included questions about
the participant’s current health status that was used to confirm inclusion criteria and for
data analysis purposes. It asked whether they were currently under the care of a
healthcare professional, had seen the health care professional in the past three months
(specifying reason), had surgeries or hospitalization (including dates and reasons), had
injuries like fractures, dislocations ,or sprains (including date), and had any diagnosed
diseases or conditions. It also asked about the use of prescription and over-the-counter
medications and vitamin/dietary supplement use. The questionnaire asked about health
risk behaviors including coffee and alcohol consumption and smoking status. The final
section asked about the history of falls in the past 12 months and the reason for the fall.
Physical activity, which may be a surrogate for outdoor activity, has been
positively associated with serum vitamin D levels such that lower levels of serum vitamin
D have been correlated with physical inactivity in middle-aged and older adults, and was
measured using the International Physical Activity Questionnaire (IPAQ).30,31 The IPAQ
provides individual domain-specific scores for walking, moderate-intensity, and vigorous
activity within the domains of work, transportation, domestic chores and gardening, and
leisure-time.32 The tool asks about the time spent doing a specific physical activity in the
last seven days, defining for the participant vigorous physical activity as that which takes
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hard physical effort and makes breathing harder than normal and moderate activaties as
that which takes moderate physical effort and makes breathing somewhat harder than
normal. For total scores, the duration (in minutes) and frequency for all types of activities
in all domains are summed, while specific domain scores are calculated by the
summation of the walking, moderate-intensity, and vigorous-intensity activities within
the specific domain. The scores for the specific type of activity across domains are added.
To measure the volume of activity, each type of activity is weighted by its energy
requirement defined as the MET-min. METs are metabolic equivalents that are computed
for each specific activity using formulas defined in the manual (see below for example)
and then MET is multiplied by the minutes performed. These MET-minute scores are
equal to kilocalories for a 60 kg person; therefore, kilocalories for a specific individual
may be calculated by multiplying the MET-min by the person’s weight divided by
60kg.32
The IPAQ was developed to derive comparable measurements of physical activity
in international settings; therefore, being suitable for use in different languages and
cultural contexts like in an ethnically-diverse city as Miami.33,34 It has also been validated
in different age groups against objective measures of physical activity, physical fitness
and health outcomes. 35 For instance, it was validated in an adult population (mean ± SD:
40.7 ± 10.3 years old) and found to have a strong positive relationship with an activity
monitor and a physical activity log (rho=0.55, P<0.001).36 It has also validated and used
in a population of elderly men and found to be reliable (test-retest reliability of 0.95) and
valid as compared against pedometer use and the physical activity log with similar results
reported for postmenopausal women. 37,38 Other studies have validated the IPAQ and used
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it successfully in populations of middle-aged and older adults and adults with different
diseases, like schizophrenia and breast cancer.34,39-42 The IPAQ correlated with
measurements to other physical activity assessment methods, such as the 2001 Behavioral
Risk Factor Surveillance System (BRFSS) physical activity, accelerometers, and energy
expenditure as measured by doubly-labeled water, among others.35,43-46
Depressive symptoms were measured as a potential covariate since it has been
associated with vitamin D deficiency.47,48 In addition, those who are depressed tend to
walk slower and take a longer time to respond to cognitive challenges.49 Depression was
assessed using the Beck Depression Inventory (BDI), which measures the existence and
severity of depressive symptoms based on the DSM-IV. It is a self-report 21-item
instrument to assess the existence and severity of depressive symptoms based on the
DSM-IV; thus having content validity. Each item corresponds to a symptom of
depression and has a four-point scale ranging from 0 to 3, except for two items that have
seven options to indicate decrease or increase in appetite and sleep. The score of all items
is summed to give a single score. A total score of 0-13 is considered minimal, 14-19
mild, 20-28 moderate, and 29-63 severe.47 Construct validity has been assessed on its
ability to differentiate non-depressed and depressed patients (0.92 for outpatients and
0.93 for college students). Test-retest reliability was found to be significant at 0.93. This
tool has been used in populations ages 13-80 years.47,50-52 In an elderly population, BDI-II
has good internal consistency (0.86), has been positively correlated with other measures
of depression, measures of stress, anxiety, and negatively to well-being. Research with
this toll has shown that there are no statistically significant effects for ethnicity, gender,
and age on BDI-II scores.53 Because item 9 of the BDI inquires about “suicidal thoughts
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or wishes,” we immediately notified Dr. Judi Woolger, study physician at the University
of Miami Internal Medicine Department, if a participant responded affirmatively to this
question, which may be indicative of suicidal ideation (SI).
Fear of falling was another potential parameter that may have interfered with the
physical assessment battery; therefore, it was assessed using the Fall Efficacy Scale
International (FES-I), which is a 16-question assessment tool that evaluates the fear of
falling while performing everyday activities.49,54 Participants were asked to rate on a
scale of 0 to 4 how concerned they are about the possibility of falling while performing
these activities with 0 meaning “not at all concerned,” 1 being “a little concerned,” 2
being “somewhat concerned,” 3 being “fairly concerned” and 4 being “very concerned.
The scores of every item were added and used as a score out of 64. The higher the score,
the more the concern for falling while performing these activities.54 The FES-I was
developed by the Prevention of Falls Network Europe (ProFaNE) to measure the
elderly’s level of concern about falling while performing physical and social activities
inside or outside the home.55 This tool is based on the original Falls Efficacy Scale, 56
which measures the levels of confidence in performing certain activities without falling,
and it is correlated with measures of balance and gait. FES also predicts future incidence
of falls and decline in physical functioning, and it is sensitive to change in fear after
clinical interventions.57-65 The FES-I was adapted from the original FES to be used in
different languages, including Spanish, and cultural contexts, which deems it appropriate
for the culturally-diverse population in Miami.
Both the internal and test-retest reliabilities of FES-I are 0.96. The inter-item
correlation ranged from 0.29 to 0.79 with an average of 0.55.55 FES-I responses were
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significantly different between those who reported no falls, one fall, and multiple falls in
the last year. They were also significantly higher in older participants, women, and those
with lower occupational categories. Furthermore, those who reported a fall risk factor like
falling in the past year, chronic diseases, polypharmacy, use of psychoactive medication,
and dizziness also had higher total FES-I scores. These data indicate FES-I is sensitive to
group differences related to risk factors and demographics.55 FES-I convergent validity
has been confirmed for fall history, depression, disability, quality of life, and physical
impairment (poor balance, slow gait, low muscle strength), and its predictive validity has
also been confirmed, since it can discriminate between certain risk factors for falling,
overall disability, and multiple fallers after 12 months.59,66-72 Scores above 23 may
indicate a high concern of falling.71
Anthropometrics were measured to assess for obesity. Obesity, whether it is
measured using body mass index (BMI), waist circumference (WC), or waist-to-hip ratio
(WHR), has been linked to vitamin D deficiency.73-75 Obesity also increases the risk of
impaired physical function.76 Therefore, obesity in this population was measured using
BMI. Height was measured using a stadiometer with a movable headpiece. Participants
were asked to stand with their back to the height rule with their feet together, while the
back of the head, back, buttocks, calves, and heels touched the upright tape. The
participant was asked to look straight ahead so that the ear canal was level with the cheek
bone. The headpiece was lowered so that the hair was pressed flat. Weight and height
were recorded to the nearest 0.1 kg and 0.1 cm, respectively. Participants were asked to
remove shoes, and heavy outer garments like coats, and to stand in the center of the
balance so that the weight is distributed evenly on both feet. Participants were asked to

81

stand with their back to the height rule with their feet together, while the back of the
head, back, buttocks, calves, and heels were touching the upright tape. The participant
was asked to look straight ahead so that the ear canal level with the cheek bone. The
headpiece was then be lowered so that the hair was pressed flat. Weight and height were
recorded to the nearest 0.1 kg and 0.1 cm, respectively. BMI was calculated using the
formula: weight (kg)/ height (m)2 and accordingly, participants were classified into
categories based on the National Heart, Lung and Blood Institute recommendations:
underweight (<18.5 kg/m2), normal weight (18.5-24.9 kg/m2); overweight (25-29.9
kg/m2), and obese (>30 kg/m2).
BMI is not a good measure of body composition and adiposity because it does not
distinguish between lean mass and fat mass. Since one of the theories that explain the link
between vitamin D deficiency and obesity is the sequestration of vitamin D in adipose
tissue, %FM was also measured in this population using the ES-BC device described
above, which utilizes bioelectrical impedance (BIA).77 Furthermore, the incidence of
CVD is also linked to vitamin D deficiency; therefore, WC and WHR were used to
measure body fat distribution around the abdomen and evaluate the risk of CVD.75,78,79
WC was measured at the umbilicus and hip circumference (HC) was measured at the
broadest circumference below the waist. Both of these measurements were done using a
flexible but not stretchable measuring tape in three replicates to ensure reliability. The
average of the three values were used to calculate WHR by dividing WC by HC.
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Data Management
The security and confidentiality of participant’s information are of greatest
concern, and appropriate data management procedures, and security clearances were
established. The confidential nature of the data was maintained by using unique PID
numbers, which were used in all research forms. The list of participants with their
assigned PIDs and the research charts were kept in a locked cabinet in the locked office
of the PI. The questionnaires and forms were carefully reviewed for completeness and
illogical, inappropriate, and discrepant responses. Data entry was started simultaneously
with the receipt of completed questionnaires and assessment forms. After entry of data
into the computer, the data were verified, checked for inconsistencies, and edited using
PIDs. Regular checks of the data were used to identify duplicate and missing data. In
cases of duplicate or missing data, the research coordinator was notified immediately.

Statistical Analysis
Data were analyzed using frequencies, percentages, ranges, means, and standard
deviations. Independent t-tests or chi-square were used to compare socio-demographic
characteristic between vitamin D status groups. Pearson (for two or more continuous
variables) and Spearman (for two or more categorical variables) correlations were
performed to evaluate the relationship of (1) vitamin D status categories to vitamin D
intake and sun exposure; and (2) vitamin D status categories to dual task gait velocity and
counting rate, and the dual to single task difference in gait velocity and counting rate; and
(3) vitamin D status and CMRS. Independent and dependent variables were also
correlated with potential covariates, such as gender, age, and race/ethnicity to determine
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the presence of multicollinearity. If multicollinearity existed between any independent
variable and one of the dependent variables of interest, then multiple linear or logistic
regressions were performed. Independent t-tests and chi-squares were used to compare
potential covariates between vitamin D insufficient and sufficient groups. Independent
sample t-tests were performed to determine differences between vitamin D sufficient and
insufficient groups in CMRS, single task and dual task gait velocity and counting rates.
Paired t-tests were used to compare single to dual task gait velocity, and counting rates in
the whole population and within each vitamin D status group. One-way repeated
measures ANOVA was used to determine the dual to single task difference between
vitamin D status categories. Multiple linear and logistic regressions were used to examine
the relationship between vitamin D status and possible correlates. Multiple logistic
regressions were used to examine the group effect (based on dual to single task difference
in gait speed and counting rate) on vitamin D status. Multiple linear regressions were also
used to examine the effect size and the change in CMRS for one unit change in vitamin D
levels when controlling for covariates. The significance level was set at α=0.05, and
statistical analyzes were performed using SPSS 21. The following table summarizes the
hypotheses, and the statistical analysis used for hypothesis testing.
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Table 2: Statistical Analyzes Methods for individual Hypotheses
Hypothesis Statistical Analyses
Hypothesis Vitamin D status was described using frequencies, percentages, ranges,
means and standard deviations. Spearman’s correlations were used to
1a
estimate, associations between vitamin D status and correlates.
Analyses
Independent t-tests and chi-squares were used to compare potential
correlates of vitamin D status between vitamin D insufficient (25(OH)D
<30 ng/ml) and sufficient (25(OH)D ≥30 ng/ml) participants. Multiple
linear and logistic regressions were used to examine the relationship
between vitamin D status and explanatory variables.
Hypothesis Vitamin D intake was described using frequencies, percentages, ranges,
means, and standard deviations. Spearman correlations were performed
1b
to evaluate the relationship between vitamin D status and vitamin D
Analyses
intake. Independent t-tests were used to compare vitamin D insufficient
(25(OH)D <30 ng/ml) and sufficient (25(OH)D ≥30 ng/ml) participants
in vitamin D dietary intake. Multiple linear and logistic regressions were
used to examine the relationship between vitamin D status and vitamin D
intake.
Hypothesis Sun exposure was described using frequencies, percentages, ranges,
means, and standard deviations. Spearman correlations were performed
1c
to evaluate the relationship between vitamin D status and sun exposure.
Analyses
Independent t-tests and chi-squares were used to compare vitamin D
insufficient (25(OH)D <30 ng/ml) and sufficient (25(OH)D ≥30 ng/ml)
participants in sun exposure. Multiple linear and logistic regressions were
used to examine the relationship between vitamin D status and sun
exposure.
Hypothesis Gait speed variables were described using frequencies, percentages,
ranges, means, and standard deviations. Spearman correlations were
2a
performed to evaluate the relationship between vitamin D status and
Analyses
single task, dual task, and the dual to single task difference in gait speed.
Independent t-tests were performed to determine the difference in mean
single and dual task gait velocities between vitamin D insufficient
(25(OH)D <30 ng/ml) and sufficient (25(OH)D ≥30 ng/ml) participants.
Paired t-tests were performed to compare dual and single task gait
velocities. One-way repeated measures ANOVAs were used to compare
the dual to single task difference in gait velocity between vitamin D
status categories. Multiple logistic regressions were used to examine the
relationship between vitamin D insufficiency and the dual to single task
difference in gait speed.
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Table 2 continued.
Hypothesis Statistical Analyses
Hypothesis Counting rate variables were described using frequencies, percentages,
ranges, means, and standard deviations. Spearman correlations were
2b
performed to evaluate the relationship between vitamin D status and
Analyses
single task, dual task, and the dual to single task difference in counting
rate. Independent t-tests were performed to determine the difference in
mean single and dual task counting rates between vitamin D insufficient
(25(OH)D <30 ng/ml) and sufficient (25(OH)D ≥30 ng/ml) participants.
Paired t-tests were performed to compare dual and single task counting
rates. One-way repeated measures ANOVAs were used to compare the
dual to single task difference in counting rates between vitamin D status
categories. Multiple logistic regressions were used to examine the
relationship between vitamin D insufficiency and the dual to single task
difference in counting rate.
Hypothesis CMRS was analyzed using frequencies, percentages, ranges, means, and
standard deviations. Spearman correlations were performed to evaluate
3a
the relationship between vitamin status and CMRS. Independent t-tests or
Analysis
chi-squares were used to compare CMRS and covariates between vitamin
D insufficient (25(OH)D <30 ng/ml) and sufficient (25(OH)D ≥30
ng/ml) participants. Multiple linear regressions were used to examine the
effect size and the change in CMRS expected from a one-unit change in
vitamin D levels after adjusting for potential confounders.
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CHAPTER IV: CORRELATES OF VITAMIN D DEFICIENCY IN SOUTH
FLORIDA OLDER ADULTS
Abstract
Objective: The purpose of this cross-sectional analysis is to determine the proportion of
vitamin D insufficient individuals and correlates of vitamin D status in an older adult
population (>55 years of age) living in Miami-Dade, Florida.
Methods: Participants (n=97) completed assessments that included vitamin D serum
levels, surveys to evaluate vitamin D intake, sun exposure, and other variables.
Spearman’s correlations, independent t-tests, chi-squares, and multiple linear and logistic
regression were used to examine the relationship between vitamin D status and
explanatory variables.
Results: The proportion of individuals with vitamin D deficiency (25(OH)D <20 ng/ml),
insufficiency (20-30 ng/ml) and sufficiency (≥30 ng/ml) were 10.3%, 36.1% and 53.6%,
respectively. Vitamin D status correlated significantly with higher vitamin/mineral
supplement use (P=0.014), and lower % fat mass (P=0.008) in linear regression models,
and increased sun exposure (P=0.016) in logistic regression models. However, ethnicity
was consistently an independent predictor of vitamin D levels in both analyses (P=0.023
and P=0.010, respectively), with Hispanics being at higher risk of insufficiency.
Conclusions: Since vitamin D deficiency is linked to health risk factors, it is important
that health professionals become aware of the connections of vitamin D status with
intake, bioavailability, and skin synthesis, to identify those at risk and develop and plan
pertinent interventions to prevent and correct deficiency.
Keywords: vitamin D insufficiency, vitamin D intake, sun exposure, elderly
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Introduction
Vitamin D deficiency in the elderly has been linked to factors associated with
disability, including cognitive impairment, poor physical performance, and increased risk
of falls and fractures.1-7 The elderly is at higher risk of vitamin D deficiency as shown by
National Health and Nutrition Examination Survey (NHANES) 1988-1994 data that
indicated serum vitamin D levels were lower among adults 65 years and older, compared
to middle aged (40-59 years of age) and younger adults (18-29 years of age).8,9 Vitamin
D is considered a steroid hormone obtained naturally from dietary sources and skin
synthesis and stored in muscle and fat tissue. The body can use muscle and fat reserves
independent of sun exposure and dietary intake, only when vitamin D concentrations are
lower than 20 ng/ml.10-12 For older adults, reaching this vitamin D threshold is difficult;
they become more dependent on their vitamin D reserve, as they encounter more barriers
for adequate dietary and skin sources, which place them at higher risk of deficiency and
insufficiency. This may be a consequence of a complex interplay between age-related
factors that affect dietary intake, bioavailability, and skin biosynthesis.10-12
In the United States, very few foods contain significant amounts of vitamin D. For
those who are not taking adequate amounts of vitamin D through diet or supplement use,
sunlight would often be their main source of vitamin D.13,14 Vitamin D is mostly
synthesized in the skin when ultraviolet B (UVB, 290–315 nm) light from the sun causes
a photochemical rearrangement of 7-dehydrocholesterol to pre-vitamin D3, which then
undergoes thermal isomerization into vitamin D3.13,15,16 The skin’s ability to synthesize
vitamin D depends on the amount of solar radiation reaching the biosphere that depends
on latitude, season, and time of day.15,16 Since 90-95% of vitamin D comes from skin
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synthesis, it would be expected that the prevalence of vitamin D deficiency and
insufficiency to be lower in a populations where sunlight for synthesis is available year
round.17,18 Thus, it has been assumed that vitamin D deficiency and insufficiency is less
prevalent in populations living at lower latitudes and/or where seasonal variations are not
as pronounced like in South Florida, one of the southernmost regions of the United States
(latitude 25.46N) where the weather is sunny and warm all year.19 However, research has
shown a considerable amount of vitamin D deficient and insufficient individuals. A
previous study reported a prevalence of 38-40% of hypovitaminosis D (25(OH)D <20
ng/ml) in adults (≥18 years old) living in South Florida.19 Lagari et al.20 found that 35%
of participants in a study conducted in Miami-Dade were vitamin D insufficient
(25(OH)D <30 ng/ml). Another study conducted in Boca Raton, Florida, evaluated
vitamin D status in a community dwelling elderly population (≥60 years old) and found
an occurrence of vitamin D insufficiency (25(OH)D <25 ng/ml) of 15.6%.21
The determinants of vitamin D status in the elderly population in Miami–Dade
have not been well studied. This is important because Miami occupies the fourth place
among cities that are graying the fastest, and it is the top county for elders, with 14.9% of
the Miami-Dade population being over the age of 65.22 Understanding the factors that
affect vitamin D status in this growing population of older adults, who have an increased
opportunity for skin biosynthesis via sun exposure, is critical to promote public health
initiatives aimed to correct and prevent nutritional deficiencies. Therefore, the purpose of
this cross-sectional analysis was to evaluate correlates of vitamin D insufficiency in older
adults living in Miami-Dade.
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Methods
Study Design and Setting
This study was approved by the IRBs of Florida International University (130390) and the University of Miami (20120195).

Participants
The study enrolled 101 participants, and four were excluded due to missing data
(n=97). Participants for this study were recruited from the parent study, a double-blinded
randomized placebo-controlled clinical trial that examined the effects of vitamin D
supplementation on vitamin D level, bone formation, resorption, and mineral density,
flexibility, and balance in the elderly, which was conducted at the University of Miami.
Briefly, each potential participant was screened over the phone by administering the
Short Portable Mental Status Questionnaire (SPMSQ)23 to evaluate mental functioning
(allowed up to 2 errors) and questions regarding general inclusion criteria such as age,
and medical, pharmacological and general exclusions. Inclusion criteria for this study
included: (1) Men and women age 55 or older; (2) English and Spanish speakers; (3)
Community-dwelling; (4) Ability to give informed consent; (5) Ability to perform motor
tasks without aid; and (6) Participating in the parent study. All participants in this study
were required to sign IRB approved informed consents for both the University of Miami
and Florida International University.
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Biomarkers
Vitamin D Status
Vitamin D status was measured by serum 25-hydroxyvitamin D (25(OH)D).
Fasting venous blood (15 ml) was collected from every participant by a certified
phlebotomist in the morning after fasting. The samples were sent the same day for
analysis to LabCorp (2700 N. 29th Ave, Suite 203A, Hollywood, Fl 33020) that used
immunochemiluminometric assays (ICMA) on the DiaSorin Liaison instrument to assess
25(OH)D. This is a highly automated test that measures total 25(OH)D, and it has been
widely used by others.24

Surveys
Sociodemographics, Health History, Health Risk Behaviors and Medications
Sociodemographic and health-related data were collected using questionnaires
developed by staff of the parent study that asked about gender, marital status,
race/ethnicity, socioeconomic status, education, income, current medical diagnoses,
medication/ supplement use and health risk behaviors such as coffee, alcohol, and
tobacco use.

Vitamin D Intake
Vitamin D intake was assessed using a vitamin D and calcium specific short food
frequency questionnaire (FFQ) developed by Blalock et al.25, which is based on the
Block-National Cancer Institute Health Habits and History Questionnaire (HHHQ). It
includes only 23 foods and beverages that were identified in the HHHQ as rich in either
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vitamin D, calcium or both. The short FFQ is associated with a database; therefore,
allowing the estimation of nutrient intakes for the reported portion size. The raw values
were multiplied by the frequencies to calculate the amount of vitamin D and calcium per
day using Microsoft Access.25 Blalock et al validated this tool and the vitamin D and
calcium intakes estimated from this short FFQ were significantly correlated with
estimates from the 7-day food diary (r=0.72 and 0.66; respectively) and the original
HHHQ (r=0.65 and 0.66, respectively).25 Positive predictive values of 100% for vitamin
D and 91.7% for calcium were reported for the short instrument in its ability to identify
those with low intakes as based on the 7-day food record.

Sun Exposure
Sun exposure was assessed using a questionnaire developed by Hanwell et al.26
This tool measures the amount of time spent outdoors and the amount of skin exposed for
every day of the week using a scoring system. The original questionnaire by Hanwell et
al. was developed for hospital workers in Southern Italy and designed to report the sun
exposure within the last week by recording time outdoors (<5 min; 5-30 min; >30 min)
and amount of skin exposed (hands and face; hands, face and arms; hands, face and legs;
bathing suit). The amount of time spent outdoors was multiplied by the amount of skin
exposed for every day of the week. The sum of the seven days was used as the sun
exposure scores. These researchers found that the sun exposure score was significantly
correlated with serum vitamin D levels during the summer, which was mostly explained
by the time in the sun than by the amount of skin exposed. Other researchers have
validated this tool in other populations in South Florida.27,28
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Physical Activity Levels
Physical activity level was measured using the International Physical Activity
Questionnaire (IPAQ), 29 which provides individual domain-specific scores for walking,
moderate-intensity and vigorous-intensity activity within the domains of work,
transportation, domestic chores and gardening, and leisure-time. To measure the volume
of activity, each type of activity was weighted by its energy requirement defined as the
MET-min. METs are metabolic equivalents that are computed for each specific activity
using defined formulas, and then multiplied by the minutes performed to derive METminute scores, which are equal to kilocalories for a 60 kg person.29
The IPAQ was developed to derive comparable measurements of physical activity
in international settings; therefore, being suitable for use in different languages and
cultural contexts like in an ethnically-diverse city as Miami.30,31 It has also been validated
in different age groups against objective measures of physical activity, physical fitness,
and health outcomes.32 For instance, it was validated in an adult population (mean ± SD
age: 40.7 ± 10.3 years) and found to have a strong positive relationship with an activity
monitor and a physical activity log (rho=0.55, P<0.001).33 It was also validated and used
in a population of elderly men and found to be reliable (test-retest reliability of 0.95) and
valid when compared against pedometer use and the physical activity log, and had similar
results in cohorts of postmenopausal women.34,35 Other studies have validated the IPAQ
and used it successfully in populations of middle-aged and older adults and adults with
different diseases, such as schizophrenia and breast cancer.31,36-39 The IPAQ correlated
with measurements to other physical activity assessment methods such as the 2001
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Behavioral Risk Factor Surveillance System (BRFSS) physical activity, accelerometers,
and energy expenditure as measured by doubly-labeled water, among others.32,40-43

Depressive Symptoms
Depressive symptoms were assessed using the Beck Depression Inventory (BDIII), which is a widely validated and used tool that evaluates the existence and severity of
depressive symptoms based on the DSM-IV.44 It is a self-report, 21-item instrument in
which each item corresponds to a symptom of depression and has a four-point scale
ranging from 0 to 3, except for two items that have seven options to indicate decrease or
increase in appetite and sleep. The score of all items are summed to give a single score. A
total score of 0-13 is considered minimal, 14-19 mild, 20-28 moderate, and 29-63 severe
depressive symptoms.44 Construct validity has been assessed on its ability to differentiate
non-depressed and depressed patients (0.92 for outpatients and 0.93 for college students).
Test-retest reliability was found to be significant at 0.93. This tool has been used in
populations ages 13-80 years.44-47 In an elderly population, BDI-II has good internal
consistency (0.86), and has been positively correlated with other measures of depression,
measures of stress, anxiety, and negatively with well-being. Research with this
instrument has shown no statistically significant effects for ethnicity, gender, and age on
BDI-II scores.48 In case a participant reported suicidal ideation, the investigators in this
study contacted the study physician and/or University of Miami Mental Health
Department, immediately.
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Anthropometrics and Body Composition
Weight was measured using an electronic balance. Participants were asked to
remove shoes and heavy outer garments like coats and to stand in the center of the
balance so that the weight was distributed evenly on both feet. Height was measured
using a stadiometer with a movable headpiece. Participants were asked to stand with their
back to the height rule with their feet together, while the back of the head, back, buttocks,
calves, and heels touched the upright tape. The participant was asked to look straight
ahead so that the ear canal was level with the cheek bone. The headpiece was lowered so
that the hair was pressed flat. Weight and height were recorded to the nearest 0.1 kg and
0.1 cm, respectively. Body mass index (BMI) was calculated using the formula: body
weight (kg)/ height (m2) and accordingly, participants were classified into categories
based on the National Heart, Lung and Blood Institute recommendations: underweight
(<18.5 kg/m2), normal weight (18.5-24.9 kg/m2); overweight (25-29.9 kg/m2), and obese
(>30 kg/m2).
Waist circumference (WC) was measured at the umbilicus and hip circumference
(HC) was measured at the broadest circumference below the waist. Both of these
measurements were done using a flexible but not stretchable measuring tape in three
replicates to ensure reproducibility. The average of the three values was used to calculate
waist-to-hip ratio (WHR) by dividing WC by HC. Body composition was measured using
bioelectrical impedance (BIA), to determine % lean (fat-free, %FFM) and fat mass
(%FM).
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Statistical Analysis
Statistical analyzes were performed on 97 participants. Data were analyzed using
frequencies, percentages, ranges, means, and standard deviations. Variables were checked
for non-normality and if necessary, they were transformed to achieve a normal
distribution. Spearman correlations between two or more categorical variables were
performed to evaluate the relationship between vitamin status, vitamin D intake, sun
exposure, sociodemographic characteristics, health-related variables, physical activity,
depressive symptoms, and anthropometries. Independent t-tests or chi-squares were used
to compare vitamin D insufficient and sufficient categories in vitamin D intake, sun
exposure, sociodemographic characteristics, health-related variables, physical activity,
depressive symptoms, and anthropometries. Multiple linear regressions were used to
examine the effect size and the change in vitamin D levels expected from a one-unit
change in a set of independent explanatory variables. Multiple logistic regression were
used to examine the relationship between vitamin D insufficiency and a set of
explanatory variables to identify independent correlates of vitamin D status and calculate
adjusted odds ratio. Collinearity was assessed, and variables that inter-correlated with
other independent variables were removed from the regressions. The significance level
was set at α=0.05, and statistical analyses were performed using SPSS 21.

Results
A total of 97 participants aged 55 years or older were included in this analysis.
The mean ± SD of 25(OH)D concentration was 30.73 ± 8.73 ng/ml and ranged from
10.00 to 59.80 ng/ml. Ten percent, 36%, and 54% of the participants were vitamin D
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deficient (25(OH)D <20 ng/ml), insufficient (20-30 ng/ml) and sufficient (≥30 ng/ml),
respectively. Since the number of vitamin D deficient individuals was low, vitamin D
deficient and insufficient individuals were grouped into vitamin D insufficient (<30
ng/ml) for data analysis. The mean ± SD age was 63.06 ± 6.48 and ranged from 55-87
years (Table 1). Participants were 63.9% and 36.10% over the age of 60 and 65
respectively, 45% were males, and 44% were Hispanics, 35% white Caucasians, and
15.5% African-Americans. Comparison of vitamin D status groups revealed no
significant difference in age, gender, and the proportion of participants who were
married, unemployed and with less than college education and income of <$30,000 per
year (data not shown).
A significant difference in sun exposure (mean difference: -6.27, P=0.01) was
observed between vitamin D categories, with those who were insufficient having lower
sun exposure scores (Table 1). No significant difference was found in vitamin D intake
between the categories (P=0.957). Furthermore, only 2.1% of the participants met the
Dietary Reference Intake (DRI) of 600 IU/day (data not shown).
A comparison between vitamin D status groups revealed several significant
differences in potential determinants of vitamin D levels. Those who were vitamin D
insufficient lived in the United States significantly fewer years (mean difference:-10.37,
P=0.018). Ethnicities were also significantly different between vitamin D groups. More
Hispanics and less white Caucasians and African Americans were in the vitamin D
insufficient group (P=0.004) (Table 1). A one-way ANOVA comparison between ethnic
groups on vitamin D levels showed significant differences between ethnicities (F (d.f.):
6.27 (3), P=0.001). Hispanics had lower vitamin D levels (mean ± SD: 27.61 ± 7.75)
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than White Caucasians (mean ± SD: 33.37 ± 7.73, P=0.015) and African-Americans
(mean ± SD: 35.77 ± 9.60, P=0.007) (Table 2).
Sixty-four percent of participants who were vitamin D insufficient used
prescription medications compared to 85% of those who were sufficient (P=0.033)
(Table 3). Also, those in the vitamin D insufficient group were taking significantly
fewer prescription medications than those in the vitamin D sufficient group (mean
difference: -0.94, P=0.033). Thirty-eight percent of those who were vitamin D
insufficient reported taking vitamin/mineral supplements compared to 54% of the
sufficient group, but this difference was not significant (P=0.153).
Physical activity was significantly different between groups with those who were
vitamin D insufficient having significantly less moderate physical activity (mean
difference: -928.61, P=0.043) (Table 3). Height was the only anthropometric variable
that was significantly different between groups, with those who were vitamin D
insufficient being shorter (mean difference: -6.06, P=0.004). BMI and %FM were
higher in the vitamin D insufficient group, but the difference was not significant (mean
difference: 0.63, P=0.559, and mean difference: 1.29, P=0.251, respectively).
Spearman correlations showed a significant association between vitamin D
categories and potential correlates of vitamin D status (Table 4). Significantly different
variables between groups were also significantly correlated with vitamin D status. Sun
exposure (r=0.274, P=0.007), years lived in the Unites States (r=0.272, P=0.007),
number of participants taking prescription medications (r=0.233, P=0.022), and number
of prescription medications (r=0.234, P=0.021) were positively correlated with vitamin
D status, while ethnicity (r=-0.365, P=0.000) and height (r=-0.298, P=0.003) were
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negatively correlated. Although vitamin D status did not significantly correlate with
vitamin D intake (r=0.05, P=0.728), it was positively correlated with vitamin/mineral
supplement use (r=0.277, P=0.006). Lastly, vitamin D status ad a negative association
with BMI (r=-0.220, P=0.030), and %FM (r=-0.263, P=0.010).
To explain the effect of sun exposure and dietary intake on vitamin D levels,
multiple linear regressions were used (Table 6). Vitamin D intake had no significant
effect (B (SE): 0.00 (0.01), P=0.648), while sun exposure significantly predicted 4% of
the variation in vitamin D levels (B (SE): 0.17 (0.07), P=0.017). In this model, vitamin
D levels were expected to increase by 0.17 ng/ml for every unit increase in sun
exposure. Adding ethnicity to the model showed that sun exposure was no longer a
predictor of vitamin D levels (P=0.052). In this model, non-Hispanics compared to
Hispanics would be expected to have 5.02 ng/ml higher vitamin D levels (B (SE): 5.02
(1.70), P=0.004). Thus, sun exposure and ethnicity explained 12% of the variation in
vitamin D levels.
Ethnicity remained a significant predictor of vitamin D levels after adding
variables that (1) were significantly different between vitamin D status categories, (2)
correlated significantly with vitamin D status; and/or (3) have been shown in previous
research to be significantly correlated with vitamin D levels (B (SE): 3.92 (1.70),
P=0.023). In this fully adjusted model, ethnicity, %FM (B (SE): -0.25 (0.09), P=0.008),
and vitamin/mineral supplement use (B (SE): 4.24 (1.70), P=0.014) explained 18.4% of
the variation in vitamin D levels. For every unit increase in %FM, vitamin D levels were
expected to decrease by 0.25 ng/ml. Furthermore, compared to those who did not use
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supplements, those who reported taking vitamin/mineral supplements were expected to
have 4.24 ng/ml higher vitamin D levels.
Multiple logistic regressions showed that higher sun exposure scores predicted
vitamin D levels with those with higher scores being 1.05 times significantly more
likely to be vitamin D sufficient (OR: 1.05, 95% CI: 1.01; 1.09, P=0.013) (Table 6). In
the fully adjusted model, sun exposure relationship to vitamin D levels remained about
the same (OR: 1.05, 95% CI: 1.01; 1.10, P=0.016). In addition, this model revealed that
Hispanics were 0.30 times less likely to be vitamin D sufficient (OR: 0.30, 95% CI:
0.12; 0.75, P=0.010).

Discussion
The proportion of vitamin D deficient (25(OH)D <20 ng/ml) and insufficient
(25(OH)D <30 ng/ml) individuals in this group of healthy community-dwelling older
adults (>55 years old) living in Miami-Dade was 10% and 36%, respectively. This was
lower than that reported for the general United States adult and older adult
population.11,49 NHANES 2005-2006 revealed that 41.6% of United States adults (18
years or older) had deficient vitamin D levels, defined as 25(OH)D < 20 ng/ml.11,49 A
previous study conducted in South Florida showed a prevalence of 38-40% of
hypovitaminosis D (25(OH)D < 20 ng/ml) in adults (≥18 years old).19 In older adults,
NHANES 1988-1994 data indicated that 23% of adults 65 years and older were vitamin
D deficient (25(OH)D <20 ng/ml), and 62.5% were vitamin D insufficient (25(OH)D <30
ng/ml).8,9 Several reports from The Health ABC cohort study described 65-68% of adults
over the age of 70 as vitamin D insufficient.50-52
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Vitamin D deficiency and insufficiency in our study group was less than half of
that previously reported for the general United States older adult population. However,
our results are similar to that reported by Lagari et al.20 who observed vitamin D
insufficiency in 35% of the older adult population (>65 years of age) participating in a
study in Miami-Dade. Furthermore, in older adults (≥60 years of age) living in Boca
Raton, Florida, Smolar et al.21 found a prevalence of 15.6% vitamin D insufficiency,
defined as 25(OH)D <25 ng/ml. Using the same cut-off value, we found a higher
occurrence with 27% of our study participants being vitamin D insufficient.
Despite the lower occurrence of vitamin D insufficiency in this study compared to
other studies and the general United States older adult population, it is still a public health
concern and identifying risk factors is critical to developing effective interventions. As
expected, vitamin D intake was not significantly correlated with vitamin D status in our
study, and our findings are supported by other studies that have previously shown that
dietary intake has minimal contribution to vitamin D status.53,54 The Institute of Medicine
(IOM) committee reported in 2010 that in order to maintain serum 25(OH)D above 20
ng/ml, which was deemed necessary to preserve bone health, the intake of vitamin D
should be 600 International Units (IU) per day for adults below the age of 70 and 800 IU
per day for adults over the age of 70, with a tolerable upper limit of 4000 IU per day.55-58
Although these are the established Dietary Reference Intakes (DRIs) for vitamin D, the
Endocrine Society recommends adults over the age of 18 should intake between 1,5002,000 IU per day, with an upper limit of 10,000 IU per day, to maintain 25(OH)D
between 40-60 ng/ml to conserve physiological functions that go beyond bone health.59
However, in our study only 2% of the participants met the DRI of 600 IU per day (not
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accounting from vitamin D from supplement use) and the mean ± SD was 170.33 ±
168.06, with a range of 4.7–1,412.3 IU per day. Inadequate dietary intake of vitamin D is
likely due to the limited availability of vitamin D rich foods in the daily diet of the
elderly. Good sources of vitamin D include fatty fish such as salmon, tuna, and sardines,
fish oil, egg yolks, organ meats, mushrooms, and fortified foods like milk and dairy
products, breakfast cereals, bread, margarine, spreads, and vegetable oils.16,60 This may
be aggravated in the elderly by age-related decline in food intake that results from an
interplay between physiological and psychological factors, such as changes in taste/smell,
chewing/swallowing problems, polypharmacy, hormonal factors regulating satiety,
comorbidities, and age-related lactose intolerance that limits the intake of fortified milk
products.49,61-66
Supplement use may compensate for the lack of vitamin D intake from foods. Use
of vitamin D supplements has increased over time in adults, with 26% of adults reporting
using vitamin D supplement in NHANES 1988-1994, 25% in NHANES 1999-2002, and
37% in NHANES 2003-2006.67 However, low vitamin D intakes from food and
supplements have been reported in older adults and associated with low serum vitamin
D.17,18,68 Although using vitamin D and calcium supplements 2 weeks before the study
were exclusion criteria in our study, we found that 46% of participants who reported a
history of vitamins/minerals use, 37.8% were vitamin D insufficient and 53.8% were
sufficient, but this difference was not significant. However, we did find that using
vitamin/mineral supplements was a significant and independent predictor of vitamin D
levels in adjusted multiple linear regressions, with those using supplements having higher
25(OH)D. In addition, we found significantly more vitamin D sufficient participants who
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reported taking prescription medications and a higher number of prescription medications
compared to the insufficient group, and these variables had a significant association with
vitamin D status. This relationship could be due to physicians recommending more
vitamin D supplements to their elderly patients because of the increased public health
awareness of the consequences of vitamin D deficiency in older adults. It could also be
possible that those who are taking prescriptions are more likely to have access to
healthcare or be more health conscious. Nonetheless, unlike vitamin/mineral supplement
use, receiving prescription medication and a higher number of prescription medications
were not predictors of vitamin D levels in neither multiple linear nor logistic regressions.
Other risk factors for vitamin D insufficiency are those that affect bioavailability.
The presence of other comorbidities and behavioral factors, like liver, kidney, and
gastrointestinal diseases, and the use of certain medications, tobacco, and alcohol, may
also affect vitamin D metabolism and bioavailability.66 However, our study excluded
participants who had any diseases/conditions or were taking any medications that
affected vitamin D metabolism and absorption and hence, its bioavailability. Thus, we
could not assess their effect on vitamin D status in our sample. We found that the
number of diseases and condition, health risk behaviors and history of
diseases/conditions, which have been significantly associated with vitamin D deficiency
in previous studies, were not significantly different between, associated with, or
predictive of vitamin D status. Obesity was the only condition that we were able to
assess its effect on vitamin D status in our sample.49,66 In the older adult, a decline in
metabolic rate and hormonal changes that occur during aging often result in weight gain,
as seen in the growing prevalence of obesity among elderly in the United States.69,70

110

Obesity has been correlated with low vitamin D status in the elderly probably due to
sequestration of vitamin D by increased body fat.18,49,66 In our sample, the mean ± SD
of BMI was 27.09 ± 5.27 with 62% of participants being overweight (BMI ≥25). Even
though vitamin D insufficient participants had higher BMIs, the number of participants
who had a BMI ≥25 kg/m2 was lower, and neither was significantly different compared
with those who were vitamin D sufficient. However, BMI was significantly correlated
with vitamin D levels, with those with lower vitamin D levels having higher BMI, but
this association was no longer significant when adjusting for covariates in regression
models. Abdominal fat accumulation, as measured by WC and WHR, were also not
significantly correlated with vitamin D levels, nor different between vitamin D groups.
However, the %FM was higher in the vitamin D insufficient group, but this difference
was not significant. Nevertheless, it had a significant negative correlation with vitamin
D levels, with those with lower 25(OH)D having higher %FM. Also, %FM was found to
predict vitamin D levels in linear regression models. Thus, body fat is a risk factor for
vitamin D deficiency in this Miami-Dade older adult population probably by affecting
bioavailability.
The other factor that may affect vitamin D status is skin biosynthesis. For those
who are not taking adequate amounts of vitamin D through diet, sunlight would often be
their main source of vitamin D.13,14 It is believed that sunlight exposure of arms and legs
for 5-15 minutes at midday during the summer months could produce about 3,000 IU of
vitamin D.12 However, the effectiveness of vitamin D synthesis in the skin is determined
by skin thickness, 7-dehydrocholesterol content, skin pigmentation, amount of skin
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exposed, sunscreen use, length of sun exposure, and amount of solar radiation (which
depends on the latitude, season, time of day, and time in the sun).
Decreased skin thickness and reduction of 7-dehydrocholesterol are two agerelated factors that place elderly at high risk for vitamin D deficiency.71 This is
aggravated by decreased sun exposure, since most people avoid sunshine to stay cool,
prevent skin aging, and reduce the risk of skin cancer by limiting the amount of time
spent outdoors. Covering the skin with clothes and using sunscreen are common practices
among the elderly, the latter interfering with UVB transmission to the skin.66 Thus,
sufficient exposure to sunlight is unusual with modern lifestyles, since most people live
and work indoors.66 A study in Europe showed that wearing short sleeves instead of long,
and thus bearing arms as well as the face, is associated with better vitamin D status in
older people living in sunnier climates.72 Furthermore, outdoor activity is associated with
vitamin D status as shown by an analysis of NHANES 1988-1994 data that revealed that
those who were 60 years or older and participated in daily outdoor activity had optimal
vitamin D levels (≥30 ng/ml) similar to young adults.73 In our study, sun exposure was
measured by assessing the amount of skin exposed and time spent outdoors during sunny
hours, and we found that sun exposure was significantly higher in participants who were
vitamin D sufficient. Our data also showed a significant positive correlation between
vitamin D status and sun exposure scores. In addition, we found that sun exposure had an
effect on vitamin D levels, explaining only 4% of vitamin D status variability, and this
was no longer significant when adjusting for covariates. However, participants with
higher sun exposure scores had higher odds of being vitamin D sufficient.
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Furthermore, physical activity, which is often used as a surrogate for outdoor
activity, has been positively associated with serum vitamin D levels such that lower
levels of serum vitamin D have been correlated with physical inactivity in middle-aged
and older adults.18,74 We only found that moderate physical activity was significantly
different between vitamin D categories, with those insufficient having less activity than
those who were sufficient. However, none of the physical activity variables were
significantly correlated with or predictive of vitamin D status. Thus in our cohort, unlike
in previous studies, physical activity was not a risk factor for vitamin D status.
Besides age-related factors that affect the skin and the usual decreased sun
exposure that accompanies modern life, skin complexion places elderly at an even higher
risk of vitamin D deficiency. Darker pigmentation decreases the skin’s capacity to use
sunlight for making vitamin D because melanin competes for UVB radiation
effectively.75 Ethnicity and race are often used as a proxy for skin pigmentation, and a
substantial amount of evidence indicates a significant difference in vitamin D deficiency
prevalence between different ethnic groups.75 For example, NHANES 2005-2006
revealed that the prevalence of vitamin D deficiency (25(OH)D <20 ng/ml) was higher in
blacks (82.1%), followed by Hispanics (69.2%) and whites (30.9%).49A more recent
study evaluated vitamin D status in a community-dwelling elderly population (≥60 years
old) in South Florida and found higher prevalence of vitamin D insufficiency (25(OH)D
<25 ng/ml) among Afro-Caribbeans (30.8%) and African Americans (30.4%) compared
to Hispanics (13%) and European Americans (13%).21 In our study, we did not find lower
levels of vitamin D and thus, higher prevalence of vitamin D insufficiency in AfricanAmericans, as expected, and this could be due to the few African Americans/Afro-
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Caribbeans participating in our study. Only 15.5% of our sample was of African descent
while 26% of the population studied by Smolar et al.21 was either African American or
Afro-Caribbean. Nevertheless, we did find a significant association between vitamin D
status and ethnicity and a significant difference between vitamin D categories in ethnic
groups. We found more Hispanics who had vitamin D insufficiency, while more whiteCaucasians and African-Americans were vitamin D sufficient. When comparing ethnic
groups, we found significant differences in vitamin D levels, with Hispanics having lower
levels compared individually to white-Caucasians and African-Americans. In all of our
regression models that included ethnicity, we found that this variable had a significant
effect on vitamin D levels, with Hispanics expected to have lower vitamin D levels and
higher odds of being insufficient. These results also differ from those of Smolar et al.,21
who reported that the prevalence of 25(OH)D insufficiency was not higher in Hispanic
participants compared with European Americans. However, their sample population had
only 28% Hispanics compared with 43% in our cohort. Thus, ethnicity was the strongest
risk factor for vitamin D insufficiency in this study population.
Interestingly, we found a significant difference in height and years lived in the
United States, with those who were vitamin D insufficient being shorter and having lived
fewer years in the United States. These two factors are related to ethnicity. The average
Hispanic person is shorter, and we found a significant difference in height between
Hispanics (mean ± SD: 163.29 ± 12.21) and non-Hispanics (mean ± SD: 171.12 ± 10.30,
P<0.001). Furthermore, Miami being one of the southernmost cities of the U.S, is the
home of one of the largest Hispanic communities in the country, which is mostly
composed of immigrants. We found a significant difference in years lived in the United
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States between Hispanics and non-Hispanics, with Hispanics having lived here for fewer
years (mean ± SD: 26.63 ± 17.4) compared with non-Hispanics (mean ± SD: 59.74 ±
10.66, P<0.001). Immigrant Hispanics may be more likely to be vitamin D deficient and
insufficient due to differences in sun exposure practices, public health awareness
initiatives in their home countries and less access to healthcare services due to their
immigration status.
In summary, the occurrence of vitamin D deficiency and insufficiency in this
study was lower than that of other American and European populations. This was
expected in a population that has a greater opportunity for vitamin D skin synthesis by
year-round sunlight availability. However, vitamin D insufficiency is still a public health
concern even in this population. We found that lack of sun exposure, higher %FM, and
lack of use of vitamin/mineral supplements were risk factors for vitamin D insufficiency.
Ethnicity, however, was the most consistent and important risk factor in this study
population, since those who were vitamin D insufficient were more likely to be Hispanic.
Since vitamin D deficiency is linked to health risk factors, it is important that health
professionals become aware of connections between vitamin D status, intake,
bioavailability and skin synthesis to develop dietary and other interventions to prevent
and correct deficiency and insufficiency effectively.
This study had several limitations. It was cross-sectional and descriptive in nature
and even though this type of investigation can establish associations among factors, it
does not prove cause and effect. Second, this study may suffer from selection bias.
Besides the expected higher sun exposure of this population, the age criterion could be a
possible explanation for the lower occurrence of vitamin D insufficiency observed in our

115

study. The study recruited a younger older adult population (>55 years of age) to have a
wider age range and the opportunity to follow them into the older years. According to
the World Health Organization, both 60 or 65 years of age are equivalent to retirement
age in most developed countries and hence, considered the beginning of old age. In the
United States, the age of 65 has been traditionally considered the beginning of senior age.
76

Some institutions like the Florida Department of Elder Affairs, however, considers

those >60 years of age as older adults.77 Furthermore, our age criterion may be a
limitation because most studies of vitamin D deficiency and insufficiency in the elderly
have been done in adults either above the age of 60, 65, or 70, making our results less
comparable. Our study participants were younger than what is considered “old age,” with
36% and 63.8% of participants being under the age of 60 and 65, respectively, and thus,
adding heterogeneity to our study. Nevertheless, we did not find a significant difference
in age, number of participants over the age of 60, and number of participants over the age
of 65, between vitamin D insufficient and sufficient groups. Moreover, age was not a risk
factor for vitamin D deficiency in this study population.
The participants in this study were not only younger, but mostly healthier, since
criteria for the parent study excluded current diagnoses of numerous diseases/conditions
that affect vitamin D metabolism and absorption, medications that disturb vitamin D
metabolism, and current vitamin D supplement use. Thus, this sample was not randomly
selected from the general older adult population in Miami-Dade, but instead were
healthier older adults who volunteered to participate and met inclusion criteria. Thus, the
results of this study cannot be extrapolated to the general Miami-Dade older adult
population, other populations in the United States or globally.
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Even though questionnaires have been validated and tested, are low-cost, and
easily administered, they have some limitations. Over or under-reporting may have
occurred due to participants’ desire to please the researchers. Understanding terms and
recalling information may interfere with the respondents’ ability to answer questions
accurately. Thus, self-report may not reflect true answers on questionnaires.
Another weakness of this study is related to vitamin D assessment. First of all,
25(OH)D measured today may not reflect a person’s level throughout the year, since it
varies with season, having the highest levels during the summer and fall and the lowest in
the winter and spring. Hence, it is not known whether the average concentrations during
the year, the peak concentration throughout the year, or the difference between the lowest
and highest peaks are the most pertinent for the pathophysiology of vitamin D-related
diseases.78 In addition, it is known that 25(OH)D measurements do not reflect an
individual’s long-term status. This means that the assay will not reflect peoples’ sun
exposure and dietary intake throughout life. For example, it will not differentiate people
who have spent a significant amount of time in regions with distinct UVB radiation or
who have made lifestyle modifications throughout time like using sunscreen or
supplements. Therefore, the intra-individual variation in vitamin D levels over years is
not considered in this research.78 Besides, the levels of 25(OH)D need to be considered in
the context of phenotype. Genetic polymorphism of vitamin D binding protein, 25hydroxylase, 1-alpha hydroxylase, 24-hydroxylase, and vitamin D receptor, which are
involved in the transport, activation, and metabolism of vitamin D may determine
peoples’ 25(OH)D levels.78 The cutoff values for vitamin D deficiency and sufficiency
are also widely debated. Previously, the delineation of vitamin D adequacy was
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associated with bone health and calcium absorption regarding the prediction of rickets in
children and osteomalacia in adults.79 Increasing evidence, however, indicates that
vitamin D is associated with other diseases beyond those related to calcium homeostasis,
so researchers argue that the threshold values should consider the point at which more
vitamin D in the body will no longer provide any health benefits whether these are due to
calcemic and/or non-calcemic effects.24, 80,81 The functions of vitamin D are still not fully
understood, so thresholds are hard to define, and optimal cutoff points are difficult to set.
Differences in cutoff values for different conditions can change the specificity and
sensitivity of the assay when identifying participant’s true vitamin D status. Finally, even
though clinicians widely use vitamin D serum assays, the inconsistency and variability
between assays and laboratories are still concerns, even when using the same assays, due
to the lack of reference standards.79,82

Conclusions
Vitamin D insufficiency is common in healthy community-dwelling older adults
living in Miami-Dade County, especially among Hispanics. Vitamin D intake from food
was not a predictor of vitamin D status; however, use of a vitamins/mineral supplement
was an independent predictor of vitamin D levels. Factors that affected skin synthesis
(ethnicity and sun exposure) and bioavailability/metabolism (obesity) were also
significant predictors of vitamin D status. However, ethnicity was the strongest risk factor
for vitamin D insufficiency in this study population. Since vitamin D deficiency is linked
to health risk factors, it is important that health professionals become aware of the
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connections of vitamin D status with intake, bioavailability, and skin synthesis and to
develop and plan pertinent interventions to prevent and correct deficiency.

119

Table 1: Comparison of Vitamin D Related Variables and Sociodemographic
Characteristics Between Vitamin D Insufficient and Sufficient Participants
Vitamin D
Vitamin D
Study
Insufficient
Sufficient
Ppopulation
MD
<30 ng/ml
≥30 ng/ml
value
(n=97)
(n=45)
(n=52)
Vitamin D levels
30.73 ± 8.73
23.31 ± 4.41
37.15 ± 6.02 -13.84 0.000
(ng/ml)
(Mean ± SD)
Vitamin D Intake
170.3 ± 168.1
171.3 ± 209.4 169.5 ± 123.8 1.86 0.957
(IU/day)
(Mean ± SD)
Sun Exposure
19.05 ± 12.13
15.69 ± 12.60 21.96 ± 11.02 -6.27 0.010
(Total Score)
(Mean ± SD)
Age¥ (years)
63.06 ± 6.48
63.22 ± 7.65
62.92 ± 5.34
0.3
0.822
(Mean ± SD)
Male gender¶
44 (45.4)
18 (40.0)
26 (50.0)
0.414
(N (%))
Ethnicity¶ (N (%))
Hispanic
43 (44.3)
27(60.0)
16 (30.8)
0.004
White Caucasian
34 (35.1)
9 (20.0)
25 (48.1)
African American
15(15.5)
5 (11.1)
10 (19.2)
Years lived in
45.26 ± 21.61
39.74 ± 22.14 50.12 ± 20.12 -10.37 0.018
United States¥
(Mean ± SD)
¥ Independent T-tests, ¶ Chi-squares. SD: Standard Deviations; N: Number; MD: Mean Difference;
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Table 2: One-Way ANOVA Comparison of Vitamin D Levels Between Ethnic
Groups
Vitamin D Levels
Ethnic group
(25(OH)D, ng/ml)
F (d.f.) (P-value)
(Mean ± SD)
33.37 ± 7.73
White, Caucasian (n=34)
35.77 ± 9.60
African-American (n=15)
6.27 (3) (0.001)
27.61 ± 7.75
Hispanic, Latino (n=43)*
24.46 ± 8.73
Other (n=5)
*Post Hoc Comparisons of Hispanic, Latino vs. White, Caucasian P=0.015 and Hispanic, Latino vs.
African-American: P=0.007
SD: Standard Deviation,d.f.: degrees of freedom
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Table 3: Comparison of Vitamin D Levels, Vitamin D Intake, Sun Exposure and
Other Potential Correlates Between Vitamin D Insufficient and Sufficient
Participants
Vitamin D
Vitamin D
Study
Insufficient
Sufficient
Ppopulation
MD
<30 ng/ml
≥30 ng/ml
value
(n=97)
(n=45)
(n=52)
Number of diseases and
4.70 ± 3.03)
4.20 ± 3.01
5.13 ± 3.01 -0.94 0.130
conditions reported¥
(Mean ± SD)
Participants reporting
73 (75.3)
29 (64.4)
44 (84.6)
0.033
prescription medication
¶
use (N (%))
Number of prescription
2.24 ± 2.20
1.73 ± 2.01
2.67 ± 2.29 -0.94 0.033
medications used¥
(Mean ± SD)
Participants reporting
45 (46.4)
17 (37.8)
28 (53.8)
0.153
vitamins/minerals
¶
supplement use (N (%))
Depressive symptoms
7.19 ± 7.56
6.22 ± 6.30
8.02 ± 8.47 -1.80 0.240
(BDI Score)¥
(Mean ± SD)
Height (cm)¥
167.6 ± 10.41 164.40 ± 10.65 170.46 ± 9.43 -6.06 0.004
(Mean ± SD)
BMI (kg/m2)¥
27.09 ± 5.27 27.44 ± 4.98 26.80 ± 5.53 0.63 0.559
(Mean ± SD)
Overweight
60 (61.9)
28 (62.2)
32 (61.5)
1.000
participants (BMI ≥25)¶
(N (%))
%FM (n=95)¥
30.92 ± 9.01 32.08 ± 9.24 29.92 ± 8.93 1.29 0.251
(Mean ± SD)
Moderate physical
activity (MET
1779 ± 2325 1281 ± 1644 2209 ± 2727 -929 0.043
equivalents per week)¥
(Mean ± SD)
Sitting minutes per day¥
299.04 ± 186 260.72 ± 130.5 332.20 ± 219.3 -71.5 0.050
Mean ± SD
¥ Independent T-tests; ¶ Chi-squares; SD: Standard Deviations N: Number; MD: Mean Difference; BDI:
Beck Depression Inventory; BMI: Body Mass Index; FM: Fat Mass; MET: Metabolic Equivalents.
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Table 4: Vitamin D Status Correlation with Vitamin D Intake, Sun Exposure, and
Other Potential Predictors
Spearman Correlation
P value
Coefficient
Vitamin D intake (IU/day) at baseline
0.05
0.728
Sun exposure
0.274
0.007
Ethnicity
-0.365
0.000
Years lived in the United States
0.272
0.007
Participants taking prescription medications
0.233
0.022
Number of prescription medications
0.234
0.021
Participants who reported vitamins/minerals
0.277
0.006
supplement use
Height (cm)
-0.298
0.003
BMI (kg/m2)
-0.220
0.030
%FM
-0.263
0.010
Average sitting minutes
0.215
0.050
Spearman Correlations between vitamin D status groups (Vitamin D insufficient = 0; Vitamin D
sufficient = 1) and continuous/categorical variables. BMI: Body Mass Index, FM: Fat Mass.
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Table 5: The Relationship Between Vitamin D Status and Potential Correlates in
Multiple Linear Regressions
PAdjusted
β (S.E.)
value
R2
Model Vitamin D Intake (IU/day)
0.00 (0.01)
0.648
0.048
1 Sun Exposure
0.17 (0.07)
0.017
Model Sun Exposure
0.138 (0.07)
0.052
0.120
2 Ethnicity (Non-Hispanic)
5.02 (1.70)
0.004
Ethnicity (Non-Hispanic)
3.92 (1.70)
0.023
Model
%FM
-0.25 (0.09)
0.008
0.184
3
Vitamin/Mineral Supplement use
4.24 (1.70)
0.014
Stepwise Multiple Linear Regressions. Dependent variable: Vitamin D levels (ng/ml). Model 1: Vitamin D
Intake, Sun exposure; Model 2: Model 1 + Ethnicity; Model 3: Model 2 + Years lived in the US, number of
participants taking prescription medications, number of prescription medications, height, moderate physical
activity, average sitting time per day, education, vitamin/mineral supplement use, BMI, %FM, age, gender,
marital status, employment, income, number of disease, coffee use, alcohol use, smoking, weight, calcium
intake, depressive symptoms. β: Beta Coefficient; S.E.: Standard Error; CI: Confidence Interval; FM: Fat
Mass.
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Table 6: The Relationship Between Vitamin D Status and Potential Correlates in
Multiple Logistic Regression
β (S.E.)
OR (95% CI)
P-value
Model 1 Sun Exposure
0.05 (0.02)
1.05 (1.01; 1.09)
0.013
Sun exposure
.05 (0.02)
1.05 (1.01; 1.10)
0.016
Model 2
Ethnicity (Being Hispanic)
-1.21 (0.47)
0.30 (0.12; 0.75)
0.010
Forward Logistic Regression. Dependent Variable: Vitamin status (0= <30 ng/ml; 1 = ≥30 ng/ml). Model
1: Vitamin D intake, Sun Exposure. Model 2: Model 1 + Ethnicity, Years lived in the US, number of
participants taking prescription medications, number of prescription medications, height, moderate physical
activity, average sitting time per day, education, vitamin/mineral supplement use, BMI, %FM, age, gender,
marital status, employment, income, number of disease, coffee use, alcohol use, smoking, weight, calcium
intake, depressive symptoms. β: Beta Coefficient; SE: Standard Error; OR: Odds Ratio; CI: Confidence
Interval.
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CHAPTER V: ASSOCIATION OF VITAMIN D STATUS WITH DUAL TASK
PHYSICAL PERFORMANCE IN OLDER ADULTS
Abstract
Objective: The purpose of this study is to evaluate the association between vitamin D
status with the age-related changes in mobility through higher order cognitive function
using a dual task physical performance test.
Methods: Participants completed assessments that included serum levels of vitamin D,
surveys, and dual task physical performance tests. Spearman’s correlations, independent
t-tests, repeated measures ANOVAs and multiple logistic regressions were used to
examine the relationship between vitamin D insufficiency (25(OH)D <30 ng/ml) and
sufficiency (≥30 ng/ml) and dual task physical performance variables. The significance
level was set at α=0.05.
Results: Dual and single task counting rate were significantly lower in the vitamin D
insufficient group compared to the sufficient group (P=0.018 and P=0.028, respectively).
Using Spearman correlations, a slower single (P=0.011) and dual counting rate
(P=0.006) were significantly associated with vitamin D insufficiency.
Conclusions: Cognitive performance for dual or single tasking was worse in the vitamin
D insufficient group. Since counting backward is a mental tracking task, which is a
component of executive function, our results support a relationship between vitamin D
insufficiency and executive dysfunction.
Keywords: vitamin D insufficiency, elderly, dual task, physical performance, executive
function.
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Introduction
In the United States, the elderly population (>65 years of age) is expected to
increase by 20%-50% by the year 2030.1 The major cause of physical disability in the
elderly is mobility limitations, which eventually may lead to falls.2 According to the
World Health Organization (WHO), a fall is defined as an event that results in the person
unintentionally coming to rest on the ground or other lower level, with or without injury,
that is not due to a major intrinsic event, like seizure, stroke, loss of consciousness,
epilepsy, or excess alcohol, or an environmental hazard like sustaining a blow.3 It is
estimated that approximately 30% of community-dwelling adults and 50% of
institutionalized adults >65 years of age experience one fall each year.4, 5 Falls can result
in increased morbidity and mortality and decreased quality of life, all of which translate
to greater burden for the individual and healthcare system.5 Hence, understanding the risk
factors and mechanisms behind falls is important for the development of effective
interventions that protect the elderly from future disability.
Gait impairments are one of the main risk factors for falls in the elderly.6 Elderly,
compared to their younger counterparts, have significantly reduced gait speed6-8 with
those over the age of 70 years experiencing a 12-16% decline in gait speed per decade.9-12
The postural control system positions the body in space for orientation and balance
depending on the integration of sensorimotor information in the central nervous system,
which, in turn, depends on the information processing capacity of the brain. As people
age, the sensorimotor system deteriorates and the information processing capacity of the
brain areas involved in postural control and gait declines.13 With aging, the ability to
perform automatic tasks, such as walking, becomes harder and more cognitively
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demanding.14 According to recent evidence, these age-related deficits in mobility might
be partially compensated by strenuous higher-order cognitive strategies involving
executive function that replace the automated sensorimotor processing.13 Executive
dysfunction is common among the elderly,15-17 and it has been associated with increased
fall risk and gait impairments, including slower gait speed.18-28 Thus, falls in the older
adults commonly occur when they engage in more than one task at a time (i.e., dual
tasking) because cognitive resources, such as the attention usually allotted to movement,
are no longer accessible for other activities such as talking, avoiding obstacles, watching
for traffic, or other gait-unrelated tasks.13 Consequently, older adults often have more
problems than younger adults in orchestrating tasks simultaneously, due to a lack of
coordination of limited cognitive resources and decreased mental processing speed.
Vitamin D deficiency in older adults has been linked to important determinants of
disability, including falls and fractures.29-37 An extensive amount of research supports the
relationship between risk of falls and vitamin D deficiency and the benefit of vitamin D
supplementation on reducing fall risk in the elderly.5,38-45 For instance, a recent metaanalysis found that those who fall have lower 25(OH)D concentrations, often <20 ng/ml,
than non-fallers.46 The mechanism by which vitamin D is related to the risk of falls is still
unclear, but potentially it may be through its relationship to both gait and cognition by
affecting the musculoskeletal and nervous systems.41,47-53 In the general older adult
population, vitamin D has not only been correlated with decreased muscle strength and
dysfunctional mobility, but also with a higher risk of cognitive decline, which together
may lead to an increased risk of falls and fractures.54 For instance, several studies have
demonstrated an association between vitamin D deficiency and impairments of gait
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(slower gait speed), global cognition, and executive function.37,54-74 Furthermore, vitamin
D status has been associated with impaired neuronal function in the caudal primary motor
cortex of older adults, which may contribute to the pathophysiology of gait disorders in
older adults with vitamin D deficiency.75 Studies that investigated vitamin D status’
relationship with gait and cognition, however, have looked at these factors independently.
There is lack of research about the role of vitamin D in cognitive function in the context
of mobility.
A way to evaluate the interaction between cognition and mobility as an indicator
of risk of falls in older adults is using the dual task paradigm, which refers to performing
an automatic primary task while executing a secondary cognitive task.19,28,76-87 During
dual tasking the information processing capacity of an individual is divided between the
performance of the secondary task (i.e., talking) and maintaining postural control and gait
stability during the performance of a motor task (i.e., walking) 88 However, in the older
adult, dual tasking becomes more challenging, as the already-limited information
processing capacity needs to be divided between two tasks, resulting in poor performance
of either one or both tasks.88 Studies that compared individual’s performance during dual
tasking to their performance of each task individually (i.e., single vs. dual task) have
shown that performing a secondary task while walking has a destabilizing effect on gait,
placing older adults at higher risk for falling.14 Until now, no study has evaluated the agerelated changes in mobility through higher-order cognitive function in relation to vitamin
D status using a dual task physical performance test. The purpose of this study was to
investigate the association of vitamin D status with cognitive processing during
movement by using the dual task physical performance tests. It was hypothesized that
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those who are vitamin D insufficient (25(OH)D <30 ng/ml), compared to those who are
vitamin D sufficient (≥30 ng/ml), will have significantly worse dual task physical
performance, as measured by a larger difference between dual and single task gait and
cognitive functioning.

Methods
Study Design and Setting
This study was approved by the IRBs of Florida International University (130390) and the University of Miami (20120195).

Participants
The study enrolled 101 participants, and four were excluded due to missing data
(n=97). Participants for this study were recruited from the parent study, a double-blinded
randomized placebo-controlled clinical trial that examined the effects of vitamin D
supplementation on vitamin D level, bone formation, resorption, and mineral density,
flexibility, and balance in the elderly, which was conducted at the University of Miami.
Briefly, each potential participant was screened over the phone by administering the
Short Portable Mental Status Questionnaire (SPMSQ)89 to evaluate mental functioning
(allowed up to 2 errors) and questions regarding general inclusion criteria such as age,
and medical, pharmacological and general exclusions. Inclusion criteria for this study
included: (1) Men and women age 55 or older; (2) English and Spanish speakers; (3)
Community-dwelling; (4) Ability to give informed consent; (5) Ability to perform motor
tasks without aid; and (6) Participating in the parent study. All participants in this study
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were required to sign IRB approved informed consents for both the University of Miami
and Florida International University.

Biomarkers
Vitamin D Status
Vitamin D status was measured by serum 25-hydroxyvitamin D (25(OH)D).
Fasting venous blood (15 ml) was collected from every participant by a certified
phlebotomist in the morning after fasting. The samples were sent the same day for
analysis to LabCorp (2700 N. 29th Ave, Suite 203A, Hollywood, Fl 33020) that used
immunochemiluminometric assays (ICMA) on the DiaSorin Liaison instrument to assess
25(OH)D. This is a highly automated test that measures total 25(OH)D, and it has been
widely used by others.90

Surveys
Sociodemographics, Health History, Health Risk Behaviors and Medications
Sociodemographic and health-related data were collected using questionnaires
developed by staff of the parent study that asked about gender, marital status,
race/ethnicity, socioeconomic status, education, income, current medical diagnoses,
medication/ supplement use and health risk behaviors such as coffee, alcohol, and
tobacco use.
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Physical Activity Levels
Physical activity level was measured using the International Physical Activity
Questionnaire (IPAQ),91 which provides individual domain-specific scores for walking,
moderate-intensity and vigorous-intensity activity within the domains of work,
transportation, domestic chores and gardening, and leisure-time. To measure the volume
of activity, each type of activity was weighted by its energy requirement defined as the
MET-min. METs are metabolic equivalents that are computed for each specific activity
using defined formulas, and then multiplied by the minutes performed to derive METminute scores, which are equal to kilocalories for a 60 kg person.91
The IPAQ was developed to derive comparable measurements of physical activity
in international settings; therefore, being suitable for use in different languages and
cultural contexts like in an ethnically-diverse city as Miami.92,93 It has also been validated
in different age groups against objective measures of physical activity, physical fitness,
and health outcomes.94 For instance, it was validated in an adult population (mean ± SD:
40.7 ± 10.3 years old) and found to have a strong positive relationship with an activity
monitor and a physical activity log (rho=0.55, P<0.001).95 It was also validated and used
in a population of elderly men and found to be reliable (test-retest reliability of 0.95) and
valid when compared against pedometer use and the physical activity log, and had similar
results in cohorts of postmenopausal women.96,97 Other studies have validated the IPAQ
and used it successfully in populations of middle-aged and older adults and adults with
different diseases, such as schizophrenia and breast cancer.93,98-101 The IPAQ correlated
with measurements to other physical activity assessment methods such as the 2001
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Behavioral Risk Factor Surveillance System (BRFSS) physical activity, accelerometers,
and energy expenditure as measured by doubly-labeled water, among others.94,102-105

Depressive Symptoms
Depressive symptoms were assessed using the Beck Depression Inventory (BDIII), which is a widely validated and used tool that evaluates the existence and severity of
depressive symptoms based on the DSM-IV.106 It is a self-report, 21-item instrument and
each item corresponds to a symptom of depression and has a four-point scale ranging
from 0 to 3, except for two items that have seven options to indicate decrease or increase
in appetite and sleep. The score of all items is summed to give a single score. A total
score of 0-13 is considered minimal, 14-19 mild, 20-28 moderate, and 29-63 severe
depressive symptoms. 106 Construct validity has been assessed on its ability to
differentiate non-depressed and depressed patients (0.92 for outpatients and 0.93 for
college students). Test-retest reliability was found to be significant at 0.93. This tool has
been used in populations ages 13-80 years.106-109 In an elderly population, BDI-II has
good internal consistency (0.86), and has been positively correlated with other measures
of depression, measures of stress, anxiety, and negatively with well-being. Research with
this instrument has shown no statistically significant effects for ethnicity, gender, and age
on BDI-II scores.110 In case a participant reported suicidal ideation, the investigators in
this study contacted the study physician and/or University of Miami Mental Health
Department, immediately.
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Fear of Falling
Fear of falling was another potential parameter that may have interfered with the
physical assessment battery; therefore, it was assessed using the Fall Efficacy Scale
International (FES-I), which evaluates the fear of falling while performing everyday
activities.111,112

Anthropometrics and Body Composition
Weight was measured using an electronic balance. Participants were asked to
remove shoes and heavy outer garments like coats and to stand in the center of the
balance so that the weight was distributed evenly on both feet. Height was measured
using a stadiometer with a movable headpiece. Participants were asked to stand with their
back to the height rule with their feet together, while the back of the head, back, buttocks,
calves, and heels touched the upright tape. The participant was asked to look straight
ahead so that the ear canal was level with the cheek bone. The headpiece was lowered so
that the hair was pressed flat. Weight and height were recorded to the nearest 0.1 kg and
0.1 cm, respectively. Body mass index (BMI) was calculated using the formula: body
weight (kg)/ height (m)2 and accordingly, participants were classified into categories
based on the National Heart, Lung and Blood Institute recommendations: underweight
(<18.5 kg/m2), normal weight (18.5-24.9 kg/m2); overweight (25-29.9 kg/m2), and obese
(>30 kg/m2).
Waist circumference (WC) was measured at the umbilicus and hip circumference
(HC) was measured at the broadest circumference below the waist. Both of these
measurements were done using a flexible but not stretchable measuring tape in three
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replicates to ensure reproducibility. The average of the three values was used to calculate
waist-to-hip ratio (WHR) by dividing WC by HC. Body composition was measured using
bioelectrical impedance (BIA), to determine % lean (fat-free, %FFM) and fat mass
(%FM).

Blood Pressure and Heart Rate
Systolic and diastolic blood pressure and heart rate were measured three times for
each participant after sitting down on a chair for 10 minutes using OMRON Automatic
blood pressure monitor Sem1.

Dual Task Physical Performance Test
Participants were asked to perform the following tasks in a random order,
determined from a random order table.
•

Usual walking (single gait task)

•

Counting backward from 50 by one while standing (single cognitive task)78

•

Counting backward from 50 by one while walking (dual task)

The spatiotemporal gait variables were measured using the GAITRite system that
includes a 6 meter-long and 64 centimeter-wide walkway mat with embedded sensors.
Participants were asked to wear comfortable, low-heeled shoes. Before each trial,
participants’ leg length was measured using a measuring tape from the trochanter of the
femur to the medial malleolus. Participants were given a demonstration on how to walk
on the walkway from the start to the finish line that were located 2 meters before and
after the walkway to account for acceleration and deceleration. Participants were given
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standardized instructions for practice and data collection trials in which they were asked
to walk only (single gait task) or walk while dual tasking without prioritizing either task
on the GAITRite walkway at their preferred gait speed. Participants were required to
perform three trials per data recording session. The first ten gait cycles of the three trials
were used for each task to determine spatial-temporal gait parameters, which were
normalized by individual leg length. The spatiotemporal variable of interest for this study
was gait speed (distance walked divided by time to walk; cm/s).113
For the secondary single cognitive task only and the dual task, the participants
were asked to count backward out loud from 50 by one until reaching 30. The number of
enumerated figures was assessed using a voice recorder while single and dual tasking,
and defined as the number achieved at the completion of the walking time for the dual
task. For both single and dual tasks, the numbers of figures were defined as those spoken
during the time required for the completion of the dual task.81 For instance, if the
participant took 30 seconds to complete the dual task, the number of figures enumerated
for the single task was counted for the first 30 seconds. The average of the three trials
was used for analysis. The difference in dual and single task variables was calculated by
subtracting the single task value from the dual task value for gait velocity and counting
rate (dual task minus single task equals the difference).

Statistical Analysis
Statistical analyses were performed on 97 participants. Data were analyzed using
frequencies, percentages, ranges, means, and standard deviations. Variables were checked
for non-normality, and if necessary, they were transformed to achieve a normal
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distribution. Spearman’s correlations were used to estimate associations between vitamin
D status (insufficient = 0 and sufficient = 1) and dual task physical performance
variables. Paired t-tests were used to compare dual task (dual task gait speed and dual
task counting rate) and single task variables (single task gait speed and single task
counting rate) within the entire group, and in subgroup analysis, considering separately
the sufficient and the insufficient groups. Independent t-tests were used to compare
vitamin D insufficient (25(OH)D <30 ng/ml) and sufficient (≥30 ng/ml) in dual task,
single task, and the difference in dual and single task variables. Repeated measures
ANOVAs were used to compare the difference in dual and single task gait velocities and
counting rates between vitamin D status categories. Logistic regressions were used to
examine the relationship of vitamin D insufficiency with dual and single task gait speed
and counting rate, controlling for covariates. The significance level was set at α=0.05,
and statistical analyses were performed using SPSS 21.

Results
A total of 97 participants aged 55 years or older were included in the analysis.
The mean ± SD age of the study population was 63.06 ± 6.48, and 45.4% were male. In
this population, 44.3% were Hispanic, 35.1% white Caucasian, and 15.5% African
American (Table 1). The mean ± SD BMI was 27.09 ± 5.27 and the number of
diseases/disorders reported were 4.70 ± 3.03. On average, 75.3% of participants reported
using a mean ± SD of 2.24 ± 2.20 prescription medications, and 46.4% reported a history
of vitamin/mineral supplement use, 79.4% consumed coffee, 42.3% drank alcohol, and
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11.3% were smokers. Fifty-one participants reported a history of injuries and 14 reported
experiencing a fall in the past 12 months.
The mean ± SD vitamin D level was 30.73 ± 8.73 ng/ml, ranging from 10.00 to
59.80 ng/ml. The mean ± SD dual task and single task gait velocities were 132.59 ±
36.61 and 154.29 ± 29.96 cm/s, respectively. The mean ± SD dual task and single task
counting rates were 1.24 ± 0.29 and 1.21 ± 0.28 figures/s, respectively (Table 1).
Spearman correlations were used to assess the relationship between vitamin D
status and physical performance (Table 2). There was a significant and positive
correlation between vitamin D insufficiency and slower single task counting rate
(r=0.278, P=0.006) and dual task counting rate (r=0.258, P<0.011). Those who were
vitamin D insufficient counted fewer figures per second in both tasks (Table 3). Vitamin
D status was not significantly correlated with gait velocity during either dual or single
task.
Paired t-tests, however, showed a significant difference in dual and single task
gait velocity within the entire group and by each vitamin D status group (Figure 1, Table
3, all P<0.001). Participants had slower gait speeds when dual tasking compared to single
tasking, indicating interference of the cognitive task on gait task when dual tasking.
Independent t-tests showed no significant differences between vitamin D insufficient and
sufficient groups in the dual task and single task gait velocities (P=0.896 and P=0.934,
respectively). Paired t-tests showed no significant difference in dual and single task
counting rate within the entire group of participants (P=0.128) and those in the vitamin D
insufficient (P=0.473) and vitamin D sufficient categories (P=0.151) (Figure 2, Table 3).
Independent t-tests showed significant differences between vitamin D insufficient and

145

sufficient groups in dual task and single task counting rates (P=0.018 and P=0.028,
respectively) (Table 3). Vitamin D insufficient participants counted significantly fewer
figures per second when single and dual tasking as compared to vitamin D sufficient, thus
having worse cognitive task performance.
One-way repeated measures ANOVA were conducted with the within-subject
factor being either gait velocity difference (defined as the difference between dual and
single task gait velocity) or counting rate difference (defined as the difference between
dual and single task counting rate); and the between-subject factor being vitamin D status
categories. The results for the ANOVAs indicated that velocity and counting rates were
not significantly different by vitamin D status (Wilk’s Lambda =0.999; F (1, 95) =.11,
P=.740) (Wilk’s Lambda =.999, F(1,95)=.13, P=.718).
Logistic regression models were built to examine the relationship between
vitamin D deficiency and gait velocity and counting rate difference in dual and single
task when controlling for covariates (Table 4). Vitamin D status was not significantly
associated with dual task physical performance (defined as the difference in dual and
single task) in gait velocity (OR=1.00, 95% CI: 0.98; 1.02, P=0.772) and counting rate
(OR=1.684, 95% CI: 0.15; 19.57, P=0.677), when controlling for variables that had
significant correlations with or have been shown in previous research to affect either the
independent and/or dependent variables like age, gender, marital status, education,
employment, income, falls, number of diseases, number of injuries, prescription
medications, vitamin/mineral supplement use, coffee consumption, alcohol use, smoking,
weight, BMI, depressive symptoms, fear of falling, physical activity, physical
performance test.
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Discussion
Vitamin D deficiency in the elderly has been linked to factors associated with
disability, including cognitive impairment, poor physical performance, and increased risk
of falls and fractures.5,29,43,83,114-116 Older adults are at higher risk of vitamin D deficiency
due to a complex interplay between aging and the factors that affect vitamin D status
such as dietary intake, skin synthesis, and bioavailability.62,117 Vitamin D deficiency has
received much attention as a risk factor for falls because of its association with gait
impairment (slower gait speed), global cognitive deficits, and compromised executive
function.5,43,48,114,118 Nonetheless, studies that investigate the relationship between vitamin
D status, gait, and cognition have looked at these factors independently. In our study a
dual task physical performance test was used to examine the relationship between vitamin
D status and cognition in the context of mobility, by evaluating the competition for
information processing capacity between gait stability during the primary automatic task
(i.e., walking) and cognitive performance during the completion of the secondary
cognitive task (i.e., counting backwards from 50 by 1).
Dual tasking usually results in worse performance in either one or both tasks
when compared to the performance of each task individually.88 In our study, we found a
marked deterioration of the automatic primary motor task during dual tasking, and not the
secondary cognitive task when compared to single tasking. Participants had a
significantly slower gait speed when walking while counting, compared to walking only.
However, counting rate was not significantly different between dual and single tasks. As
shown in previous studies that compared individual’s performance during dual tasking
with their performance of each task individually (i.e., single vs. dual task), our results
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showed that performing a secondary cognitive task like counting backwards from 50 to
one, while walking, had a destabilizing effect on gait as shown by decreased gait
speed.76,77,80,83,119 This can be explained by participants prioritizing the cognitive task
when dividing their limited information processing capacity during dual tasking,
therefore, sacrificing gait stability by decreasing gait speed to compensate for the
increased need for higher cognitive processing demanded by the secondary cognitive
task.
When examining the relationship between vitamin D status and dual task physical
performance, we did not find a significant association. Our results supported our
hypothesis that those who were vitamin D insufficient were more likely to have cognitive
deficits that would limit their information processing capacity when dual tasking. Slower
dual task gait speeds and/or counting rates were compared to single task, which resulted
in larger differences in both variables between tasks. Surprisingly, gait velocity and
counting rate were not different for either single or dual task between the vitamin D
insufficient and sufficient group. Thus, those who were vitamin D insufficient did not
perform worse in dual or single task physical performance tests compared to those who
were sufficient. Of importance, in subgroup analysis, when the participants in each of the
vitamin D groups were considered independently, in each group those performing dual
tasks seem to prioritize the cognitive over the walking task for the use of resources, since
counting rate was not significantly different in counting rate, but a significant difference
in gait speed compared to single tasks (Figure 1).
Even though counting rate was not significantly different between dual task and
single cognitive task between vitamin D groups, we did find a significant weak
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correlation between vitamin D insufficiency and single and dual task counting rate (Table
3). An interesting finding of our study was that single and dual task counting rates were
significantly lower in the vitamin D insufficient group. Those who were vitamin D
insufficient had worse cognitive performance, since they counted significantly fewer
figures per second compared to the vitamin D sufficient group when performing either
single or dual tasks. Counting backward is a mental tracking task, meaning it is task that
requires holding information while performing a mental process. Thus, mental tracking
tasks are typically used to examine information processing speed, working memory, and
sustained attention, all of which are part of executive function.83 Executive function
refers to the cognitive processes that orchestrate goal-directed behavior and decisionmaking, like problem-solving, initiating and maintaining tasks, working memory (holding
multiple pieces of transitory information and manipulating it), abstract reasoning, and
dividing attention.22,120 Counting backward from 50 by 1 is a mental tracking task that
can assess to some extent executive functioning; therefore, our results support previous
research that found an association between vitamin D status and executive dysfunction.
Several studies have found a significant positive correlation between vitamin D and
scores of cognitive tests that assess executive function like the Digit Symbol Substitution
Test 56,70,121, Trail Making Test A56,61,65, Trail Making Test B56,61,64-66,73, Block Design56,
and Verbal Fluency. 56,65
Executive dysfunction is common among elderly15-17, and it has been associated
with increased fall risk and gait impairments.18-28 Several studies have found a significant
positive association between vitamin D deficiency and slower gait speed when walking
(i.e., single tasking).122-126 Although we found worse executive function in vitamin D
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insufficient subjects, we did not find a significant correlation between single gait velocity
and vitamin D levels nor a difference in single gait velocity between vitamin D
insufficient and sufficient groups. Executive dysfunction is sometimes present even in the
absence of global cognitive impairment, and it may be present in the older adult before
gait impairments are evident.15,18,22 This can explain why we observed an association
between vitamin D deficiency and worse performance on the cognitive task and not the
gait tasks. Thus, in this healthy older adult population executive function may not be
diminished enough to affect gait significantly and may be more sensitive to vitamin D
deficiencies than mobility limitations.
This study had several limitations. First of all, cross-sectional studies are
descriptive in nature and even though they can establish association among factors, they
do not prove cause and effect. Second, this study may suffer from selection bias. Age
could be a possible explanation for the lack of association between gait velocity and
vitamin D deficiency observed in our study. We included younger older adult participants
(>55 years of age) to have a wider age range for recruitment purposes; therefore, our
participants were younger than what is considered “old age,” with 36% and 63.8% of our
participants being under the age of 60 and 65, respectively. This added heterogeneity to
our study, and since gait instability increases with age, it might be possible that our
population was too young to exhibit mobility limitations. Furthermore, most studies
evaluating vitamin D deficiency and physical and cognitive performance in the elderly
have been done in adults either above the age of 60, 65, or 70, making our results less
comparable.
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Moreover, the participants in this study were not only younger, but also mostly
healthy, since the exclusion criteria for the parent study included current diagnoses of
numerous diseases/conditions that affect vitamin D metabolism/absorption and mobility,
medications that disturb vitamin D metabolism, and vitamin D supplement use. Thus, this
population might not be representative of the older adult population in Miami-Dade, but
instead were healthy older adults who volunteered to participate and met inclusion
criteria. Thus, the results of this study are not generalizable to the general Miami-Dade
older adult population.
The small sample size could have also affected the results of this study. Using an
independent t-test with 5% significance and 80% power and assuming an allocation ratio
of 40%, based on published prevalence of vitamin D deficiency, and an effect size of 0.5
for the change in gait speed between dual and single task, the total sample size was 134
(expected 54 vitamin D deficient and 80 vitamin D sufficient). However, due to
limitations of time and resources, we were only able to recruit 101 participants of which
97 were included in the analysis, reducing the power to detect significant differences in
this study. Using an independent t-test with 5% significance, the actual sample size for
each group and the mean +/- SD of single and dual task gait velocity and the difference
between dual and single task gait velocity to calculate effect size, we calculated power to
be 5%. With the sample size in this study were did not have enough power to detect
significant differences between vitamin D status groups. In addition, our sample had a
significantly lower prevalence of vitamin D deficiency, with 10.3% of our population
having 25(OH)D < 20 ng/ml and 36.1% having between (20-30 ng/ml). Previous studies
that have evaluated the relationship between vitamin D and physical performance have
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included participants with lower 25(OH)D levels, showing a relationship between
vitamin D deficiency and motor capacity. This, together with the younger age group,
might be why we did not find a significant association between vitamin D insufficiency
and gait speed.
An additional limitation of this study was the low adjusted R2, which assesses the
percentage of the variation of the dependent variable that is explained by the linear
regression model. Even though it is indicative of how well the linear model fits the
observations, it doesn’t provide a hypothesis test for this relationship. A low adjusted R2
means that the model is not precise. However, if the adjusted R2 is low but the predictors
are statistically significant, conclusions can still be drawn about the relationship between
the dependent variable and predictors. Thus, highly variable data, as indicated by low
adjusted R2, can still have a significant trend that indicates the dependent variable is
affected by the predictors.
Another weakness of this study is related to dual task physical performance tests.
Overall, many studies show the importance of dual task effects on gait performance in
older adults and its usefulness in the prediction of falls. Even though previous metaanalyses and systematic reviews concluded that gait control places demand on cognitive
systems and this may increase the risk for falls in older adults, researchers recognize that
methodological variations complicate the interpretation of data and challenge deriving
concrete conclusions from the literature available. Therefore, the different results on dual
task-related gait changes and their relationship with falls elicit some concern about the
usefulness of this technique for fall prediction. The main concerns are the lack of
methodological standardization, as different primary motor tasks and cognitive secondary
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tasks with diverse levels of complexity and different gait parameters, are evaluated
during dual task analysis. Furthermore, even though most studies had their participants
perform the single task alone, not all studies evaluated the difference in performance
between a single and dual task in one or both tasks (i.e., change in performance).76,83
Some studies only compared dual task performance between groups. This raises the
question of whether it is the difference in performance from single to dual tasking or the
difference in dual task performance only, which is relevant for fall prediction.
To better understand the dual task-related changes and gait control mechanisms, it
is important to standardize methodologies and improve their ecological validity.80 One of
the criticisms of the dual task methodology used in research studies is that it does not
resemble the everyday activities of the participants like street crossing; therefore, not
having ecological validity. It is difficult to analyze quantitatively, however, a nonstandardized cognitive task such as engaging in a conversation or street crossing, so
having a well-defined mental tracking task improves the reliability, validity, and
comparability of results.80 Thus from a review of literature we found that changes in
speed while performing a simple gait task, like walking in a straight line, and a simple
mental tracking secondary task, like counting backwards from 50 by 1, using the speed
analysis method or even better, a spatiotemporal assessment system like the GAITRite,
yielded enough sensitivity and predictive value for falls.
Moreover, studies that use dual task physical performance tests found that
decrease in speed during dual tasking was consistently found to predict falls in elderly.
Previous studies have used dual task testing using gait velocity as the primary outcome
variable because it is a highly reproducible and reliable measurement of mobility in older
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adults.2,19,127 Experts suggest that changes in other gait parameters, however, may be
more relevant for assessing fall risk besides speed. 118 For instance, stride time and stride
length variability due to inconsistent stepping patterns and reduced postural control are
common in many older adults whether or not they have any pathology present.128
Therefore, these variables are considered very good markers of gait control because they
reflect regularity of the walking rhythm129-132 and have also been identified as risk factors
for falls in prospective studies. Hence, using a different spatiotemporal variable to assess
gait rather than gait speed may have yielded different results in our study.

Conclusions
When dual tasking, this healthy older adult sample prioritized the secondary
cognitive task at the expense of compromising their motor capacity. Despite of these
findings, we did not find a significant association between vitamin D status and the
change in performance in cognitive and gait tasks when dual vs. single tasking; thus
vitamin D insufficient participants did not have worse dual task performance. Motor
functioning was not significantly different between vitamin D categories, but
performance on the cognitive task was significantly lower in the vitamin D insufficient
group. Since counting backward is a mental tracking task, which is a component of
executive function, our results support a relationship between vitamin D insufficiency
and impaired executive function. Executive dysfunction has been previously associated
with fall risks in the elderly, and it could be a possible mediator between vitamin D and
falls. 73 Our data suggest that cognition may play a significant role in vitamin D’s
influence on falls, while motor function may play a lesser role.72
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Due to the nature of this cross-sectional study, we cannot conclude that vitamin D
deficiency is a cause of executive dysfunction that leads to decreased performance in
mental tracking tasks. Future randomized control studies, with sufficient resources, are
warranted to evaluate the change in dual task physical performance in vitamin D
insufficient older adults supplemented with vitamin D and to examine the cause-effect
relationship.
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Table 1: Characteristics of Participants (n=97)
Age (years) (Mean ± SD)
Age categories: (N (%))
55-60 years
60-65 years
65-70 years
>70 years
Male gender (N (%))
Ethnicity: (N (%))
Hispanic
White Caucasian
African American
Other
Vitamin D levels (ng/ml) (Mean ± SD)
Dual task gait velocity (cm/s) (Mean ± SD)
Single task gait velocity (cm/s) (Mean ± SD)
Dual task counting rate (figures/sec) (Mean ± SD)
Single task counting rate (figures/sec) (Mean ± SD)
BMI (kg/m2) (Mean ± SD)
%FM (Mean ± SD)
SBP (mmHg) (Mean ± SD)
DBP (mmHg) (Mean ± SD)
HR (bpm) (Mean ± SD)
Depressive symptoms (BDI Score) (Mean ± SD)
Fear of falling (FES-I score) (Mean ± SD)
Participants reporting injuries (N (%))
Participants reporting falls in last 12 months (N (%))
Number of diseases and conditions reported (Mean ± SD)
Participants using prescription medications (N (%))
Number of prescription medications used (Mean ± SD)
Participants reporting vitamins/minerals supplement use (N
(%))
Total physical activity (IPAQ score) (Mean ± SD)

63.1 ± 6.5
35 (36.1)
27 (27.8)
21 (21.6)
14 (14.4)
44 (45.4)
43 (44.3)
34 (35.1)
15 (15.5)
5 (5.2)
30.7 ± 8.7
132.6 ± 36.6
154.4 ± 30.0
1.2 ± 0.3
1.21 ± 0.3
27.1 ± 5.3
30.9 ± 9.0
132.6 ± 22.0
76.0 ± 14.5
70.4 ± 11.8
7.2 ± 7.6
20.0 ± 5.9
51 (52.6)
14 (14.4)
4.7 ± 3.0
73 (75.3)
2.2 ± 2.2
45 (46.4)
4283 ± 4318

SD: Standard Deviation; BMI: Body Mass Index; FM: Fat Mass; SBP: Systolic Blood Pressure; DBP: Diastolic
Blood Pressure; HR: Heart Rate; bpm: beats per minute; IPAQ: International Physical Activity Questionnaire; BDI:
Beck Depression Inventory; FES-I: Falls Efficacy Scale International
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Table 2: Vitamin D Status Correlation with Dual Task Physical Performance
Variables
Spearman Correlation
P- value
Coefficient
Dual task gait velocity (cm/s)
-0.003
0.977
Single task gait velocity (cm/s)
-0.040
0.698
Dual and single task difference gait velocity
-0.051
0.623
(cm/s)£
Dual task counting rate (figures/sec)
0.258
0.011
Single task counting rate (figures/sec)
0.278
0.006
Dual and single task difference counting rate
-0.026
0.802
(figures/sec)£
Spearman Correlations between vitamin D status groups (Vitamin D insufficient = 0; Vitamin D sufficient
= 1) and continuous/categorical variables. £Difference in dual and single task variables is calculating by
subtracting single task value from dual task value (dual task – single task = difference).
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Figure 1: Comparison of Dual and Single Task Gait Velocity Within and Between
Vitamin D Insufficient and Sufficient Participants.
Legend: Gait velocity is significantly higher for the entire group and the vitamin D status
subgroups for single task compared to dual tasks.
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*

Figure 2: Comparison of Dual and Single Task Counting Rate Within and Between
Vitamin D Insufficient and Sufficient Participants.
Legend: Counting rate is significantly lower in the vitamin D insufficient group
compared to the sufficient group while performing dual or single task.
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Table 3: Comparison of Dual Task Physical Performance Variables Between Vitamin D Insufficient And Sufficient
Participants
Vitamin D
Vitamin D sufficient
MD between
Total
insufficient <30
≥30 ng/ml
vitamin D status
P(n=97)
ng/ml
value£
(n=52)
groups
(n=45)
132.6 ± 36.6
132.1 ± 36.4
133.1 ± 37.1
-0.99
0.896
Dual task
Velocity
(cm/s)
(Mean ± SD)

Counting
rate
(figures/ sec)
(Mean ± SD)

Single task
Dual and
single task
difference
Pair sample
P-value¥
Dual task
Single task
Dual and
single task
difference
Pair sample
P-value¥

154.4 ± 30.0

154.7 ± 30.3

154.2 ± 30.0

0.51

0.934

-21.8 ± 21.9

-22.6 ± 26.1

-21.1 ± 17.8

-1.5

0.740

<0.001

<0.001

<0.001

1.2 ± 0.3
1.2 ± 0.3

1.17 ± 0.3
1.15 ± 0.31

1.3 ± 0.27
1.27 ± 0.25

-0.14
-0.06

0.018
0.028

0.03 ± 0.19

0.02 ± 0.20

0.04 ± 0.18

-0.01

0.718

0.128

0.473

0.151

¥

Paired sample t-test comparing dual and single task within total group and each vitamin D category; £Independent t-test comparing vitamin D status
categories. SD: Standard Deviation; MD: Mean Difference.
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Table 4: The Relationship Between Vitamin D Status and Dual to Single Task
Difference in Gait Velocity and Counting Rate in Multiple Logistic Regressions

Dual to single task difference in
gait velocity
Dual to single ask difference in
counting rate.

β (S.E.)

OR (95% CI)

P- value

0.00 (0.010)

1.003 (0.98, 1.02)

0.772

0.52 (1.25)

1.684 (0.15, 19.57)

0.677

Dependent: Vitamin D insufficient <30 ng/ml=0; Vitamin D sufficient ≥30 = 1. Adjusted for: age, gender,
marital status, education, employment, income, falls, number of diseases, number of injuries, prescription
medications, vitamin/mineral supplement use, coffee consumption, alcohol use, smoking, weight, BMI,
depressive symptoms, fear of falling, physical activity, physical performance test. β: Beta Coefficient; SE:
Standard Error; OR: Odds Ratio; CI: Confidence Interval.
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CHAPTER VI: RELATIONSHIP BETWEEN VITAMIN D STATUS AND
CARDIOMETABOLIC RISK
Abstract
Objective: The purpose of this study was to investigate the relationship between vitamin
D status and a composite cardiometabolic risk score (CMRS).
Methods: Participants completed assessments that included serum vitamin D levels,
surveys, and measurement of CMRS using a system that integrates body composition,
endothelial function, and autonomic nervous system (ANS) activity markers. Spearman’s
correlations, independent t-tests and multiple linear regressions were used to examine the
relationship of vitamin D insufficiency (25(OH)D <30 ng/ml) and sufficiency (25(OH)D
≥30 ng/ml) with CMRS. The significance level was set at α=0.05.
Results: The mean ± SD vitamin D (25(OH)D) level was 30.71 ± 8.78, and CMRS was
5.17 ± 3.58. Spearman correlations showed a significant inverse correlation between
insufficient vitamin D levels and CMRS (P=0.019). Vitamin D insufficient participants
had a significantly higher CMRS compared with vitamin D sufficient (P=0.046). In
adjusted multiple linear regressions, vitamin D status had a significant effect on CMRS
(P=0.016).
Conclusions: An inverse association between vitamin D levels and CMRS was found,
possibly by mediating genomic and non-genomic mechanisms that influence ANS
activity and vascular function. Thus, vitamin D insufficiency may affect cardiac
performance.
Keywords: vitamin D, cardiometabolic risk, autonomic nervous system, endothelial
dysfunction
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Introduction
Vitamin D deficiency and cardiovascular disease (CVD) are prevalent
worldwide.1,2 Furthermore, the prevalence of vitamin D deficiency is high among those
with CVD. Analysis of data from the National Health and Nutrition Examination Survey
(NHANES) 2001-2004, showed that 68% of whites, 88% of Hispanics, and 97% of
blacks with CVD also had vitamin D levels of less than 30 ng/ml, as measured by 25hydroxyvitamin (25(OH)D).3,4 Several observational studies and meta-analyses have
suggested an association of vitamin D deficiency with CVD-related outcomes and
mortality.5-19 These studies reported a linear, inverse relationship between CVD risk and
25(OH)D levels between 8-24 ng/ml.12 Furthermore, vitamin D supplementation
demonstrated a reduction in CVD-related death, with vitamin D intake of more than 500
IU per day improving all-cause mortality, partly by decreasing CVD mortality.9,15,19
The possible relationship between vitamin D deficiency and CVD-related
outcomes and mortality in both diseased and healthy populations is a growing area of
research.2 The most studied role of vitamin D is in regulating calcium homeostasis and
mineral metabolism to maintain bone health.20 Vitamin D, via genomic and non-genomic
actions mediated by vitamin D receptors (VDRs), however, may affect multiple cellular
signaling pathways that have the potential to affect cardiovascular health. These include
vitamin D effects on parathyroid hormone (PTH), the renin-angiotensin-aldosterone
system (RAAS), cytokine production, endothelial growth and function, and myocyte
calcium influx.21 Furthermore, vitamin D has also been shown to be involved in
molecular mechanisms like biosynthesis of neurotransmitters and inflammatory signaling
in areas of the central nervous system (CNS) that regulate cardiovascular activity.22,23
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Vitamin D can permeate the blood-brain barrier and bind to VDRs located in extremely
high concentrations in the midbrain and brainstem where some autonomic nervous
system (ANS) neurons are located.22,23
Recent studies in healthy and diseased populations have found an association
between vitamin D status and cardiac ANS function, with vitamin D deficiency related to
cardiac ANS imbalance, more specifically with decreased parasympathetic nervous
system (PNS) activity.2,24-29 The ANS is a branch of the peripheral nervous system that
controls involuntary processes throughout the body like cardiovascular activity.30 The
cardiac ANS is composed of the stimulatory post-ganglionic sympathetic plexus of
nerves and the inhibitory parasympathetic Vagus nerve, which both innervate the heart
and act concomitantly to control heart rate by responding to internal and external
stimuli.26,30 Dysfunction of cardiac autonomic function, more specifically of the
cardioprotective vagal tone, results in an imbalance between SNS and PNS, that has been
well established as a risk factor for adverse cardiovascular events, such as sudden cardiac
death (SCD) and congestive heart failure (CHF) in both healthy and diseased
populations.31-36
Besides its effect on heart rate, ANS activity plays a role in vascular dynamics
and blood pressure control, which is also influenced by endothelial function. Low vitamin
D status has also been associated with endothelial dysfunction, characterized by a
decreased ability to balance vasodilation and vasoconstriction. It is usually due to an
imbalance of nitric oxide bioavailability and related to prothrombotic and
proinflammatory states that increase arterial stiffness.4,37-39 Thus, vitamin D plays a role
in vascular health by participating in the control of vascular tone and blood pressure via
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indirect ANS activity or directly affecting the endothelium. These findings suggest that
vitamin D may contribute to CVD-risk by orchestrating genomic and non-genomic
regulatory activity at the vascular level and higher brain centers of the ANS.5,18,40
Currently, the links between vitamin D status, ANS, and endothelial function have
been evaluated independently, and no study has investigated the relationship between
vitamin D and cardiometabolic risk score (CMRS) as a composite measure that integrates
various CVD risk factors such as body composition, ANS activity, and endothelial
function. The purpose of this study was to investigate the association between vitamin D
status and CMRS. We hypothesized that those who are vitamin D insufficient (25(OH)D
<30 ng/ml) will have significantly lower CMRS than those who are vitamin D sufficient
(≥30 ng/ml).

Methods
Study Design and Setting
This study was approved by the IRBs of Florida International University (130390) and the University of Miami (20120195).

Participants
The study enrolled 101 participants, and six were excluded due to missing data
(n=95). Participants for this study were recruited from the parent study, a double-blinded
randomized placebo-controlled clinical trial that examined the effects of vitamin D
supplementation on vitamin D level, bone formation, resorption, and mineral density,
flexibility, and balance in the elderly, which was conducted at the University of Miami.
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Briefly, each potential participant was screened over the phone by administering the
Short Portable Mental Status Questionnaire (SPMSQ) 41 to evaluate mental functioning
(allowed up to 2 errors) and questions regarding general inclusion criteria such as age,
and medical, pharmacological and general exclusions. Inclusion criteria for this study
included: (1) Men and women age 55 or older; (2) English and Spanish speakers; (3)
Community-dwelling; (4) Ability to give informed consent; (5) Ability to perform motor
tasks without aid; and (6) Participating in the parent study. All participants in this study
were required to sign IRB approved informed consents for both the University of Miami
and Florida International University.

Biomarkers
Vitamin D Status
Vitamin D status was measured by serum 25-hydroxyvitamin D (25(OH)D).
Fasting venous blood (15 ml) was collected from every participant by a certified
phlebotomist in the morning after fasting. The samples were sent the same day for
analysis to LabCorp (2700 N. 29th Ave, Suite 203A, Hollywood, Fl 33020) that used
immunochemiluminometric assays (ICMA) on the DiaSorin Liaison instrument to assess
25(OH)D. This is a highly automated test that measures total 25(OH)D, and it has been
widely used by others.42
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Surveys
Sociodemographics, Health History, Health Risk Behaviors and Medications
Sociodemographic and health-related data were collected using questionnaires
developed by staff of the parent study that asked about gender, marital status,
race/ethnicity, socioeconomic status, education, income, current medical diagnoses,
medication/ supplement use and health risk behaviors such as coffee, alcohol, and
tobacco use.

Physical Activity Levels
Physical activity level was measured using the International Physical Activity
Questionnaire (IPAQ),43 which provides individual domain-specific scores for walking,
moderate-intensity and vigorous-intensity activity within the domains of work,
transportation, domestic chores and gardening, and leisure-time. To measure the volume
of activity, each type of activity was weighted by its energy requirement defined as the
MET-min. METs are metabolic equivalents that are computed for each specific activity
using defined formulas, and then multiplied by the minutes performed to derive METminute scores, which are equal to kilocalories for a 60 kg person.43
The IPAQ was developed to derive comparable measurements of physical activity
in international settings; therefore, being suitable for use in different languages and
cultural contexts like in an ethnically-diverse city as Miami.44,45 It has also been validated
in different age groups against objective measures of physical activity, physical fitness,
and health outcomes.46 For instance, it was validated in an adult population (mean ± SD:
40.7 ± 10.3 years old) and found to have a strong positive relationship with an activity
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monitor and a physical activity log (rho=0.55, P<0.001).47 It was also validated and used
in a population of elderly men and found to be reliable (test-retest reliability of 0.95) and
valid when compared against pedometer use and the physical activity log, and had similar
results in cohorts of postmenopausal women.48,49 Other studies have validated the IPAQ
and used it successfully in populations of middle-aged and older adults and adults with
different diseases, such as schizophrenia and breast cancer.45,50-53 The IPAQ correlated
with measurements to other physical activity assessment methods such as the 2001
Behavioral Risk Factor Surveillance System (BRFSS) physical activity, accelerometers,
and energy expenditure as measured by doubly-labeled water, among others.46,54-57

Depressive Symptoms
Depressive symptoms were assessed using the Beck Depression Inventory (BDIII), which is a widely validated and used tool that evaluates the existence and severity of
depressive symptoms based on the DSM-IV.58 It is a self-report, 21-item instrument and
each item corresponds to a symptom of depression and has a four-point scale ranging
from 0 to 3, except for two items that have seven options to indicate decrease or increase
in appetite and sleep. The score of all items is summed to give a single score. A total
score of 0-13 is considered minimal, 14-19 mild, 20-28 moderate, and 29-63 severe
depressive symptoms.58 Construct validity has been assessed on its ability to differentiate
non-depressed and depressed patients (0.92 for outpatients and 0.93 for college students).
Test-retest reliability was found to be significant at 0.93. This tool has been used in
populations ages 13-80 years.58-61 In an elderly population, BDI-II has good internal
consistency (0.86), and has been positively correlated with other measures of depression,
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measures of stress, anxiety, and negatively with well-being. Research with this
instrument has shown no statistically significant effects for ethnicity, gender, and age on
BDI-II scores.62 In case a participant reported suicidal ideation, the investigators in this
study contacted the study physician and/or University of Miami Mental Health
Department, immediately.

Anthropometrics and Body Composition
Weight was measured using an electronic balance. Participants were asked to
remove shoes and heavy outer garments like coats and to stand in the center of the
balance so that the weight was distributed evenly on both feet. Height was measured
using a stadiometer with a movable headpiece. Participants were asked to stand with their
back to the height rule with their feet together, while the back of the head, back, buttocks,
calves, and heels touched the upright tape. The participant was asked to look straight
ahead so that the ear canal was level with the cheek bone. The headpiece was lowered so
that the hair was pressed flat. Weight and height were recorded to the nearest 0.1 kg and
0.1 cm, respectively. Body mass index (BMI) was calculated using the formula: body
weight (kg)/ height (m)2 and accordingly, participants were classified into categories
based on the National Heart, Lung and Blood Institute recommendations: underweight
(<18.5 kg/m2), normal weight (18.5-24.9 kg/m2); overweight (25-29.9 kg/m2), and obese
(>30 kg/m2).
Waist circumference (WC) was measured at the umbilicus and hip circumference
(HC) was measured at the broadest circumference below the waist. Both of these were
done using a flexible but not stretchable measuring tape in three replicates to ensure
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reproducibility. The average of the three values was used to calculate waist-to-hip ratio
(WHR) by dividing WC by HC. Body composition was measured using bioelectrical
impedance (BIA), to determine % lean (fat-free, %FFM) and fat mass (%FM).

Cardiometabolic Risk Score (CMRS)
FDA approved and patented Electro Sensor Complex (ESC) software was used to
determine CMRS. This instrument combines three devices (ES-BC, TM-Oxi and
SudoPath) that use bioelectrical impedance, galvanic skin response, spectrophotometry
and an oscillometric blood pressure device. It measures different parameters of body
composition, endothelial function (based on pulse wave velocity) and ANS activity
(based on heart rate variability and sudomotor function) during baseline and the
performance of cardiac autonomic function tests (i.e., Valsalva maneuver, deep
breathing, and standing up).63,64
Steps of the procedure are described elsewhere.63,64 Briefly, study staff, trained
by the manufacturer, asked participants to sit on a confortable chair with their shoes and
socks off, feet on the metal plates, right index finger in the pulse oximeter, and blood
pressure cuff on the left arm. After inputting demographic, anthropometric and physical
activity data, the software initiated the baseline assessment for 1-2 minutes while the
participant was sitting down. Then the participant was asked to perform the Valsalva
maneuver by clamping their nose with their left hand while trying to breath out for 15
seconds with their mouth closed, building pressure like when popping ears. After
releasing their nose, participants were asked to breath deeply for 30 seconds, inhaling for
5 seconds and exhaling for 5 seconds. Finally, participants were asked to stand up, while
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straightening their left arm to their side and keeping their index finger in the pulse
oximeter, and remain standing up until the assessment was completed. The whole
assessment lasted about 5 minutes.
Details of the devices are discussed in previous publications and the
manufacturer’s website (http://www.ldteck.com).63,64 The Electro-Sensor Body
Composition (ES-BC) device uses a single-frequency bioelectrical impedance analyzer to
compute %FM using accepted peer reviewed published algorithms tailored to the general
and obese population based on gender, height, weight, age, and activity level.63,65-68
The TM-Oxi system assesses cardiac ANS function, including both SNS and
PNS, during baseline and validated cardiac autonomic reflex tests. It uses an automatic
oscillometric blood pressure device and pulse oximeter, which uses an optical technique
(spectrophotometry) to measure vascular dynamics and HRV, defined as the variation in
time intervals between each heart beat (i.e., R-R interval).69,70 The assessment of HRV is
a valid and useful method to measure cardiac ANS activity and identifies patients with
cardiac ANS dysfunction, which places them at risk of cardiac events.69,70 Briefly, the
pulse oximeter directs red and infrared light into the nail bed area of the right index finger
and measures the change in light absorption, reflection, and scattering between systole
and diastole creating a pulsatile signal or waveform, illustrated as a plethysmograph
(PTG) that varies in time with each heartbeat. The TM-Oxi applies a mathematical
algorithm, the Fast Fourier Transform (FFT), to the PTG recording (FFTPTG) to
manipulate the beat to beat R-R intervals and convert the signal from a time domain to
frequency domains. The frequency domains are then categorized by oscillating
frequency, which are the three frequencies of HRV: (1) very low frequency (PTGVLF)
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associated with thermoregulation and sweating that results in oscillation in vasomotor
tone controlled by SNS; (2) low frequency (PTGLF) related to baroreflex that is under
control of both SNS and PNS; (3) high frequency (PTGHF) associated with R-R interval
changes due to breathing, which is under PNS control.64 The pulse oximeter and
oscillometric blood pressure device are used to measure HRV and changes in blood
pressure at rest and during cardiac ANS tests to assess SNS and PNS balance.
PTG also provides information about arterial stiffness and endothelial function.
The TM-Oxi system quantifies PTG into a digital volume pulse (DVP) waveform that
represents the pressure wave that spreads from the heart to the periphery (systolic peak)
and reflects back to the heart (diastolic peak) during the cardiac cycle.64,71-73 Arterial
stiffness, which is partially a result of endothelial dysfunction, is defined as the
opposition to the pressure wave in the arteries, resulting in abnormal systolic and
diastolic peaks. Thus, the DVP waveform is mainly regulated by myocardial and arterial
characteristics and is used by the software to calculate indicators of vascular health and
arterial status.63,64
The SudoPath system measures sudomotor activity, which is controlled by post
sympathetic cholinergic nerve fibers (C-fibers) that innervate sweat glands, using 2
stainless steel electrodes on which the participant places their soles of the feet, where a
very high density of sweat glands are located.64 This system evaluates skin blood flow
(microcirculation), C-fiber condition, and sweat gland activity using the galvanic skin
response. The device generates a low voltage signal with weak DC current that
electrically stimulates C-fibers, which release acetylcholine, and thus, stimulate nicotinic
muscarinic receptors (M-receptors) in the skin and sweat glands.64,74 This causes a
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change in blood flow and sweat production that disturbs the electrical conductance of the
skin, which is then measured by the device using the principles of electrolysis as a marker
for SNS function.64
The software integrates these measurements with demographic, anthropometric
and physical activity data to calculate a CMRS, which is categorized as normal (≤4,) mild
(5-7), moderate (8-10), or high risk (≥11). Previous studies have shown the accuracy of
these three devices, compared to standardized assessments of body composition, ANS
activity, and cardiac output, and thus supporting the usefulness of these devices in
detecting complications related to metabolic syndrome, diabetes and CVD.63 Recently, a
study comparing diabetic and healthy controls showed that the CMRS calculated by this
software is significantly correlated with glucose and insulin measured during an oral
glucose tolerance tests (OGTT) and was significantly higher in participants with diabetes.
Also, specificity (92%) and sensitivity (83%) were high for the CMRS in differentiating
patients with diabetes from healthy control.64

Statistical Analysis
Statistical analyzes were performed on 95 participants. Data were analyzed using
frequencies, percentages, ranges, means, and standard deviations. Variables were checked
for non-normality and, if necessary, they were transformed to achieve a normal
distribution. Spearman correlations between two or more categorical variables were
performed to evaluate the relationship of vitamin status with CMRS. Independent t-tests
or chi-square were used to compare CMRS between vitamin D insufficient (25(OH)D
<30 ng/ml) and sufficient (≥30 ng/ml) participants. Multiple linear regressions were used
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to examine the effect size and the change in CMRS expected from a one-unit change in
vitamin D levels after adjusting for potential confounders. The significance level was set
at α=0.05, and statistical analyses were performed using SPSS 21.
Results
The mean ± SD 25(OH)D level was 30.71 ± 8.78, with 46.3% being insufficient
(<30 ng/ml) and 53.7% being sufficient (≥30 ng/ml) (Table 1). Mean ± SD age of the
participants was 63 ± 8.8 years, and 45% of participants were males, 45% Hispanic, 35%
white Caucasian and 16% African American. Mean ± SD number of diseases reported
were 4.73 ± 3.1. The percent of participants who reported diagnoses of diseases/diorders
related to the cardiovascular system are as follows: 3.2% had arrhythmia, angina or heart
murmur; 38.9% high blood pressure; 4.2% low blood pressure; 33.7% high cholesterol;
16.8% high triglycerides; 6.3% circulation problems; 7.4% shortness of breath; 2.1%
chronic obstructive pulmonary disease; 4.2% chronic bronchitis; 3.2% type 1 diabetes;
11.6% type 2 diabetes; and 2.1% hypoglycemia. Three-quarters reported taking
prescription medications and 80% taking over the counter (OTC) medications with an
mean ± SD number of 2.3 ± 2.2 and 1.5 ± 1.1 of prescription and OTC medications,
respectively. In respect to health risk behaviors, 78.9%, and 11.6% reported caffeine and
tobacco use, respectively. The mean ± SD number of alcoholic drinks consumed per
week was 2.1 ± 3.7.
The mean ± SD weight and BMI of the participants were 76.1 ± 17.1 kg and
27.01 ± 5.3 kg/m2, respectively. Sixty-one percent of the participants had BMI ≥25 and
the mean ± SD %FM was 30.9 ± 9.1. The mean ± SD systolic and diastolic blood
pressures were 132.6 ± 22.0 and 76.0 ± 14.5 mmHg, respectively, and the mean ± SD

186

heart rate was 70.4 ± 11.8 bpm. The mean ± SD CMRS was 5.17 ± 3.58, with 50.5%
having normal CMRS scores while 22.1%, 17.9% and 8.4% of the participants having
mild, moderate and high risk of CVD, respectively.
There was a significant inverse correlation between vitamin D status and CMRS,
with vitamin D insufficient participants having lower CMRS (r=-0.241, P=0.019).
Participants who were vitamin D insufficient had a significantly higher CMRS compared
with the vitamin D sufficient group (mean difference: 1.48, P=0.046) (Table 2).
Multiple linear regressions were used to evaluate the effect of vitamin D status on
CMRS (B (SE): -0.11 (0.05), 95% CI: -0.20; -0.02, P=0.016), after controlling for
covariates (Table 3). In this fully adjusted model, CMRS was expected to decrease by
0.11 points for every unit increase in vitamin D levels. Vitamin D and number of
prescription medications predicted about 7% of the variation in CMRS.

Discussion
CVD risk and vitamin D status and the benefit of vitamin D supplementation on
cardiovascular health is well established.5-10,12-16,18,19,75 The observations that vitamin D
deficiency, cardiac ANS and endothelial dysfunction are independently linked to CVDrelated outcomes suggest a potential relationship between vitamin D deficiency and
cardiovascular risk in diseased and healthy humans.5,18,40 Vitamin D affects multiple
cellular signaling pathways via genomic and non-genomic actions that have the potential
to affect cardiovascular health.76,77 These include vitamin D effects on PTH, RAAS,
cytokine production, myocyte calcium influx, endothelial growth and function, and
cardiac ANS activity.21 Our results support the findings from previous studies on the
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association between vitamin D deficiency and CMRS, possibly by mediating genomic
and non-genomic mechanisms that influence ANS activity and vascular function, thus
affecting cardiac performance. This is the first study to investigate the relationship
between vitamin D status and cardiometabolic risk, using a rapid, non-invasive method
that integrates measures of ANS and endothelial function, anthropometrics, lifestyle
characteristics, and body composition data. Previous studies have shown a relationship
between vitamin D and cardiac ANS, independent of other cardiovascular risk factors
like endothelial dysfunction and increased %FM.
In humans, the relationship between vitamin D status and ANS function has been
studied in diseased and healthy populations. For instance, in 36 patients with nonischemic dilated cardiomyopathy (NIDCM), 25(OH)D was positively correlated with
HRV parameters, with vitamin D insufficiency having deleterious effects on cardiac ANS
function.28 Krause et al.78 showed that patients with chronic kidney disease (CKD), who
have impaired vitamin D synthesis, when exposed to short-term artificial sunlight
heliotherapy had a significant increase in 25(OH)D levels and an elevation in
measurements of vagal activity that were severely depressed at baseline. The magnitude
of 25(OH)D increase was directly correlated with the magnitude of increased
cardioprotective PNS activity, implying that vitamin D levels may constitute an important
role in the development of common CVD-related outcomes in this population by
affecting the ANS. Chan et al.79 reported that patients with CKD demonstrated poor
cardiac ANS activity, which was characterized by decreased activity of the inhibitory
PNS. Furthermore, in patients with end-stage kidney disease (ESKD), depressed HRV is
extremely common and usually presents as suppressed PNS activity with increased SNS
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input to the sino-atrial node.26,79 For the dissertation by Mann,26 a cross-over study was
conducted in which 56 participants with ESKD on hemodialysis were randomized to
either conventional (0.25 mg alfacalcidol 3 times per week plus placebo 3 times per week
for 6 weeks) or intensive (0.25 mg alfacalcidol 3 times per week plus 50,000 IU
ergocalciferol once a week plus placebo 2 days per week for 6 weeks) vitamin D therapy
followed by a 12-week washout period and another 6 weeks of vitamin D therapy. They
did not observe significant changes in measures of cardiac autonomic tone, mineral
metabolism or RAAS activity but an exploratory subgroup analysis found that after
treatment, participants who remained vitamin D deficient (25(OH)D <20 ng/ml),
compared to those who achieved sufficiency (> 30 ng/ml), had significant ANS
imbalance. In the ESKD population, abnormal HRV and ANS dysfunction is also
common in this population; thus, putting them at higher risk of sudden arrhythmic
death.79-85
Currently, only one study has evaluated the relationship between vitamin D status
and Cardiac Autonomic Neuropathy (CAN) in type 2 diabetics using cardiac autonomic
reflex tests.29 In this study, several HRV parameters during ANS tests were assessed and
scored as normal, borderline and abnormal to calculate a CAN risk score. They found that
vitamin D deficiency (25(OH)D <10ng/ml) was significantly correlated with decreased
HRV in the supine and upright position and those participants with vitamin D levels <10
ng/ml had significantly increased CAN risk compared to those with 25(OH)D between
10-20 ng/ml.29
In a healthy Korean population over the age of 20 years, investigators observed
that 25(OH)D was positively associated with decreased HRV.27 They observed that
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vitamin D deficient individuals (25(OH)D <15 ng/ml) were 3.1 times more likely to have
low HRV. In 2013, Mann et al.24 used power spectral analysis of electrocardiogram
recordings to measure HRV and thus assess cardiac ANS activity at baseline and during a
graded angiotensin II challenge in 34 healthy humans. They found a significant
suppression of ANS balance in vitamin D deficient (25(OH)D <20 ng/ml) participants at
baseline, but no difference was observed during the challenge. In an intervention study,
the same group demonstrated that healthy adults supplemented with 10,000 IU of vitamin
D for four weeks had a significant improvement in cardiac ANS balance, specifically in
enhancing the cardio-protective PNS activity.25
Besides the link between vitamin D and ANS, 25(OH)D levels have been
independently associated with several tests of endothelial dysfunction, arterial stiffness,
and coronary flow reserve.86,87 In addition, studies have demonstrated that vitamin D
treatment improves arterial stiffness as measured by pulse wave velocity.88,89 Thus,
vitamin D may affect vascular tone and blood pressure indirectly via modulation of
cardiac ANS activity or directly by affecting endothelial function.
Our study, like other cross-sectional and longitudinal studies, supports a
relationship between low vitamin D metabolites and cardiovascular risk.21 Crosssectional studies are descriptive in nature, and even though they can establish association
among factors, they do not prove cause and effect. Thus, these associations may be
confounded by reverse causality, as cardiovascular outcomes may affect vitamin D status.
Interventional studies until today show a modest effect of vitamin D on hypertension and
equivocal impact on arterial stiffness, endothelial function, and ANS activity.21 Despite
observational and mechanistic data, which support vitamin D having a protective role in
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CVD, intervention studies to date are not promising. The mechanism by which vitamin D
affects cardiovascular health is still unclear and the need for long-term intervention
studies using cardiovascular events as a primary outcome is clear to provide answers to
the many remaining questions. It is essential to determine if vitamin D supplementation
has the potential for reversing the increase in CVD risk associated with vitamin D
deficiency. Vitamin D supplementation may be a cost-effective treatment to improve
ANS and endothelial function in healthy and chronic disease populations and thus reduce
CVD risk. Based on the acceptance of preliminary findings on the effect of
supplementation on CVD, a cost-benefit analysis has estimated a reduction of as many as
a total of 336,000 deaths per year, including 180,000 deaths from CVD, if the United
States adult population were to raise vitamin D levels above 40 ng/ml. This also
translates into a reduction of about $130 billion per year in direct care costs.90
Besides its cross-sectional nature, this study has other limitations. This study may
suffer from selection bias. First, we included younger older adult participants (>55 years
of age) to have a wider age range for recruitment purposes. Therefore, some of our
participants were younger than what is considered “old age,” with 36% and 63.8% of our
participants being under the age of 60 and 65, respectively, and thus, adding
heterogeneity to our study. Nevertheless, we did not find a significant difference in age,
number of participants over the age of 60, and number of participants over the age of 65
between vitamin D insufficient and sufficient groups. Moreover, age was not a risk factor
for vitamin D insufficiency or CMRS in this study population since it was not a
significant predictor of any of these two variables in regression models. Second, the
participants in this study were mostly healthy, since the criteria for the parent study
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excluded current diagnoses of numerous diseases/conditions that affect vitamin D
metabolism and absorption, medications that disturb vitamin D metabolism, and current
vitamin D supplement use. Our sample was not randomly selected from the general older
adult population in Miami-Dade, but instead were healthier older adults who volunteered
to participate and met inclusion criteria. The results of this study cannot be extrapolated
to the general Miami-Dade older adult population, other populationa in the United States,
or globally.
An additional limitation of this study was the low adjusted R2, which assesses the
percentage of the variation of the dependent variable that is explained by the linear
regression model. Even though it is indicative of how well the linear model fits the
observations, it doesn’t provide a hypothesis test for this relationship. A low adjusted R2
means that the model is not precise. However, if the adjusted R2 is low but the predictors
are statistically significant, conclusions can still be drawn about the relationship between
the dependent variable and predictors. Thus, highly variable data, as indicated by low
adjusted R2, can still have a significant trend that indicates the dependent variable is
affected by the predictors.
Furthermore, vitamin D is part of complex mineral metabolism functions that
involves measures known to influence cardiovascular risk, including PTH, phosphate,
and calcium. Our study did not measure any of these potential intermediaries between
vitamin D and cardiovascular health. PTH, possibly through alteration in calcium
homeostasis, has been associated with cardiomyocyte hypertrophy, increased myocardial
contractility, calcification of heart valves and myocardium, and arterial stiffness, and
predisposition to increased blood pressure.91-93 Also, these studies did not measure
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biomarkers that are clinically established as risk factors for CVD, such as cholesterol,
triglycerides, glucose, hemoglobin A1C, and others. Moreover, we did not find a
significant association between vitamin D and self-reported CVD outcomes that may
affect CMRS, such as hypertension, dyslipidemia and diabetes. Thus, future studies need
to consider measuring other biomarkers related to vitamin D and mineral metabolism to
examine the possible mechanism by which this nutrient may affect cardiovascular health.
The ESC system software may need to be updated to include cardiometabolic biomarker
information integrated into the calculation of CMRS.
Finally, although plethysmography and pulse wave velocity have been considered
valid tools for measuring HRV and arterial stiffness to evaluate ANS activity and
endothelial function, no one parameter has been established as superior in their predictive
ability as surrogate marker for adverse cardiovascular outcomes.69,94-97 Although shortterm analysis of HRV and endothelial function at rest may provide significant prognostic
value, it limits the comparison of HRV parameters obtained during various activities that
can challenge the cardiac ANS like exercise and sleep. Thus, it only measured relative
changes in ANS activity rather than the absolute intensity of SNS and PNS activity. An
advantage of this study, however, is the use of established tests of cardiac autonomic
reflex that have been validated to detect CAN, by measuring changes in HRV and
vascular dynamics during different challenges to the body.

Conclusions
Our study found a significant association of vitamin D status with CMRS,
calculated from composite measures of body composition, ANS activity, and endothelial
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function by using a novel system. Thus, data suggest that vitamin D may play a
significant role in CVD, probably through modulation of cardiac performance by
affecting ANS activity, vascular tone, and endothelial function. Due to the nature of this
cross-sectional study, we cannot conclude that vitamin D deficiency is a cause of
increased cardiovascular risk. Future prospective randomized control studies, with
sufficient resources, are warranted to evaluate the change in cardiometabolic risk in
vitamin D insufficient older adults supplemented with vitamin D and to examine the
cause-effect relationship.
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Table 1: Characteristics of Participants (n=95)
Vitamin D levels (ng/ml) (Mean ± SD)
30.71 ± 8.78
Age (years) (Mean ± SD)
62.96 ± 6.45
Male gender (N (%))
43 (45.3)
Ethnicity (N (%))
Hispanic
43 (45.3)
White Caucasian
33 (34.7)
African-American
15 (15.8)
Other
4 (4.2)
Years lived in the United States (Mean ± SD)
44.98 ± 21.62
Number of diseases or conditions (Mean ± SD)
4.73 ± 3.05
Participants reporting prescription medication use (N (%))
71 (74.7)
Number of prescription medications (Mean ± SD)
2.27 ± 2.21
Participants reporting OTC medication use (N (%))
76 (80.0)
Number of OTC medications (Mean ± SD)
1.47 ± 1.12
Caffeine consumers (N (%))
75 (78.9)
Cups of caffeinated coffee or caffeine containing beverages per
1.64 ± 1.38
day (Mean ± SD)
Alcoholic drinks per week (Mean ± SD)
2.11 ± 3.70
Smokers (N (%))
11 (11.6)
Weight (kg) (Mean ± SD)
76.12 ± 17.11
2
BMI (kg/m ) (Mean ± SD)
27.01 ± 5.27
%FM (Mean ± SD)
30.92 ± 9.09
SBP (mmHg) (Mean ± SD)
132.60 ± 21.97
DBP (mmHg) (Mean ± SD)
76.03 ± 14.48
HR (bpm) (Mean ± SD)
70.43 ± 11.83
4353.75 ±
Total physical activity (IPAQ MET minutes per week)
(Mean ± SD)
4333.15
Depressive symptoms (BDI score) (Mean ± SD)
7.21 ± 7.62
SD: Standard Deviation; N: Number; BMI: Body Mass Index; FM: Fat Mass; SBP:
Systolic Blood Pressure; DBP: Diastolic Blood Pressure; HR: Heart Rate; bpm: beats
per minute; IPAQ: International Physical Activity Questionnaire; BDI: Beck
Depression Inventory.
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Table 2: Comparison of Cardiometabolic Risk Scores (CMRS) Between Vitamin D
Insufficient and Sufficient Participants
Vitamin D
Vitamin D
Study
Insufficient
Sufficient
population
MD P-Value
<30 ng/ml
≥ 30 ng/ml
(n=95)
(n=44)
(n=51)
CMRS
5.17 ± 3.58
5.95 ± 3.29
4.48 ± 3.72
1.48
0.046
(Mean ± SD)
Independent t-tests. SD: Standard Deviation; MD: Mean Difference.
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Table 3: The Relationship Between Vitamin D Levels and CMRS in Multiple
Linear Regressions
Adjusted
β (S.E.)
P-Value
R2
Model 1 Vitamin D status (ng/ml)
-0.09 (0.05)
0.056
0.029
Vitamin D status (ng/ml)
-0.11 (0.05)
0.016
Model 2
0.069
Number of prescription medications 0.37 (0.17)
0.029
Stepwise linear regression. Dependent variable:CMRS. Model 1: Vitamin D status; Model 2: Model 1
+ age, gender, marital status, race, years living in United States, education, employment, income,
surgery, injury, falls, number of diseases, presence of diseases that can affect cardiovascular system
(arrhythmias, high blood pressure, low blood pressure, high cholesterol, high triglycerides, circulation
problems, stroke, COPD, bronchitis, shortness of breath, type 1 and type 2 diabetes, hypoglycemia),
prescription medications, over the counter medications, vitamin/ mineral supplement use, coffee use,
alcohol use, smoking, depressive symptoms, fear of falling, physical activity. β: Beta Coefficient; SE:
Standard Error; CI: Confidence Interval.
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CHAPTER VII: SUMMARY AND CONCLUSIONS

Our study showed that vitamin D insufficiency is common in healthy communitydwelling older adults (>55 years old) living in Miami-Dade County, especially among
Hispanics. The prevalence of vitamin D deficiency (25(OH)D <20 ng/ml) and
insufficiency (25(OH)D <30 ng/ml) was 10% and 36%, respectively, which, as expected,
was lower than that reported for the general United States adult and older adult
population. This was expected in a population that has a greater opportunity for vitamin
D skin synthesis due to year-round sunlight availability. Our results, however, are similar
to that reported in previous studies conducted in South Florida.1,2
Despite the lower prevalence of vitamin D insufficiency in this study compared to
the general United States older adult population, it is still a public health concern, and
identifying risk factors is critical to develop effective interventions. As expected, vitamin
D intake was not significantly correlated with vitamin D status in our study, and our
findings are supported by other studies that have previously shown that dietary intake has
minimal contribution to vitamin D status.3,4 On the other hand, we found that lack of sun
exposure, higher percent fat mass (%FM), and lack of use of vitamin/mineral
supplements were risk factors for vitamin D deficiency in this older group. Ethnicity,
however, was the most consistent and important risk factor in this study population, since
those who were vitamin D insufficient were more likely to be Hispanic, and thus
Hispanics had significantly lower vitamin D levels than white Caucasians and AfricanAmericans. The reasons why immigrant Hispanics may be more likely to be vitamin D
deficient and insufficient are unknown, but it may be due to differences in sun exposure
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behaviors, public health awareness initiatives in their home countries and less access to
healthcare services due to their immigration status. Since vitamin D deficiency is linked
to health risk factors, it is important that health professionals become aware of the
connections of vitamin D status with intake, bioavailability, and skin synthesis, so that
they are able to identify patients at risk and develop and plan pertinent interventions to
prevent and correct deficiency and insufficiency, especially in vulnerable populations like
Hispanics.
Vitamin D deficiency in older adults has been linked to leading causes of
disability and death in the United States including cancer, diabetes, falls, fractures, and
cardiovascular disease (CVD).5-14 Vitamin D deficiency has received much attention as a
risk factor for falls because of its association with gait impairment (slower gait speed),
global cognitive deficits, and compromised executive function.15-19 Nonetheless, studies
that investigate the relationship between vitamin D status, gait and cognition have looked
at these factors independently. We used the dual task physical performance test to assess
the relationship between vitamin D and cognition, especially executive function, in the
context of mobility. We evaluated the competition for information processing capacity
between gait stability during the primary automatic task (i.e., walking) and cognitive
performance during the completion of the secondary cognitive task (i.e., counting
backwards from 50 by 1). Dual tasking usually results in worse performance in either one
or both tasks when compared to performance of each task individually.20 As
hypothesized, in our study we found a marked deterioration of the automatic primary
motor task during dual tasking, and not the secondary cognitive task, when compared to
single tasking. Thus, when dual tasking, this healthy older adult population prioritized the
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secondary cognitive task at the expense of compromising their motor capacity. Despite
these findings, we did not find a significant assocation between vitamin D status and the
change in peformance in cogntive and gait tasks from dual to single tasking; thus, vitamin
D insufficient participants did not have worse dual task performance. No signficant
differences were found between vitamin D status in motor functioning during each
individual task. Interestingly, we found counting rates were significantly lower in the
vitamin D insufficient group, meaning they had worse cognitive performance, since they
counted significantly less figures per second compared to the vitamin D sufficient group
when performing either single or dual tasks. Since counting backwards is a mental
tracking task, which is a component of executive function, our results support a
relationship between vitamin D insufficiency and impaired executive function. Executive
dysfunction has been previously associated with fall risks in the elderly, and it could be a
possible mediator between vitamin D and falls.21 Our data suggest that cognition may
play a signifcant role in vitamin D’s influence on falls, while motor function may play a
lesser role in healthy young older adults.22
Furthermore, our results support previous studies that found an association
between vitamin D deficiency and cardiometabolic risk, We found a significant
association of vitamin D status with cardiometabolic risk score (CMRS), calculated from
composite measures of body composition, autonomic nervous system (ANS) activity and
endothelial function by using a novel system. Our data suggest that vitamin D may play a
signifcant role on CVD, probably through modulation of cardic performance by
mediating genomic and non-genomic mechanisms that affect ANS activity, vascular tone
and endothelial function. This is the first study to investigate the relationship between
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vitamin D status and cardiometabolic risk, using a rapid, non-invasive method that
integrates measures of ANS and endothelial function, anthropometrics, lifestyle
characteristics, and body composition data. Previous studies have shown a relationship
between vitamin D and cardiac ANS, independent of other cardiovascular risk factors
like endothelial dysfunction and increased %FM.
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CHAPTER VIII: STRENGTHS AND LIMITATIONS

Cross-sectional studies can establish association among factors; however, they do
not prove cause and effect. However, understanding the relationship between nutrition
and disease is the foundation for developing interventions that seek to enhance nutritional
status to prevent or ameliorate continued proliferation of chronic diseases during the
process of aging. Thus, this study provides the foundation for future longitudinal
interventional studies that investigate the cause and effect relationship between vitamin D
status, nutritional supplementation, and non-skeletal outcomes such as cardiometabolic
risk and falls associated with cognitive executive function during mobility.
Another limitation of this study was selection bias. Besides the expected higher
sun exposure of this population, the broader age criterion could be a possible explanation
for the lower prevalence of vitamin D insufficiency observed in our study. In addition,
the participants in this study were healthier, since the exclusion criteria for the parent
study included current diagnoses of numerous diseases/conditions. Thus, this was not a
randomly selected sample from the general older adult population in Miami-Dade, but
instead were healthier older adults who volunteered to participate and met inclusion
criteria. Volunteer bias may be a strong limitation, as volunteers have been found to be
more intelligent, have higher social status and the need for approval, and be less
authoritarian and conforming than the general population.1 Furthermore, small sample
size could have also affected the results of this study. Due to limitations of time and
resources, we were only able to recruit 97 participants, reducing the power to detect
significant differences in this study.
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Other limitations include over-and under- reporting in surveys, the amount of
error inherent to short food frequency questionnaires, and the lack of ecological validity
of the dual task physical performance test and cardiometabolic risk assessment. Despite
the limitations in study design and tools used, we did find significant findings in relation
with vitamin D status and executive function and cardiovascular risk in this healthy
young older adult population. This may indicate that healthy older adults may be at risk
of developing health consequences from vitamin D insufficiency at a younger age and
before any cognitive impairment and cardiometabolic risks are evident. Furthermore, the
major strength of this study was that it used novel tests to assess non-skeletal outcomes
that have been previously associated with vitamin D insufficiency and deficiency. These
allowed for the evaluation of the relationship of vitamin D status with cognition in the
context of mobility and with other risk factors for cardiovascular disease. Thus, future
studies evaluating the relationship between this nutrient and nonskeletal health outcomes
in the elderly should consider including younger older adults to determine the early onset
of health consequences related to vitamin D status
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CHAPTER IX: FUTURE RESEARCH
Future double-blind longitudinal randomized controlled clinical trials, with
significant resources to support a bigger sample size, are warranted to evaluate the
determinants of vitamin D status, the long-term consequences of vitamin D
deficiency/insufficiency, and the effect of vitamin D supplementation on non-skeletal
outcomes in healthy middle-aged and older adults with vitamin D insufficiency and/or
deficiency. This type of study is necessary to determine a causal relationship between
vitamin D status and non-skeletal outcomes, such as cognition in the context of mobility
(as measured by dual task physical performance tests) and cardiometabolic risk (as
measured by a composite score involving several cardiovascular risk factors).
This study provides data to support the need for further research that investigates
the determinants of vitamin D status living in sunny South Florida. Despite the lower
prevalence of vitamin D insufficiency in this study compared to the general United States
older adult population, it is still a public health concern. Identifying risk factors is critical,
so that health professionals become aware of the connections of vitamin D status with
intake, bioavailability, and skin synthesis. Thus, clinicians need to identify patients at risk
of vitamin D deficiency and insufficiency and develop pertinent interventions in order to
prevent and correct these, especially in vulnerable populations such as the immigrant
Hispanic community. It is important to determine the barriers to sun exposure and
vitamin D supplementation that makes this population vulnerable to vitamin D
insufficiency and at risk of developing chronic diseases associated with this nutrient
deficiency.
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Findings from our study support further research that investigates the benefit of
vitamin D supplementation in this population. Our results support a relationship between
vitamin D deficiency and executive dysfunction, suggesting that cognition may play a
signifcant role in vitamin D’s influence on falls, while motor function may play a lesser
role in this healthy younger older adult population. Future interventions are warranted to
determine if vitamin D deficiency is a cause of executive dysfunction that leads to
decreased performance in mental tracking tasks during dual tasking. Furthermore, our
study supports a relationship between vitamin D and cardiometabolic risk, suggesting
vitamin D may mediate its effects on cardiovascular health through modulation of the
autonomic nervous system (ANS) and vascular dynamics. Despite observational and
mechanistic data, which support vitamin D having protective role in CVD, intervention
studies to date are controversial. The mechanism by which vitamin D affects
cardiovascular health is still unclear and the need for long-term intervention studies using
cardiovascular events as a primary outcome is clear to provide answers to the many
remaining questions. It is essential to determine if vitamin D supplementation has the
potential for reversing the increase in CVD risk associated with vitamin D deficiency.
Vitamin D supplementation may be a cost-effective treatment for improving
and/or maintaining the health of both healthy and populations with chronic disease. This
type of intervention may reduce the risk of developing chronic disease. A cost-benefit
analysis has estimated a reduction of as many as a total of 336,000 deaths per year if the
United States adult population were to raise vitamin D levels above 40 ng/ml. This also
translates into a reduction of about $130 billion per year in direct healthcare costs.1
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Table 1: Observational Studies Investigating the Association Between Vitamin D Status and Gait Velocity in Healthy
Community-Dwelling Older Adults
Author,
Study
Outcomes
Conclusions
Year, Study Population
Design
1 Verreault et 628
25(OH)D (ng/ml) No significant findings. 25(OH)D Continuous: mean of 21.2 and
1
al. (2002)
postmenopausal Gait velocity (time median of 19.8. Categorical, 25(OH)D cut off groups and %
Longitudinal women (>65
(s) to walk 4m at
sample: <10: 12.4%. Baseline 25(OH)D to gait velocity: not
(3 yrs.)
years old) from usual gait)
significant (p value NR). No association between low 25(OH)D
WHAS study in
and decline in gait velocity through time (<10ng/ml: p=0.98; 10USA.
21ng/ml: p=0.76).
2 Zamboni et
269 adults (6825(OH)D (ng/ml) No significant findings. 25(OH)D Continuous: mean +/- SD for
al. (2002)2
75 years old) in Gait velocity
women and men of 13.2+/-9.6 and 22.6+/-15.0, respectively. Men
CrossVerona. Mean
(distance (cm)
vs. women: p<0.001. 25(OH)D cut off categories and % sample:
sectional
+/- SD age of
walked in 6 min.
women <15: 50.8% and >15: 49.2%; men <15: 35.1% and >15:
women and men at normal velocity) 64.9%. Gait velocity: mean distance +/- SD for women and men
71.9+/-2.4 and
of 340.9+/-64.2 and 391.2+/-69.4, respectively. Men vs., women:
71.8+/-2.1
p<0.001. 25(OH)D to distance: not significant in men (r=0.04) and
years.
women (r= 0.13; both p>0.05). Difference in distance between
25(OH)D <15 and >15: not significant in men (p=0.214) and
women (p=0.156).
3 Bischoff4100 adults (60- 25(OH)D (ng/ml) Significant findings: lower 25(OH)D, slower gait velocity.
Ferrari et al. 90 years old)
25(OH)D continuous: mean of 26.3. 25(OH)D quintiles and
3
(2004)
from NHANES Gait velocity (time ranges: Q1: 3.5-17.4; Q2: 17.5-22.7; Q3: 22.7-27.8; Q4: 27.9Cross
1988-1994.
(s) to walk 8ft
34.4; Q5: 34.5-160.3. Gait velocity: mean time +/- SD (s) of
Mean +/- SD
(2.4m).
3.7+/-1.6s. Difference in time between quintiles: p for trend
sectional
age: 71.4+/-7.9
<0.0001. Fully adjusted model: Q2-Q5 were significantly different
years.
(all p<0.05) from Q1 (p for trend <0.001). Regression plots: time
decreased throughout range of 9.0-37.6ng/ml but most
improvement between 9-16ng/ml
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Table 1 continued.
Author, Year,
Study Design
4 Gerdhem et al.
(2005)4
Cross-sectional

5

Faulkner et al.
(2006)5
Cross-sectional

6

Suzuki et al.
(2008)6
Cross-sectional

Study
Population
986
ambulatory
women (>75
years old)
from OPRA
study in
Sweden.

Outcomes

Conclusions

25(OH)D
(ng/ml)
Gait velocity
(time (s) to walk
30m and turn
back at fastest
pace)

Significant findings: lower 25(OH)D, slower gait velocity. 25(OH)D
Continuous: mean +/- SD of 38+/-12. 25(OH)D cut off categories
and % sample: <20: 4%; <30: 26%. Gait velocity: mean time +/- SD
for <20: 29+/-10; >20: 24+/-19 (difference: 19%); <30: 27+/-12; >30:
24+/-7 (difference: 14%)). 25(OH)D to time: significant (r=0.17,
p<0.001). Difference in time between groups: significant for both cutoff values (p <0.001).

389 women
(>65 years
old) from
SOF in USA.
Median age
(IQR): 70
years (67-75)
2044 adults
(>65 years
old) in Tokyo.
Mean +/- SD
age of men
and women:
74.5+/-5.1
and 75.4+/4.7 years,
respectively.

25(OH)D
(ng/ml)
Gait velocity
(calculated from
time (s) to walk
6m at rapid or
usual pace; m/s)
25(OH)D
(ng/ml)
Gait velocity
(calculated from
time (s) to walk
5m at normal
velocity, m/s)

No significant findings. 25(OH)D Continuous (ng/ml): median
(IQR) of 25 (19.0-31.0). 25(OH)D cut off categories and % sample:
<10: 2.6%. 25(OH)D quartiles and range: Q1: 7-22; Q2: 23-30; Q3:
31-40; Q4: 41-220. Gait velocity: mean +/- SD of 1.01+/-0.22.
25(OH)D to gait velocity: not significant (p>0.05). Difference in Gait
between quartiles: not significant (p trend= 0.784).
Significant findings: lower 25(OH)D, slower gait velocity. 25(OH)D
continuous: mean +/- SD men and women of 28.5+/-5 and 24.2+/4.9, respectively. Men vs. women: p<0.001. 25(OH)D quartiles and
ranges for men (Q1: <25; Q2: 25-29; Q3: 29-32; Q4: >32) and
women (Q1: <21; Q2: 21-24; Q3: 24-28; Q4: >28). 25(OH)D cut of
groups and % sample for men (< 20: 4.8%) and women (<20:
17.7%). Gait velocity: mean +/- SD of men (1.23+/-0.26) and
women: (1.18+/-0.29). Difference in gait between Q1 and Q4 and cut
off groups: not significant in men, significant in women (both
p<0.001). Adjusted model: significant in men: (p=0.012) and women
(p<0.001)
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Table 1 continued.
Author,
Study Population
Year, Study
Design
7 Annweiler et 739 women (>75
al. (2010)7
years old) from
CrossEPIDOS study
sectional
cohort in France.
Mean +/- SD
age: 80.2 +/-3.5
years.
8

Chan et al.
(2012)8
Longitudinal
(4 yrs.)

9

Boersma et
al. (2012)9
Crosssectional

Outcomes

25(OH)D
(ng/ml)
Gait velocity
(calculated
from time (s) to
walk 6m at
usual and
fastest)
714 men (>65
25(OH)D
years old) from
(ng/ml)
MrOS in Hong
Gait velocity
Kong. Mean +/(calculated
SD age: 72.8 +/from time (s) to
5.1 years.
walk 6m at
normal pace).
145 adult (>65
25(OH)D
years old) fallers
(ng/ml)
in Australia. Mean Gait velocity
+/- SD age
(measured
(range): 79.1+/using
7.8 years (73-88). GAITRITE,
m/s).

Conclusions

Significant findings: lower 25(OH)D, slower fast gait velocity.
25(OH)D cut offs categories and % sample: <10: 17%; 10-20:
55%; 20-30: 18%; >30:10%. Gait velocity: mean +/- SD of usual
and fastest 0.87+/-0.22 and 1.010+/-0.27, respectively. Difference
in usual gait velocity between groups: not significant (p = 0.145).
Difference in fast gait velocity between groups: significant (p =
0.021, p trend 0.007). Adjusted model for fast pace: significant (β =
0.18, p=0.033).
No significant findings. 25(OH)D Continuous: mean of 31.2.
25(OH)D cut off categories and % sample: < 20: 5.9%; 20-30:
41.5%; > 30: 52.6%. 25(OH)D quartiles and ranges: Q1: <25; Q2:
25.3-30.4; Q3: 30.5-36.5; Q4:>36.5. Difference in gait velocity
between quartiles: not significant (p=0.08). Change at 4 years for
ALL quartiles: not significant (p=0.93).
Significant findings: lower 25(OH)D, slower gait velocity.
25(OH)D cut off categories and % sample: < 12: 26%; 12-20:19%;
>20:54%. Gait velocity: mean +/- SD of 0.55+/-0.5. Gait velocity
difference between groups: significant (p<0.05). Adjusted model:
significant (B=0.26, p=0.045).
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Table 1 continued.
Author,
Study Population
Year, Study
Design
10 Kositsawat
1826 adults (>50
et al.
years old) from
(2013)10
NHANES 2001Cross2002.
sectional

11 Mathei et al.
(2013)11
Crosssectional

367 Caucasian
adults (>80 years
old) from BFc80+
study, Belgium.
Mean +/- SD age:
84.7+/-3.6

Outcomes

Conclusions

25(OH)D (ng/ml)
Gait velocity
(calculated from
time to walk 20ft
(6m) at usual
velocity, m/s).
Slow gait
<0.8m/s
25(OH)D (ng/ml)
Gait velocity
(calculated from
time (s) to walk
3m, turn around
and walk back as
quickly as
possible; m/s).
Converted into
gender-adjusted
quartiles,
dichotomized
into a score
above or in the
lowest quartile
(<p25).

Significant findings: lower 25(OH)D, slower gait velocity.
25(OH)D cut off categories and % sample: <10: 30.8%; 10-19.9:
19.7%; 20-29.9: 13.5%; >30: 10.1%. Difference in % subjects
with slow gait velocity between all 25(OH)D groups:
significantly higher in those with lower vitamin D (p trend
<0.001). Difference in % subjects with slow gait velocity between
<10 and >30: <10 more likely than >30 to have slow gait
velocity (<10: OR 2.77; CI 1.08-7.10: p=0.03; >30: ref).
No significant findings. 25(OH)D cut off categories and %
sample: <10: 32.7%; 10-19: 32.9%; 20-29: 21.5%; >30: 12.8%.
Gait velocity: 24.6% were in the lowest quartile of walking
velocity. Difference % participants with walking velocity <p25
between 25(OH)D groups: not significant (p=0.286).

221

Table 2: Interventional Studies Investigating the Effect of Vitamin D on Gait Velocity in Healthy Community-Dwelling
Elderly
Author,
Study
Intervention Outcomes
Conclusions
Year,
Population
Study
Design
1 Kenny et al. 65 men
1. Placebo.
25(OH)D
No significant findings. Baseline 25(OH)D for placebo and
12
(2003)
(>65 years
(ng/ml)
intervention: mean +/- SD of 23.6+/-7.5 and 26.0+/-6.7,
2. 1000
Double
old), in the IU/day
respectively; Between groups: p=0.21. F/U 25(OH)D for
Gait velocity
blind RCT
USA. Mean Vitamin D.
(time (s) to
placebo and intervention: mean +/- SD of 22.6+/-6.8 and
+/- SD age: All received walk 8ft)
34.9+/-5.5, respectively. Baseline to F/U change in placebo
76+/-4
500mg
and intervention: p>0.05 and p<0.001, respectively. Baseline
years.
calcium. F/U
gait velocity between groups: p=0.63. Difference in gait
6months.
velocity between placebo vs. intervention at F/U: p =0.128;
group x time p value = 0.678.
2 Gallagher,
48 adults
1. Hormone
25(OH)D
No significant findings. Decline in timed walk at 3yrs:
J.C.
(age
calcitriol vs. placebo: p>0.1.
treatment. 2. (ng/ml)
(2004)13
inclusion
0.25ug
Gait velocity
Double
not
(calculated
calcitriol
blind RCT
reported),
from time (s)
twice daily.
including
to walk 5m at
3. Hormone
hysterectom treatment +
normal and fast
ized women calcitriol. 4. velocity; m/s)
in USA.
Placebo. F/U
Mean age: 6 months for
72 years.
3 yrs.
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Table 2 continued.
Author, Year,
Study Design
3 Bunout et al.
(2006)14
Double blind RCT

Study
Population
96 adults (>70
years old) in
Chile. Mean +/SD age: 76+/-4
years.

4 Brunner et al.
2301
(2008)15
postmenopausal
Double blind RCT women (50-79
years old) from
WHI, USA

Intervention

Outcomes

Conclusions

1. Control. 2.
400IU/day
only. 3.
Training only.
4. 400IU/day
and training.
All groups
received
800mg/ml
calcium. F/U
9 months.

25(OH)D
(ng/ml)
Gait velocity
(Distance
(m) walked
at constant
pace for 12
min.)

1. Placebo.
2.1000mg
calcium
carbonate +
400IU vitamin
D3 per day.
F/U: 2 yrs.
and 5 yrs.

25(OH)D
(ng/ml)
Gait velocity
(Time (s) to
walk 6m at
usual
velocity).

Significant findings: Increased distance
(faster gait velocity) in vitamin D only group
compared to control and in vitamin D
supplemented groups (2 and 4) compared to
non-supplemented. 25(OH)D at baseline for
vitamin D supplemented and nonsupplemented: mean +/- SD of 12.4+/-2.2 and
13.1+/-2.7, respectively. 25(OH)D at F/U for
vitamin D supplemented and non-supplemented
groups: mean +/- SD of 25.8+/-6.4 and
14.5+/-4.6, respectively; baseline vs. F/U:
p<0.001. Gait velocity: between group
difference at baseline: p=0.61. Difference in
gait velocity between control vs. vitamin D only
at F/U: significant (p<0.01). Difference in gait
velocity in vitamin D supplemented vs. nonsupplemented at F/U: significant (p=0.02).
Significant findings: Less increase in time to
walk distance (smaller change in gait velocity)
from baseline to F/U in the control group
compared to intervention. Gait velocity: no
difference between groups at baseline
(p=0.114). Time difference between baseline
and 5 years F/U: significant (mean difference
between groups: -.054 +/-26; p=0.030.
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Table 2 continued.
Author, Year,
Study Design
5 Lips et al.
(2010)16
Double blind RCT

6 Lagari et al.
(2013)17
RCT

Study
Population
226 adults (>70
years) with
25(OH)D
between 6-20
ng/ml. Mean +/SD age placebo
and intervention:
77.6+/-6.6 and
78.5+/-6.2 years,
respectively.
86 adults (65-95
years old) in
Miami Dade.
Mean +/- SD
age: 73.4+/-6.4
years.

Intervention

Outcomes

1. Placebo. 2.
Weekly oral
8400 IU D3.
F/U 16 weeks.

25(OH)D
(ng/ml)
Gait velocity
(calculated
from time (s)
to walk 4m;
cm/s)

1. 400 IU/day
D3. 2. 2000
IU/day D3.
F/U 6 months

Conclusions

No significant findings. 25(OH)D at baseline for
placebo and intervention: mean +/- SD of 14.1+/5.5 and 13.7+/-4.4, respectively; mean difference
of 13; p>0.05. 25(OH)D at F/U for placebo and
intervention: mean of 14.0 and 26, respectively.
25(OH)D difference in intervention from baseline
to F/U: p<0.001. 25(OH)D difference between
placebo and intervention at F/U: p<0.001.
Difference in change in gait velocity from baseline
to F/U between groups: not significant (p=0.717).
25(OH)D
No significant findings. 25(OH)D at baseline for
(ng/ml)
all: mean +/- SD of 33.0+/-10; not significantly
Gait velocity different between groups within men and women
(calculated
(p=0.865 and p=0.832, respectively). 25(OH)D
from time (s) change at F/U: the change from baseline to follow
up between groups was not significant for men and
to walk 4m
at usual
significant for women (p=0.208 and p=0.004). Gait
velocity).
velocity at baseline: not significantly different
between groups for men (p=0.600) and women
(p=0.628). Difference in change in gait velocity
from baseline to F/U between groups: nonsignificant for men and women (p=0.291 and
p=0.438, respectively).
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Table 3: Observational Studies Investigating the Association Between Vitamin D Status and Cognition in Healthy
Community-Dwelling Older Adults
Author,
Study Population
Outcomes
Conclusions
Year, Study
Design
1 Przybelski
32 adults in United
25(OH)D
Significant findings: lower 25(OH)D, lower MMSE score.
et al.
States Mean +/- SD
(ng/ml)
25(OH)D Continuous: Mean +/- SD of 21.6+/-1.6. 25(OH)D to
18
(2007)
age: 79.5+/-1.6 years.
MMSE score: significant (p=0.006).
Cognitive test:
CrossMMSE
sectional
2 Buell et al.
3133 adults (65-99 years 25(OH)D
Significant findings: lower 25(OH)D, worse cognitive
19
(2009)
old) from NAME study (ng/ml)
performance, especially in executive function tests. 25(OH)D
Crossin USA. Mean +/- SD
Cognitive tests: cut off categories and % sample: <10: 18%; 10- 20: 47%; >20:
sectional
age: 75.0+/-8.5 years.
NAART.
35%. 25(OH)D to cognitive tests: TMT-A ( p<0.03), TMT-B
WMS-III WLL, (p<0.02), DSST (p<0.001), MR (p<0.02), WAIS-III BD
WMS-III LM,
(p<0.04). Differences in cognitive test scores between
DSST, TMT-A, 25(OH)D groups: TMT-A (p<0.05), TMT-B (p<0.05). MR
TMT-B, MA,
(p=0.03), DSST (p<0.01). 25(OH)D to executive function:
WAIS-III BD,
significant (β =0.01, p=0.001). 25(OH)D to
MR, COWA.
attention/processing velocity: significant (β = 0.01, p=0.03).
3 Lee et al.
3369 men (40-79 years
25(OH)D
Significant findings: lower 25(OH)D, worse cognitive
(2009)20
old) from EMAS, USA. (ng/ml)
performance, especially for executive function tests.
CrossMean +/- SD age: 60+/- Cognitive tests: 25(OH)D continuous: mean +/- SD of 25.2+/-12.4. 25(OH)D
sectional
11 years.
ROCF, CTRM
cut off categories and % sample: <10: 7.9%; 10-19.9: 32.8%;
test, DSST.
20-29.9: 30.5%; >30: 28.8%. Adjusted models, 25(OH)D to
cognitive tests: only DSST significant (p<0.01). Difference in
cognitive test scores between groups: significant for DSST
(p<0/05). Locally weighted and spline regression: significant
relationship between 25(OH)D and cognitive function,
stronger at <14ng/ml.
Table 3 continued.
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4

Author,
Year, Study
Design
Llewellyn et
al. (2009)21
Crosssectional

5

Wilkins et
al. (2009)22
Crosssectional.

6

Annweiler et
al. (2010)23
Crosssectional

7

Llewellyn et
al. (2010)24
Longitudinal
(6 yrs.)

Study Population

Outcomes

1766 community- dwelling
and institutionalized adults
(>65 years old) in England.
Mean +/- SD age: 78.2+/8.6 years.

25(OH)D
(ng/ml)
Cognitive tests:
AMT Score.
MCI defined as
3 errors of 10.
60 adults (>55 years old)
25(OH)D
African and European
(ng/ml)
Americans from ADRC study Cognitive tests:
MMSE, SBT.
in United States Mean +/SD age: 74.99+/-8.2 years.
752 women (>75 years old)
25(OH)D
from EPIDOS in France.
(ng/ml)
Mean +/- SD age: 80.4+/-3.6 Cognitive tests:
SPMSQ score to
years.
define MCI
(score <8).
858 adults (>65 years old)
from InCHIANTI study in
Italy. Mean +/- SD age:
73.8+/-6.4 years.

25(OH)D
(ng/ml)
Cognitive tests:
MMSE, TMTA, TMT-B.

Table 3 continued.
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Conclusions

Significant findings: increased odds of MCI in the lower
quartiles of 25(OH)D. 25(OH)D quartiles and ranges: Q1:
3-12; Q2: 12-18; Q3: 18-26; Q4: 26-68. Cognitive status:
12% MCI. Difference in odds for cognitive impairment of
non-institutionalized participants between quartiles:
significant (p trend =0.001).
Significant findings: lower 25OH, worse performance in
SBT. 25(OH)D continuous: mean +/- SD of 21.59+/-7.8.
25(OH)D cut off categories and % sample: <20: 52%; >20:
48%. Difference in cognitive test scores between groups:
significant for SBT only (p=0.016).
Significant findings: lower 25(OH)D, higher odds of MCI.
Mean : 7.21+/-2.09. 25(OH)D cut off categories and %
sample: <10: 17.2%; >10 82.8%. MCI: 10%. Difference in
SPMSQ scores between groups: significant (p<0.001).
Difference in % SPMSQ <8 (i.e.,MCI) between groups
(p=0.006). Odds of having MCI when 25(OH)D <10:
significant (adjusted OR=1.99, p=0.017)
Significant findings: lower 25(OH)D, worse performance
in cognitive tests, especially for executive function.
25(OH)D cut off categories and % sample: <10: 20%; 1020: 42%; 20-30: 19%; >30: 18%. Cognitive score
differences between groups: significant MMSE, TMT-A,
TMT-B (all, p trend: p<0.001). Cognitive score differences
between <10 vs. >20: significant MMSE (p trend =0.02)
and TMT-B (p trend =0.04).

Author,
Year,
Study
Design
Seaman
s et al.
(2010)25
Crosssectiona
l

Study
Population

Outcomes

Conclusions

25(OH)D
(ng/ml)
Cognitive tests:
SWM assessed
by 4 parameters
from CANTAB

Significant findings: lower 25(OH)D, lower SWM scores. 25(OH)D
continuous: mean +/- SD of 30.5+/-19.3. 25(OH)D cut off categories and
% sample: <12: 12%; <20: 36%; <32: 64%. 25(OH)D tertiles and range:
Q1: <19.1; Q2: 19.1-34.4; Q3: >34.4. 25(OH)D to 4 parameters of SWM:
significant (all p<0.005). SWM scores of three assessments were
significantly lower in subjects in Q3, but not Q2, compared to Q1 (p trend
=0.084).

9

Slinin et
al.
(2010)26
Longitu
dinal
(4.6
yrs.)

380 adults
(55-87 years
old) from
ZENITH study
in Europe.
Mean +/- SD
age: 68.1+/-4.1
years.
1376 men (>65
years old) from
MrOS in USA.

10

Chan et
al.
(2011)27
Case
control

25(OH)D
(ng/ml)
Cognitive tests:
3MS <80 as
MCI; decline
>5 points in
F/U. MCI as
change in
TMT-B at F/U.
939 men (>65
25(OH)D
years old) from (ng/ml)
Os Study in
Cognitive tests:
Hong Kong.
MCI defined by
Mean +/- SD CSI-D < 28.4.
age: 75.2+/-5.3
years.

No significant findings. 25(OH)D cut-off categories and % sample: <30:
75%. 25(OH)D quartiles and range:Q1: < 19.9; Q2: 20.0-25.09; Q3: 25.1
-29.79; Q4: >29.8. Cognitive status: baseline 3.4% and F/U 22.8% MCI
per 3MS, and baseline 9.3% and F/U 8.0% per TMT=B. Adjusted models,
Difference in odds of MCI (3MS) between quartiles: not significant (p
trend: p=0.97). Difference in odds of MCI (TMTB) between quartiles: not
significant (p trend: p=0.96). Difference in odds of incident MCI (3MS)
between quartiles: not significant (p trend = 0.10). Difference in odds of
incident MCI (TMTB) between quartiles: not significant (p trend >0.5).
No significant findings. 25 OHD Continuous: mean +/- SD for No MCI
of 31.2+/-8.3 and MCI of 31.6+/-7.6. 25(OH)D cut off categories and %
sample: <20: 6%; 20-30: 42%; 30-40: 39%; >40: 14%. 25(OH)D
quartiles and range: Q1: <25; Q2: 26-30; Q3: 31-36; Q4: >37. Cognitive
status: 94% No MCI, 6% MCI. Difference in 25(OH)D levels in No MCI
vs. MCI: not significant (p=0.735). Difference MCI odds per quartiles:
not significant (p trend= 0.843). per groups: not significant (p
trend=0.911).

8

Table 3 continued.
Author,
Study Population

Outcomes

Conclusions
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11

12

Year,
Study
Design
Llewellyn
et al.
(2011)28
Crosssectional

Annweiler
et al.
(2012)29
Crosssectional

3396 adults (age
inclusion not reported)
from NHANES 19881994. Mean +/- SD
age: 73.7+/-10.9 years.

25(OH)D (ng/ml)
Cognitive tests: Global cognitive
function score from sum of 6 tests
including:
MMSE, East BMT, and WAIS.
MCI defined as lowest 10% of the
distribution of cognitive
performance.

95 non demented
Caucasian adults (age
inclusion not reported)
with subjective memory
complaint from GAIT
study in France. Mean
+/- SD age: 71.1+/-6.4
years.

25(OH)D (ng/ml)
Cognitive tests: MCI diagnosed by
multidisplinary meetings with
geriatricians, neurologist and
neuropsychologists based on
standardized neuropsychological
tests, physical examination, blood
tests and MRI brain imaging. MCI
diagnosed according to Winblad et
al. criteria.
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Significant findings: higher odds of MCI
in lower 25(OH)D groups. 25(OH)D cut
off categories and % sample: <10: 1.8%;
10-20: 21.8%; 20-30: 39.0%; >30: 37.5%.
Adjusted model: Difference in odds for
MCI between 25(OH)D group: (p
trend=0.03). Difference in odds for MCI
between 25(OH)D <20 vs. >20: p
trend=0.002. Cognitive status: 90% No
MCI and 10% MCI.
Significant findings: higher odds of MCI
in lower 25(OH)D quartiles. 25(OH)D
Continuous: mean +/- SD of 25.2+/-12.1 in
all, MCI: 21.4+/-8.7 in MCI and 28.3+/13.7 in healthy. 25(OH)D quartiles and
ranges: Q1: 4-16; Q2: 16-23.6; Q3: 24.031.7; Q4: 32.1-75.7. Cognitive status: 45%
MCI. Difference in 25(OH)D levels
between MCI and healthy: significant (p =
0.006). Fully adjusted model: Difference in
odds for MCI between quartiles:
significant (p trend =0.003) and between
each quartile compared to ref (all p<0.03).

Table 3 continued.
Author,
Year, Study
Design
13 Slinin et al.
(2012)30
Longitudinal
(2 and 4 yr)

14 BrouwerBrolsma et al.
(2013)31
Crosssectional

Study
Population

Outcomes

Conclusions

6257 Caucasian
women (>65
years old) from
SOF in United
States Mean +/SD age: 76.6+/4.7 years.

25(OH)D (ng/ml)
Cognitive tests:
3MS to define
MCI as score
<21.6 and TMTB to define MCI
as >250s

127 adults (>65
years old) frail
or prefrail from
ProMuscle
Study in
Netherlands.
Mean +/- SD
age: 79+/-7.6
years.

25(OH)D (ng/ml)
Cognitive tests:
MMSE, WLT,
WDS forward
and backward
test, TMT-A,
TMT-B, ST, VF,
RT.

Significant findings: higher odds of MCI at baseline and
cognitive decline at F/U, defined by MMSE, in those with lower
25(OH)D, not significant when MCI defined by TMT-B.
25(OH)D cut off categories and % sample: <10: 7.3%; 10-19.9:
32.7%; 20-29.9: 38.6%; >30: 21.4%. Cognitive status: 7.2% MCI
with both tests. Full adjusted models, Difference in odds of MCI
at BL (MMSE) between groups: significant (p trend = 0.029).
Difference in odds of cognitive decline at F/U (MMSE) between
groups: significant (p trend=0.003). Difference in odds of MCI at
baseline (TMT-B) between groups: not significant (p trend =
0.314). Difference in odds of cognitive decline at F/U (TMT-B)
between groups: (p trend = 0.931)
Significant findings: lower 25(OH)D, worse cognitive
performance in executive function test. 25(OH)D continuous:
mean of 21.6. 25(OH)D cut off categories and % sample: <12:
17%; <20: 53%; <30: 77%. 25(OH)D tertiles and range: T1: 5.215.2; T2: 15.2-26.0; T3: 26.0-65.3. Difference in cognitive test
score between tertiles: significant for VF and RT combined
(p=0.04) and TMT-A and B combined (p=0.05). Fully adjusted
model: significantly better performance in executive function per
0.4ng increase in serum 25(OH)D (B: 0.007, p=0.01).
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Table 3 continued.
Author, Year,
Study Design
15 Annweiler et al.
(2014)32
Cross-sectional

16 Chei et al.
(2014)33
Cross-sectional

Study
Population
100 Caucasian
adults (>60
years old) with
memory
complaint in
France. Mean
+/- SD age:
71.02+/-0.74
years.

Outcomes

Conclusions

25(OH)D (ng/ml)
Cognitive tests:
MMSE, TMT-B, Nback test, ST, Go/NoGo.

2004 adults
(>60 years old)
from CLHLS
study in China.
Mean +/- SD
age: 84.9+/12.7 years.

25(OH)D (ng/ml)
Cognitive tests:
Chinese version of
MMSE to categorize
MCI (score <30).

Signficant findings: lower 25(OH)D, worse cognitive
performance, especially in mental flexibility. 25(OH)D
continuous: mean +/- SD of 24.2+/-1.6. 25(OH)D cut off
categories and %sample: <10: 6%; 10-20: 36%; >20:
58%. Cognitive test scores differences between group:
not significant for MMSE, N-back test, ST, and Go/NoGo (p>0.05 for all) and significant for TMT-B
(p<0.001) Fully adjusted model: TMT-B significantly
associated with 25(OH)D <10: B: 1.48; CI: 0.36-2.61;
p=0.011.
Significant findings: those with MCI had lower
25(OH)D and odd of MCI is greater in low 25(OH)D.
25(OH)D continuous: mean +/- SD of 17.3+/-7.9 in all,
12.8+/-6.1 in MCI and 18.2+/-7.8 in No MCI. 25(OH)D
quartiles and ranges: Q4: 2.3-12.7; Q3: 12.7-17.2; Q2:
21.2-22.8; Q1: 22.8-83.6. Cognitive status: 18% MCI
and 82% No MCI. Difference in 25(OH)D between MCI
and No MCI: Significant (p=0.001). Difference in odds
of MCI between quartiles: significant, (p trend =0.05).
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Table 3 continued.
Author, Year,
Study Design
17
Hooshmand et
al. (2014)34
Cross-sectional

18

Schneider et al.
(2014)35
Cross-sectional
and
longitudinal (3
and 10.6 years)

Study
Population
75 adults (age
inclusion not
reported) in
Sweden. Mean
+/- SD age:
61.6+/-9.1
years.

1652 adults
(45-65 years
old) from
ARIC study in
United States
Mean +/- SD
age: 62.3+/4.45 years.

Outcomes

Conclusions

25(OH)D (ng/ml)
Cognitive tests:
Dementia and AD:
DSM-IV and
NINCDS-ADRDA.
MCI: not demented,
report of cognitive
impartment but
preserved basic ADL.
SCI: subjective
complaints, objective
impairment cognitive
tests.
25(OH)D (ng/ml)
Cognitive tests:
DWRT, DSST, VF

Significant findings: lower 25(OH)D in MCI groups
and higher odds of MCI with lower 25(OH)D.
25(OH)D Continuous: mean +/ SD of 67.3+/-26.5,
median (IQR) for AD of 24.0 (19.0, 28.8), MCI of
24.2 (16.5, 29.8) and SCI of 28.0 (24.0, 38.5).
Difference in 25(OH)D between cognitive groups:
significant difference between SCI vs. AD (p=0.014)
and SCI vs. MCI (p=0.027) The OR for worse
cognitive status for each increase of 0.4ng/ml in
25(OH)D was 0.972 (CI 0.953-0.991).
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No significant findings. 25(OH)D Continuous: mean
+/- SD for whites of 25.5+/-7.9 and blacks: 17.3+/6.3. 25(OH)D tertiles and ranges: whites (T3: <21.8;
T2: 21.8-28.3; T1: >28.3) and blacks (T3: > 19.3; T2:
14.0-19.3; T1: <14.0). 25(OH)D to cognitive test
score in whites or in blacks: not significant (all
p>0.05). Difference in 25(OH)D levels between
quintiles of cognitive decline on all of the cognitive
tests in white or blacks at either 3 years or 10.6 years:
not significant (all p>0.05). Association of 25(OH)D
with linear change in cognitive test scores: not
significant (all p>0.05)

Table 3 continued.
Author,
Year, Study
Design
19 Toffanello et
al. (2014)36
Crosssectional and
Longitudinal
(4.4 years)

20

Wilson et al.
(2014)37
Crosssectional and
longitudinal
(4 years)

Study Population

Outcomes

Conclusions

1927 Caucasian
adults (age
inclusion not
reported) from Pro
V.A. study in Italy.
Mean +/- SD age:
73.9+/-6.7 years.

25(OH)D (ng/ml)
Cognitive tests:
MMSE to define
MCI as score <24.
A decline of 3 or
more points at F/U
defined as
substantial cognitive
decline.

Significant findings: lower 25(OH)D, worse MMSE
scores, MCI and cognitive decline. 25(OH)D Continuous:
mean +/- SD of 33.7+/-21.6. 25(OH)D cut off categories
and % sample: <20: 27.9%; 20-30: 22.4%; >30: 49.7%.
Cognitive status: 31% MCI. Difference in MMSE scores
between groups at baseline: Significant (p<0.0001). Those
with lower 25(OH)D were more likely to be cognitively
impaired (p=0.0001). Difference in MMSE scores between
groups at 4.4 year F/U: <20 more likely of cognitive decline
than >30 (RR: 1.26; CI: 1.09-1.52,p=0.005).
Significant findings: lower 25(OH)D, worse cognitive
performance but not greater cognitive decline. 25(OH)D
cut off categories and % sample: <20: 32.9%; 20-30:
35.5%; >30: 31.6. Baseline (adjusted model): 25(OH)D<20
scored lower on 3MS (p=0.02) and DSST than 25(OH)D>
30 (p=0.01). 4 year F/U (adjusted model): 25(OH)D to
cognitive decline defined by 3MS and DSST: not
significant.

2777 adults (70-79 25(OH)D (ng/ml)
years old) from
Cognitive tests:
Health ABC cohort 3MS, DSST
in United States
Mean +/- SD age:
73.6+/-2.9 years.
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Table 4: Observational Studies Investigating the Association Between Vitamin D Status, Gait Velocity and Cognition
(Independently) in Healthy Community-Dwelling Older Adults
Author,
Study
Outcomes
Conclusions
Year,
Population
Study
Design
1
Beauchet et 411 adults
25(OH)D (ng/ml)
Significant findings: lower 25(OH)D, slower
38
al. (2011)
(>65 years
Gait velocity: SMTEC system:
velocity. No significant findings with cognition.
Crossold) in
footswitches to measure temporal step 25(OH)D cut off categories and % sample: <10:
sectional
France.
parameters. One trial at usual velocity 16.6%; 10-30: 70.3%; >30: 13.1%. % Cognitive
Mean +/calculated from the Timed Up and Go impaired in each group: <10: 48.5%; 10-30:
SD age:
test (m/s). Cognitive tests: Abnormal
39.8% >30: 38.9% Difference in gait velocity
70.4 +/-1.8 episodic memory (6 memory items
between groups: significant (p=0.003). Difference
years.
from MMSE; score < 6) and abnormal in gait velocity between <10 vs. >30: significant
CDT were considered as cognitive
(p=0.002). Difference in % cognitive impaired
impairment.
between groups: not significant (p=0.394).
2
Houston et 307 adults
25(OH)D (ng/ml)
Significant findings: lower 25(OH)D, slower gait
al. (2011)39 (70-89 years Gait velocity: time (s) to walk 400m
velocity. No significant findings with cognition.
Cohort
old) from x by walking 10 times 20m.
25(OH)D continuous: mean of 20.9. , 25(OH)D
LIFE-P
Cognitive tests: MMSE
cut off categories and % sample: <20: 50% and
study in
>30 ng/ml 10%. Difference in gait velocity
United
between <20 vs. >20: significant (p=0.01).
States Mean
Difference in MMSE between groups: not
+/- SD age:
significant (p = 0.17). Change in vitamin D status
76.7+/-4.3
in 12 months association with changes in gait
years.
velocity: not significant for increase or decrease
(p = 0.64 and p=0.13).
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Table 4 continued.
Author,
Year, Study
Design
3 Houston et al.
(2012)40
Longitudinal
(2,4 6 yrs.)

4 Peterson et al.
(2012)41
Cohort

Study
Population

Outcomes

2307 adults
(70-79 years
old) from
Health ABC
study in
United
States Mean
+/- SD age:
74.7+/-2.9
years.

25(OH)D (ng/ml)
Gait velocity: calculated from time to
walk 20m at usual velocity (m/s)
Cognitive tests: 3MS

159 adults
(>70 years
old) from
ISAAC
study in
United
States Mean
age: 85.5
years.

Conclusions

Significant findings: lower 25(OH)D, slower
gait. Lower 25(OH)D, lower MMSE scores.
25(OH)D cut off groups and % sample: <20:
32.3%; 20-30: 35.0%; >30: 32.7%. Difference
in MMSE between groups at BL: Significant
(p<0.001). Difference in gait velocity between
groups at baseline: significant (p<0.001).
25(OH)D threshold for gait velocity: 33.2
(27.2-39.1) ng/ml (p<0.0001). Adjusted model:
gait velocity difference between <20 vs. >30:
significant (p<0.001 and p trend =0.003).
Those who at baseline had <20 had slower gait
velocity at 2, 4, 6 years compared to >30
(p<0.01 for all).
25(OH)D (ng/ml)
Significant findings: Lower 25(OH)D in those
Gait velocity: Tinetti gait velocity,
with MCI. Lower 25(OH)D, lower global
m/s.
cognition score (MMSE). No significant
Cognitive tests: CDR to define MCI as findings with gait. 25(OH)D Continuous:
<0.5. DSF, DSST, TMT-A, Simple
mean of 37.7 for all. 32.9 for fallers vs. 39.3
and Choice RT, COT, DSB, LNS,
for non-fallers (p<0.01), and 31.0 for MCI and
LM, DVR, CERAD WL, CERAD,
no MC 0: 38.9 (p<0.05). Adjusted models, Gait
VFR language, WRAT-R, EBMT,
velocity to 25(OH)D: not significant (r=-0.08,
TMT-B, ST, VF, OMOT, PC, BD.
p=0.33); MMSE to 25(OH)D: significant
(r=0.24, p<0.01); MCI to 25(OH)D: significant
(p=0.02)

234

Table 4 continued.
Author, Year,
Study Design
5 Menant et al.
(2012)42
Crosssectional

6 Toffanello et
al. (2012)43
Crosssectional

Study Population

Outcomes

Conclusions

463 adult (70-90 years
old), independent in
ADL and able to walk
independently in
Australia. Mean +/- SD
age: 78.0+/-4.6 years.

25(OH)D (ng/ml)
Gait velocity:
calculated from time to
walk 6m as part of the
Physiological Profile
Assessment.
Cognitive tests:
MMSE, DSST, TMTA, TMT-B.

2694 older adults (age
inclusion NR) Pro.V.A.,
Italy
Women: 75.6 +/-7.5
Men: 76.2 +/- 7.8.

25(OH)D (ng/ml)
Gait velocity:
calculated from best
time (s) in 2 walks at
usual pace along a 4m.
Cognitive tests:
Indexed MMSE

Significant findings: lower 25(OH)D, slower gait.
Lower 25(OH)D, worse cognitive performance,
especially in executive function tests. (TMT-B).
25(OH)D continuous: mean +/- SD of 24.9+/-9.9.
25(OH)D cut off categories and % sample: all (<20:
33.3%), men (<20: 22%), and women (<20: 44%).
Difference in gait velocity between groups:
significant (p<0.01). Difference in MMSE, TMT-A,
DSST and BD between groups: not significant.
Difference in TMT-B between groups: significant
(p<0.05).
Significant findings: gait velocity increased
significantly for 25(OH)D levels up to 40ng/ml,
mostly improving at 20-30 ng/ml. Lower 25(OH)D,
lower MMSE scores. 25(OH)D continuous: mean
+/- SD of 26.3+/-4.8 for all, 26.0+/-16.5 for women;
40.8+/-25.0 for men. 25(OH)D cut-off categories and
% sample: women (<20: 40%; <10:13.5%) and men
(<20: 20%; <10: 5.9%). 25(OH)D quintiles and
ranges: women (Q1: <13; Q2: 13-20; Q3: 20-27; Q4:
27-37; Q5: >37) and men (Q1: <21; Q2: 21-32; Q3:
32-41; Q4: 41-57; Q5: >57ng/ml. Adjusted models,
Difference in MMSE between quintiles: significant in
women (p trend = 0.006) and men (p trend =0.007).
Difference in gait velocity between quintiles:
significant in women and men (both p trend p<0.001)
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Table 4 continued.
Author,
Study Population
Year, Study
Design
7 Houston et
2099 adults (70-79
44
al. (2013)
years) from Health ABC
Crossstudy in United States
sectional
Mean +/- SD age:
74.6+/-2.9 years.
8 Gschwind et
al. (2014)45
Crosssectional

404 older adult
attending memory clinic
(>65 year old). Mean
+/- SD age: 77.6+/-5.8
years.

Outcomes

Conclusions

25(OH)D (ng/ml)
Gait velocity:
calculated from time
(s) used to calculate
gait velocity, m/s.
Cognitive tests: 3MS
25(OH)D (ng/ml)
Gait velocity
GAITRite measured
usual and fast walking
velocity (no practice,
one walk, cm/s)
Cognitive tests:
MMSE

Significant findings: Lower 25(OH)D, slower gait
velocity and lower MMSE scores. 25(OH)D cut off
categories and % sample: <20: 28.9%; 50-30: 36.1%;
>30: 35%. Difference in gait velocity between groups:
significant (p <0.001). Difference in MMSE between
groups: Significant (p<0.001)
Significant findings: Those in highest quartile
performed 9.4% better in usual (p=0.02) and 9.2% in
fast (p=0.004) walking velocity. Lower 25(OH)D,
lower MMSE. 25(OH)D cut off categories and %
sample: <20: 41.3% and <30: 69.8%. 25(OH)D
quartiles and range: (Q1 <15.6; Q2 15.6-21.6; Q3 22.032.4; Q4 >32.4. Difference in usual gait velocity
between quartiles: significant (p<0.001). Difference in
fast gait velocity between quartiles: significant
(p<0.001). Difference in MMSE between quartiles:
significant (p<0.006)
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APPENDIX B
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DUAL TASK PHYSICAL PERFORMANCE TEST INSTRUCTIONS
Participant ID: __________________________

Date: ________/____/_______
month/day/year

Practice trials (Same order for all participants, RECORD FOR SINGLE TASK
GAIT)
1
Single gait task
Data collection trials (random order) PARTICIPANT RANDOM ORDER
NUMBER ______________
1
Single gait task
Single cognitive task Dual task
2
Single gait task
Dual task
Single cognitive
task
3
Single cognitive task Single gait task
Dual task
4
Single cognitive task Dual task
Single gait task
5
Dual task
Single cognitive task Single gait task
6
Dual task
Single gait task
Single cognitive
task
If the participant brings heeled-shoes, have them remove it. NOTE: ______________
Enter the participant ID, height, weight and leg length. Leg length: ________
Press start
Read Instructions before each trial.
Practice single gait task: This is the walkway that we will use for some walking tests.
For each walk, you must start behind the line in front of you and continue walking until
you pass the line at the other end of the walkway. To familiarize yourself with walkway,
start at this line and walk across the mat at the pace you prefer during daily activities. Do
not run. Continue walking until you reach the line at the other side. You can start when
you are ready.
Este es el camino que vamos a utilizar para algunas pruebas de marcha. Por cada
caminata, debe comenzar detrás de la línea en frente de usted y seguir caminando hasta
pasar la línea en el otro extremo del camino. Para familiarizarse con el camino, comience
en esta línea y camine por la alfombra al ritmo que usualmente camina durante las
actividades diarias. No corra. Continúe caminando hasta llegar a la línea en el otro lado.
Puede empezar cuando esté listo.
Single cognitive task: Have participant stand in the starting line. While you are
standing, count backwards out loud from 50 by 1 starting. Count all the way down to 1. If
you make a mistake, don’t stop and continue counting.
Haga que el participante se pare en la línea de inicio. Mientras que usted está de pie,
cuente hacia atrás en voz alta de SDe 50 por 1. Cuente hasta llegar a 1. Si comete un
error, no se detenga y siga contando.
Single gait task: Have participant stand in the starting line. Starting at this line, walk
across the mat at a pace you prefer during daily activities. Do not run. Continue walking
until you reach the line at the other side. You can start whenever you are ready.
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Haga que el participante se pare en la línea de inicio .A partir de esta línea, camine por
la alfombra al ritmo que usualmente camina durante las actividades diarias. No corra.
Continúe caminando hasta llegar a la línea en el otro lado. Puede empezar cuando esté
listo.
Dual task: Have participant stand in the starting line. For the following test, you will
walk across the mat at a pace you prefer during daily activities, while you simultaneously
count backwards out loud from 50 by 1. Do not run. If you make mistakes during
counting keep on going. Continue walking without prioritizing either of the tasks until
you reach the line at the other side. You can start when you are ready.
Haga que el participante se pare en la línea de inicio. Para la siguiente prueba, usted
caminará a través de la alfombra al ritmo que usualmente camina durante las actividades
diarias, mientras cuenta al mismo tiempo hacia atrás en voz alta de SDe 50 por 1. No
corra. Si se cometen errores durante el conteo siga contando. Continúe caminando sin dar
prioridad a ninguna de las tareas hasta llegar a la línea en el otro lado. Puede empezar
cuando esté listo.
DUAL TASK PHYSICAL PERFORMANCE RANDOM ORDER TABLE
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Figure 1: The GAITRite Walkay for the Assessment of Gait. Images taken from
GAITRITE manual and software.
Legend: The GAITRite is a 6 m long walkway. The start and finish lines were placed 2
meters before and after to account for acceleration and deceleration (above). The
participants were asked to walk on GAITRite during single walking and dual tasking
(middle). The mat is connected to a computer software that calculates spation-temporal
variables from the information gathered by the sensors (below).
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ELECTRO SENSOR COMPLEX INSTRUCTIONS
1. Clean foot plates and oximeter
2. Turn on computer: password: 12345
3. Open program using the “CMS” shortcut on desktop.
a. Write participant ID: last 2 numbers of year of birthday, 2 last numbers of
phone number, space, 4 first letters of last name.
b. Gender, DOB
c. Ht, Wt, daily activity
4. Ask them to:
a. Seat
b. take of shoes and socks
c. place feet on metal foot plates
d. Make sure they are not wearing nail polish or acrylic nails. Right
index finger in oximeter – push white button until power on, allow 30s to
stabilize.
e. BP cuff on left arm, cord above arm and the hand resting on the table in
front.
f. Arms must be placed in an extended but relaxed and comfortable position.
g. Remain perfectly still. If move, retake.
5. Move screen out of their site if possible.
6. When it starts, ask them to relax, no talking
7. Valsalva:
a. Remove feet from the plates
b. Now you are going to clamp your nose with your left hand and try to
breathe out your nose while plugging it for 15 seconds, and keeping your
mouth closed like you were trying to pop your ears. I will tell you when to
start and when you can breathe normally.
c. Ahora se va a apretar la nariz con la mano izquierda y va a tratar de
respirar por la nariz mientras la tapona durante 15 segundos y
manteniendo la boca cerrada como si estuviera tratando de destapar los
oídos. Le diré cuándo comenzar y cuándo puede respirar normalmente.
8. Deep Breathing 30sec:
a. Now you are going to inhale for 5 seconds and exhale for 5 seconds. I will
direct you when to inhale and exhale.
b. Ahora usted va a inhalar durante 5 segundos y exhalar durante 5
segundos. Le indicare cuando inhalar y cuando exhalar.
9. Stand up
a. Finally, when I say go, I want you to stand up and remain standing up
until the machine finishes measuring your blood pressure.
b. Finalmente, cuando le indique, quiero que se levante de la silla y
permanezca de pie hasta que el equipo termine de tomar su presión
arterial.
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Figure 2: The Electro Sensor Complex Device and Procedure. Images taken from
company website and computer software.46,47
Legend: The Electro Sensor Complex combines three devices into computer software
(above). After placing the blood pressure cuff on the participant’s arm, feet on the metal
plates and index right finger on the pulse oximeter, the software calibrates and measures
baseline data. Then the participant is asked to perform the valsava maneuver, deep
breathing and standing up cardiac autonomic reflex tests (middle). Once it finishes, the
software provides a result scoreboard (below).
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Figure 3: Heart Rate Variability Time and Frequency Domains. Images taken from
company website and computer software.46,47
Legend: Example of plethysmograph used to measure heart rate variability (time from R
to R intervals) in time domain (above), application of Fourier transform to the
plethysmograph to convert from time domain into frequency domains (middle) and the
three frequencies of heart rate variability (below).
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Table 1: Description of ESC software variables used to calculate CMRS
Name (Acronym)
Normal
Representation
values
ANS activity markers
<2
Standard deviation of the
40-80ms
HRV time domain. Variation between each successive heartbeat. Reflects
normal wave ( SDNN)
overall cyclic components of HRV. Marker of SNS PNS. Decreased SDNN is
associated to reduced left ventricular function.
Square root of the mean
35-65ms
HRV time domain. Indicator of PNS. Reflects the electrical stability of the
squared differences of
heart.
successive normal to normal
R-R intervals (RMS SD)
Total power (PTGTP)
>=780ms2
HRV frequency domain. Total power of the FFT (Fast Fourier transform)
performed on oximeter waveform. It is the sum of the areas under the curve
covered by the 3-frequency domains. Main indicator of ANS activity used to
define HRV score. It is usually decreased in those with chronic stress or with
disease.
ANS balance markers
<2
Low frequency (PTGLF)
<220ms2
HRV frequency domain. Indicator of both PNS and SNS. It is controversial
since it may also represent contribution influenced by RAAS and baroreceptor
activity generating vagal outflow.
High frequency (PTGHF)
>=220ms2
HRV frequency domain. Indicator of PNS. Associated with R-R interval
changes related to breathing, which is under PNS control.
LF/HF
0.5-2.0
HRV frequency domain. Overall estimate of relative ANS balance within the
entire cardiac ANS. >2% mean s SNS predominance <0.5% indicates PNS
predominance
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Table 1 continued.
Name (Acronym)
Lipid biomarkers
Fat mass
Body mas index
(BMI)
Arterial stiffness
PTG (AIPTG)
Blood pressure
markers
Systolic blood
pressure (SBP)
Diastolic blood
pressure (DBP)
Systemic Vascular
Resistance (SVR)
Insulin resistance /
IGT markers
Total power index
(PTGTPi)

Normal
values
<2
25-31%
18.5-24.9

Representation

<0.45%

Systematic arterial stiffness marker derived from the ascending aortic pressure waveform.
Marker of lipid levels, related to atherosclerosis.

Energy storage of the body
Body mass index (kg/m2)

<2
110-140
mmHg
78-90
mmHg
<1500 dyns-cm2
<2

SBP average performed during measurement. Refers to the pressure of blood in the artery
when the heart contracts.
DBP average performed during measurement. Refers to the pressure of blood in the artery
when the heart relaxes.
Indicator of peripheral resistance to flow that must be overcome to push blood through the
circulatory system.

<377ms2

HRV frequency domain. PTGTP adjusted for fat mass. Significant marker of insulin
resistance. Comparing PTGTPi marker versus the euglycemic clamp, it has a sensitivity of
90% and specificity of 90% to detect insulin resistance.
HRV frequency domain. Associated with thermoregulation and sweating that results in
oscillation in vasomotor tone controlled by SNS and/or RAAS.
PTGVLF adjusted by ESRNO. Marker of IGT

Very low frequency
(PTGVLF)
Very low frequency <33ms2
index (PTGVLFi)
Stress index
<=180%
(Stress_I)

Marker of SNS activity. Correlated with C-Reactive protein level.
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Table 1 continued.
Name (Acronym)

Normal
values
<2

Sympatethic skin response
markers using Sudo Test (used to
calculate Sudomotor Response
Score (SMRS))
Electric Skin Respond to Nitric
>=50 μ Si
Oxide (ESRNO)

Electric Skin Response to the
Chloride Ion (ESRCI)
Sweat Peak (Sweat_P)

>= 53 μ Si

SNS tests (used to calculate
Sympathetic Test Response
Score (STRS))
SBP response to Valsalva
maneuver in phase 2 (SPRV2)
SBP response to Valsalva
maneuver in phase 4 (SPRV4)
Blood pressure response to
standing (BPRS)

<2

>=90 μ Si

-20- 40mmHg
10-20
mmHg
<10
mmHg

Representation
Cholinergic SNS function. Earliest detectable neurophysiologic abnormalities
in distal small fiber neuropathy, often associated with higher risk of kidney
nephropathy and retinopathy. SMRS has a sensitivity of 91.4% and specificity
of 79.1% to detect peripheral neuropathy in diabetic patients.
Marker of SNS function and microcirculation. The peak of the
electrochemical reaction on the bulk of the electrode reflects skin blood flow.
It has a sensitivity of 68.4% and specificity of 84.4% as a marker of
microcirculation disorder in diabetic patients.
Electrochemical reaction on the bulk of the electrode. Peak reflects sweat
gland nerve density.
Reflects sweat gland function (sweat output) in respond to the electrical
stimulation
Adrenergic SNS function. Sympathetic response failure could increase
cardiovascular events, and it is an indicator of CAN.
Correlated with norepinephrine response (adrenergic).
Correlated with epinephrine response.
Reflects SNS adrenergic response to standing.
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Table 1 continued.
Name (Acronym)
PNS tests (used to calculate
Parasympathetic Test Response Score
(PTRS))

Normal
values
<2

Valsalva Ratio (Vals_R)

>1.18%

Heart Rate Change to Standing
position (K30/15 Ratio)

>1.10%

Expiration/Inhalation ratio (E/I Ratio) >1.18%

Systolic time index (used to calculate
Systolic Time Interval Score (STIS))
Left ventricle ejection time index
(LVETi)
Pre-Ejection Period (Pep)
Preejection Period Index / Left
Ventricle Ejection Time Index Ratio.
(PEPi/LVET Ratio)

<2
370420ms
90110ms
<0.35%

Representation
It is based on the analysis of the beat to beat heart rate changes during the
Valsalva maneuver, deep breathing, and postural change. PNS response
failure could increase cardiovascular events, and it is an indicator of CAN.
Associated with symptoms of dizziness or orthostatic hypotension.
Ratio of SPRV4 and SPVR2. Reflects PNS response. Uses heart rate
response to Valsalva Maneuver.
Evaluates the change in heart rate during the standing position. Heart rate
increases during the first 15 seconds and decreases until it stabilizes at 30
seconds. It reflects PNS response to the change of posture and orthostatic
hypotension.
The heart rate ratio between expiration and inhalation during deep
breathing. Calculated by the longest RR interval divided by shorter RR
interval. Reflects PNS and it’s a test of sinus arrhythmia.
Reflects cardiac performance
Cardiac output adjusted with heart rate
Systolic time interval inversely correlated with left ventricle contractility.
Primarily controlled by SNS beta-adrenergic activity.
Correlated to cardiac performance.
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Table 1 continued.
Name (Acronym)
Endothelial Tests (used to calculate
Endothelial function test Score
(EndoTS))
Reflection Index (RI)
Photoplethysmography Index
(PTGi)
Plethysmography ratio (PTGr)
Cardiometabolic risk score
(CMRS)

Name
(Acronym)
<2

Name (Acronym)

<45%
>40 ms2

Indicator of stiffness of the small and medium arteries.
HRV frequency domain. The sum of the amplitudes of the 3 frequency
domains.
HRV frequency domain. Ratio of the spectral analysis components
Calculated from anthropometric data input in the system and the 10
markers shown in grey. Each marker measured is scored as
0=normal, 1=borderline or 2=abnormal and then used to calculate
CMRS, which is normal if <=4, or represents mild risk (5-7),
moderate risk (8-10) or high risk (>=11). The CMRS had a sensitivity
of 92% and specificity of 83% (cut-off score > 4) to detect type 2
diabetes.

<2.1%
≤4 normal
5-7 mild
risk
8-10
Moderate
Risks
≥11 high
risk

Earliest clinically detectable stage of cardiovascular disease. Marker of
endothelial dysfunction.
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ABBREVIATIONS AND ACRONYMS IN APPENDIX A AND B TABLES
25(OH)D

25- Hydroxyvitamin D

AD

Alzheimer’s Disease

BMI

Body Mass Index

CAN

Cardiac Autonomic Neuropathy

CE SDS

Center for Epidemiologic Studies Depression Scale

CI

Confidence Interval

cm

Centimeter

cm/s

Centimeters per second

DBP

Diastolic Blood Pressure

F/U

Follow up

ft

feet

GDS

Geriatric Depression Scale

HRV

Heart Rate Variability

IGT

Impaired Glucose Tolerance

m

Meters

m/s

Meters per second

MCI

Mild Cognitive Impairment

min

Minutes

OR

Odds Ratio

PNS

Parasympathetic Nervous System

PTH

Parathyroid Hormone

s

Seconds

SBP

Systolic Blood Pressure

SNS

Sympathetic Nervous System

SCI

Subjective Cognitive Impairment

SD

Standard Deviation
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ABBREVIATIONS AND ACRONYMS OF STUDIES IN APPENDIX A AND B
TABLES
ADRC

Alzheimer’s Disease Research Center

ARIC

Atherosclerosis Risk in Communities Study

BFc80+

Befrail study >80 years old cohort.

CLHLS

Chinese Longitudinal Healthy Longevity Survey

EMAS

European Male Ageing Study

EPIDOS

European Patient Information and Documentation Systems

GAIT

Glucosamine/Chondroitin Arthritis Intervention Trial.

Health ABC

The Health, Aging and Body Composition Study

HSE 2000

Healthy Survey for England 2000

InCHIANTI

Invecchiare in Chianti study

ISAAC

Intelligent Systems for Assessment of Aging Changes Study

LIFE-P
Elders Pilot

The Lifestyle Interventionot significant and Independence for

MrOS

Osteoporotic Fractures in Men Study

NAME

Nutrition and Memory in Elders Study

NHANES

National Health and Nutrition Examination Survey

OPRA

Osteoporosis Prospective Risk Assessment

Pro. V.A.

Progetto Veneto Anziani study

SOF

Study of Osteoporotic Fractures.

WHAS

Women’s Health and Aging Study

WHI

Women’s Health Initiative

ZENITH

Zinc Effects in Nutrient Interactionot significant and Trends in
Health and Ageing
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ABBREVIATIONS, ACRONYMS AND DESCRIPTION OF COGNITIVE TESTS IN
APPENDIX A AND B TABLES

3MS

Modified Mini Mental State Examination: global cognition

AMT

Abbreviated Mental Test: global cognition

BD

Block Design: visuospatial conot significanttruction

CANTAB

Cambridge Neuropsychological Testing Automated Battery: visual
memory and executive function.

CDR

Clinical Dementia Rate

CDT

Clock Drawing Test: global executive function

CERAD WL

Consortium to Establish A Registry for Alzheimer’s Disease Word
Recall: memory

CERAD VFR

Consortium to Establish A Registry for Alzheimer’s Disease
Visual Figures Recall: memory

COT

Crossing Off Test: processing velocity

COWA

Controlled Oral Word Association: verbal fluency

CSI-D

Community Screening Instrument for Dementia: global cognitive
impairment.

CTRM

Camden Topographical Recognition Memory (CTRM) test: visual
memory and recognition and episodic memory.

DMS-IV

Diagnostic and Statistical Manual of Mental Disorders IV

DSB

Digit Span Backward: information updating and verbal working
memory

DSF

Digit Span Forward: information updating and verbal working
memory

DSST

Digit Symbol Substitution in the Wechsler Adult Intelligence
Scale: attention, concentration, processing velocity, working
memory and executive function

DVR

Delayed Visual Reproduction: working memory

DWRT

Delayed Word Recall Test: verbal learning and recent memory.

EBMT

East Boston Memory Test: episodic memory
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FAB

Frontal Assessment Battery: global executive function

Go/No-Go

Go/No-Go score: motor inhibition.

Language WRAT-R Wide Range Achievement Test – Reading: memory
LM

Logical Memory

Lnot significant

Letter-Number Sequencing: working memory

MA

Mental abbreviations

MMSE

Mini Mental State Examination: global cognition

MR

Matrix Reasoning: visual construction and fluid reasoning

N-back

N-back test: information updating.

NAART

North American Adult Reading Test: verbal intelligence

NINCDS-ADRDA

US. National Institute of Neurologic and Communicative
Disorders and Stroke-Alzheimer’s Disease and Related Disorders
Association.

OMOT

Odd Man Out task: executive function

PC

Picture Completion: visuo-spatial construction

ROCF

Rey-Osterrieth Complex Figure test: visuo-constructional ability
and episodic memory.

RT

Reaction Time: processing velocity

SBT

Short Blessed Test: memory, orientation and attention

SPMSQ

Pfeiffer Short Portable Mental State Questionnaire: global
cognition

ST

Stroop Tests- Stroop Color-Word Test for selective attention and
susceptibility to behavioral interference and Stroop Interference
Test for cognitive inhibition and executive function.

SWM

Spatial Working Memory, 4 parameters measured using the
Cambridge Neuropsychological Testing Automated Battery

TMT

Trail Making Tests: visual attention, visuo-spatial scanning, task
switching ability, sequential processing, motor velocity, attention,
and executive function

TMT-A

Trail Making Test Part A: information processing

TMT-B

Trail Making Test Part B: mental shifting
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VF

Verbal Fluency: executive function

WAIS-II BD

Wechsler Adult Intelligence Scale Block Design: visuo-spatial
construction.

WDS

Wechsler Digit Span: forward and backward test for attention and
working memory for executive function.

WLT

World Learning Test: direct recall, decayed recall and recognition
for episodic memory.

WMS-III LM

Wechsler Memory Scale III Logical Memory: episodic memory

WMS-III WLL

Wechsler Memory Scale III Word List Learning: episodic memor
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